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ABSTRACT
CHEMICAL MANIPULATION OF MACROPHAGES: NANOMATERIAL AND
MOLECULAR APPROACHES
MAY 2020
JOSEPH M. HARDIE
B.S., THE COLLEGE OF NEW JERSEY
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Michelle E. Farkas, Professor Vincent M. Rotello
Macrophages, phagocytic cells of the innate immune system, are the body’s first
line of defense against pathogens and are responsible for tissue maintenance. Macrophages
are capable of sensing and internalizing external stimuli, and in response change their
morphology and phenotype accordingly. Because macrophages are integral to immune
function and tissue maintenance, dysregulation of macrophage behavior is associated with
a range of diseases including infections, cancer, autoimmune disorders, atherosclerosis,
and more. Because of the implications of macrophage failure, there is interest in creating
new materials to manipulate macrophage behavior for a therapeutic effect. In this thesis, I
describe the application of several new nanomaterials and chemical methods for the
therapeutic manipulation of macrophages. Initially, I generated a gold nanoparticlestabilized nanocapsule (NPSC) for delivering siRNA directly to the cytosol of cells. After
demonstrating effective siRNA delivery in vitro, I utilized NPSCs to deliver TNF-α
targeted siRNA into macrophages in vivo to reduce over-inflammation in a LPS challenge
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model. In a related system, I worked with a gold nanoparticle-based nanocomposite
delivery system for delivery of engineered proteins. Specifically, this system was used to
deliver glutamate tagged Cas9 into macrophages to alter macrophage DNA. This system
was used to knockout SIRP-α in macrophages to increase macrophage killing of cancer
cells. I also chemically modified macrophage cell surfaces through biorthogonal reactions
to attach fluorescent molecules. Once modified, the natural tumor homing ability of
macrophages turned the modified macrophages into tumor imaging agents. I then again
took advantage of macrophage tumor homing ability by loading nanoparticle embedded
bioorthogonal catalysts, “nanozymes,” into macrophages for delivery to tumor sites. The
nanozymes activate pro-chemotherapeutics into active drugs that specifically kill
surrounding tumor cells. I also produced a mannose-functionalized macrophage-targeted
nanozyme to generate antibiotics to specifically kill macrophage-invading bacteria.
Additionally, I generated and characterized a small molecule TLR4 agonist to activate
macrophages into a pro-inflammatory state, with increased anti-cancer activity. Finally, I
utilized an array-based polymer sensor to detect macrophages in different activation states
in a high-throughput manner. In summary, this thesis provides evidence of the utility of
next generation chemical and nanomaterial tools in macrophage-based applications.

viii

TABLE OF CONTENTS
Page
ACKNOWLEDGEMENTS.................................................................................................v
ABSTRACT......................................................................................................................vii
LIST OF TABLES............................................................................................................xvi
LIST OF FIGURES.........................................................................................................xvii
CHAPTER
1. CREATING NOVEL MATERIALS FOR MACROPHAGE MODULATION...........1
1.1. Macrophage overview.............................................................................................1
1.1.1. The macrophage cell type...........................................................................1
1.1.2. Macrophage polarization............................................................................2
1.1.3. Disease implications...................................................................................3
1.2. Controlling macrophage behavior and phenotype..................................................4
1.2.1. Important macrophage functions................................................................4
1.2.2. Macrophage surface receptors....................................................................4
1.2.3. Macrophage phagocytosis..........................................................................5
1.2.4. Macrophage repolarization.........................................................................6
1.3. Chemical methods for macrophage manipulation..................................................7
1.3.1. Small molecule agonists/antagonists..........................................................7
1.3.2. Covalently linked cell surface conjugation................................................8
1.4. Nanomaterials for macrophage manipulation.........................................................9
1.4.1. General properties of nanomaterials...........................................................9
1.4.2. Inorganic particles....................................................................................10
1.4.3. Polymer materials.....................................................................................12
1.5 Dissertation overview............................................................................................13
1.6 References..............................................................................................................16
2. NANOPARTICLE-STABILIZED CAPSULES FOR SIRNA DELIVERY...............19
2.1. Simultaneous cytosolic delivery of a chemotherapeutic and siRNA using
nanoparticle-stabilized nanocapsules...........................................................................19
2.1.1. Introduction................................................................................................19
ix

2.1.2. Methods......................................................................................................24
2.1.2.1. General methods...........................................................................24
2.1.2.2. NPSC, drug and siRNA complexation..........................................24
2.1.2.3. Cell culture....................................................................................25
2.1.2.4. Fluorescently labeled siRNA and oil delivery..............................25
2.1.2.5. NPSC/siSurv delivery for the evaluation of survivin
expression..................................................................................................25
2.1.2.6. RNA extraction.............................................................................25
2.1.2.7. Real-time polymerase chain reaction (RT-PCR)..........................26
2.1.2.8. Serum stability gel electrophoresis assay.....................................26
2.1.2.9. Cytotoxicity of NPSC/siRNA complex........................................27
2.1.2.10. Apoptosis assay...........................................................................27
2.1.3. Results and discussion................................................................................28
2.1.4. Conclusion..................................................................................................34
2.1.5. References .................................................................................................34
2.2. Nanocapsule-mediated cytosolic siRNA delivery for anti-inflammatory
treatment......................................................................................................................36
2.2.1. Introduction................................................................................................36
2.2.2. Material and methods.................................................................................38
2.2.2.1. General..........................................................................................38
2.2.2.2. NPSC/siRNA preparation.............................................................38
2.2.2.3. Cytotoxicity of NPSC/siRNA complex........................................39
2.2.2.4. Fluorescently labeled siRNA delivery..........................................39
2.2.2.5. In vitro TNF-α knockdown...........................................................40
2.2.2.6. Animal care...................................................................................41
2.2.2.7. In vivo gene silencing....................................................................41
2.2.2.8. Real time polymerase chain reaction (RT-PCR) analysis.............42
2.2.2.9. ICP-MS sample preparation and conditions.................................42
2.2.3. Results and discussion................................................................................43
x

2.2.3.1. NPSCs deliver fluorescent siRNA to RAW 264.7
macrophages..............................................................................................43
2.2.3.2. RNAi mediated knockdown of TNF-α expression in vitro...........45
2.2.3.3. NPSC delivery of siRNA in vivo..................................................45
2.2.4. Conclusion..................................................................................................50
2.2.5. References..................................................................................................50
3. CRISPRED MACROPHAGES FOR CELL-BASED CANCER
IMMUNOTHERAPY…………………………………………………………...……….53
3.1. Introduction ...........................................................................................................53
3.2. Results and discussion ...........................................................................................55
3.2.1. Delivery of CRISPR-Cas9 protein and subsequent knockout of SIRP-α
gene…....................................................................................................................55
3.2.2. SIRP-α knockout RAW 264.7 macrophages promote phagocytosis of
cancer cells………………………………………………………...……………..58
3.3. Methods.................................................................................................................61
3.3.1. Engineering Cas9 ......................................................................................61
3.3.2. Expression and purification of Cas9E20....................................................62
3.3.3. sgRNA design and synthesis .....................................................................62
3.3.4. Nanoparticle synthesis and characterization..............................................63
3.3.5. Nanoassembly fabrication .........................................................................63
3.3.6. Cell culture ................................................................................................64
3.3.7. Delivery......................................................................................................64
3.3.8. Time lapse video imaging .........................................................................64
3.3.9. Indel analysis..............................................................................................65
3.3.10. Single cell isolation……..........................................................................65
3.3.11. Antibody staining and flow cytometry assay...........................................65
3.3.12. In vitro phagocytosis assay.......................................................................66
3.3.13. Image-based assessment of phagocytosis by flow cytometry……..........67
3.3.14. Experimental design of CRISPR-Cas9 mediated gene
editing...................................................................................................................67
xi

3.3.15. Analysis by IDEAS 6.1 image data analysis software…….....................68
3.4. Conclusion…........................................................................................................68
3.5. References….........................................................................................................68
4. SURFACE-MODIFIED MACROPHAGES FACILITATE TRACKING OF
BREAST CANCER-IMMUNE INTERACTIONS...........................................................71
4.1. Introduction............................................................................................................71
4.2. Results and discussion............................................................................................75
4.2.1. Modification of Macrophages to Install Fluorescent Molecules.................74
4.2.2. Macrophage Migration and Chemotaxis......................................................78
4.2.3. Macrophage Association with in Vitro Models of Breast Cancer...............82
4.2.4. Chemically Modified Macrophages Show Tumor Homing Capabilities
in a Mouse Model of Cancer..................................................................................84
4.3. Conclusion..............................................................................................................86
4.4. Methods..................................................................................................................87
4.4.1. Reagents and Cell Lines...............................................................................87
4.4.2. Biotin-(Strept)avidin Modification of Macrophages...................................87
4.4.3. Direct NHS-Ester Modification of Macrophages........................................88
4.4.4. Metabolic Labeling/Staudinger Ligation Modification of Macrophages....88
4.4.5. Wound Healing/Scratch Assay....................................................................89
4.4.6. Chemotaxis/Boyden Chamber Assay..........................................................89
4.4.7. Coculture Assays.........................................................................................90
4.4.8. Generation of in Vivo Tumor Models and Macrophage Biodistribution
Studies....................................................................................................................90
4.5. References.............................................................................................................91
5. MACROPHAGE-ENCAPSULATED BIOORTHOGONAL
NANOZYMES: TOOLS FOR TARGETED CANCER THERAPY................................95
5.1. Summary ............................................................................................................95
5.2. References ........................................................................................................104

xii

6. TARGETING OF INVADING PATHOGENIC BACTERIA USING
BIOORTHOGONAL NANOZYMES.............................................................................107
6.1. Introduction.......................................................................................................107
6.2. Results and discussion.......................................................................................109
6.2.1. Activation of pro-fluorophore inside of macrophages............................114
6.2.2. Selective killing of Salmonella in a pathogenic/non-pathogenic
bacterial coculture model..................................................................................116
6.3. Conclusion.........................................................................................................118
6.4. Methods.............................................................................................................118
6.4.1. Materials.................................................................................................118
6.4.2. Synthesis of mannose-decorated gold nanoparticles (AuNPs)...............118
6.4.3. Mass spectrometric characterization of ligands on AuNP monolayer....119
6.4.4. Zeta potential characterization of AuNP.................................................119
6.4.5. Catalyst encapsulation in AuNP monolayer to fabricate nanozyme
(NZ)...................................................................................................................120
6.4.6. DLS and TEM characterization of AuNP...............................................120
6.4.7. Quantification of catalyst per AuNP using ICP-MS characterization....120
6.4.8. Mammalian and bacterial cell culture.....................................................121
6.4.9. Cytotoxicity.............................................................................................121
6.4.10. Macrophage NZ uptake.........................................................................121
6.4.11. Intracellular pro-fluorophore activation................................................122
6.4.12. Salmonella killing assays......................................................................122
6.4.13. Bacterial coculture assays using transwell membrane………...……...123
6.5 References……………………………………………………………………….123
7. MACROPHAGE ACTIVATION BY A SUBSTITUTED
PYRIMIDO[5,4-b]INDOLE INCREASES ANTI-CANCER ACTIVITY.....................125
7.1. Introduction..........................................................................................................125
7.2. Material and Methods...........................................................................................128
xiii

7.2.1. Cell culture..................................................................................................129
7.2.2. Synthesis......................................................................................................129
7.2.3. RT-PCR preparation....................................................................................129
7.2.4. RNA extraction and cDNA conversion.......................................................130
7.2.5. Quantitative RT-PCR..................................................................................131
7.2.6. Phagocytosis assay with flow cytometry.....................................................132
7.2.7. Griess assay.................................................................................................133
7.2.8. Confocal microscopy...................................................................................133
7.2.9. ELISA..........................................................................................................134
7.3. Results..................................................................................................................135
7.3.1. Confocal Microscopy..................................................................................135
7.3.2. RT-PCR analysis.........................................................................................136
7.3.3. ELISA analysis............................................................................................138
7.3.4. Griess assay.................................................................................................138
7.3.5. Phagocytosis................................................................................................139
7.4. Discussion............................................................................................................141
7.5. Conclusion............................................................................................................143
7.6. References…........................................................................................................143
8. HIGH-CONTENT AND HIGH-THROUGHPUT IDENTIFICATION OF
MACROPHAGE POLARIZATION PHENOTYPES.....................................................146
8.1 Introduction ..........................................................................................................146
8.2 Results ..................................................................................................................150
8.2.1 Supramolecular Assembly of Sensor...........................................................150
8.2.2. Discrimination of M1 and M2 subtypes using RAW 264.7 cells...............154
8.2.3. Discrimination of M1 and M2 subtypes with primary macrophages..........158
8.2.4. Discrimination of macrophages exposed to conditioned
media from different cancer cells……………..………………………………....160
8.3. Discussion…….......................................................................................................162
8.4. Experimental methods……………...........................................................................165
xiv

8.4.1. Materials....................................................................................................165
8.4.2. PONI-C3-Guanidine polymer synthesis....................................................165
8.4.3. Green fluorescent protein expression ........................................................165
8.4.4. Transmission electron microscopy............................................................165
8.4.5. Fluorescent titration...................................................................................166
8.4.6. Binding affinity calculation.......................................................................166
8.4.7. Linear discriminant analysis......................................................................166
8.4.8. Unknown identification.............................................................................167
8.4.9. Cell culture.................................................................................................167
8.4.10. Macrophage polarization via activation agents........................................167
8.4.11. Macrophage polarization via cancer cell conditioned media……...........168
8.4.12. Sensing studies.........................................................................................168
8.4.13. RT-PCR preparation................................................................................169
8.4.14. RNA extraction and cDNA conversion...................................................169
8.4.15. Quantitative RT-PCR...............................................................................169
8.5. References...........................................................................................................170
9. CONCLUSION AND OUTLOOK…………………………………………...……...174
BIBLIOGRAPHY............................................................................................................176

xv

LIST OF TABLES
Table

Page

Table 5.1. Quantification of encapsulated catalysts in the 2 nm TTMA-AuNP…...........98
Table 6.1. ICP-MS determination of TPP catalyst concentration in Man-NZ................111
Table 8.1. Mechanisms and effects of in vitro macrophage polarization via different
cytokines..........................................................................................................................154

xvi

LIST OF FIGURES
Figure

Page

Figure 1.1. Illustration of the life cycle of tissue and circulating macrophages.................2
Figure 1.2. Macrophage polarization state and diseases affected by polarization state......4
Figure 1.3. Depiction of a macrophage phagocytosing an apoptotic cell and the pathways
involved………………………………………………………………….…………….......6
Figure 1.4. Different chemical methods for conjugating molecules directly to the
macrophage surface....……….............................................................................................9
Figure 1.5. Different surface functionalizations of gold particles result in different
interactions with biological environments…………………………….............................11
Figure 1.6. Example of a degradable polymer-drug micelle vehicle for specific drug
accumulation at a tumor site…………………………….…………….............................13
Figure 2.1. Schematic presentation of NPSC-mediated delivery of both siSurv and
tamoxifen for enhanced cancer therapy……………………………….............................22
Figure 2.2. A) Dynamic light scattering (DLS) measurements of size (number average)
of NPSC/drug (red line), NPSC/siRNA (blue line), and NPSC/siRNA/drug complexes
(black line). B) TEM images of NPSC/siRNA/drug
complexes..........................................................................................................................28
Figure 2.3. Dynamic light scattering (DLS) measurements of size (number average) of
NPSCs in 5 mM PB or 10% serum at various time points.…...........................................30
Figure 2.4. Agarose gel electrophoresis assay of NPSC serum stability..........................30
Figure 2.5. Confocal microscopy images of MCF-7 cells following treatment with
NPSC/FAM-siRNA/Nile red complex.……….................................................................31
Figure 2.6. RT-PCR of normalized survivin mRNA levels in MCF7 cells 48 h after
treatment…..................................................................................................................…. 31
Figure 2.7. Alamar blue evaluation of MCF7 cell viability..............................................33
Figure 2.8 Confocal microscopy images of MCF-7 cells after 48 hours treatment with
NPSC/Surv/TM (siSurv: 35 nM, and TM: 2.3 μM), NPSC/Scr (siScr: 35 nM),
NPSC/Surv (siSurv: 35 nM), and NPSC/TM (TM: 2.3 μM) complex..............................33
Figure 2.9. Schematic of nanoparticle-stabilized nanocapsule/siRNA in vivo TNF-α
silencing in lipopolysaccharide-induced inflammation.....................................................37
Figure 2.10. In vitro siRNA delivery into RAW 264.7 cells..…………..........................44
Figure 2.11. CLSM imaging of NPSC delivery into RAW 264.7 cells treated with
chloropromazine (CPM), wortmannin, and methyl-cyclo-β-dextrin (MCβD)..................45
xvii

Figure 2.12. In vivo distribution and gene silencing of NPSC/siRNA…....................… 47
Figure 2.13. Average mouse weight during treatment with PBS, NPSC/si_Scr, and
NPSC/si_GAPDH…..........................................................................................................48
Figure 2.14. Clinical chemistry parameters......................................................................49
Figure 2.15. No significant changes of serum a) TNF-α, or b) IFN-γ levels following the
injection of PBS, NPSC/si_Scr, and NPSC/si_GAPDH to BALB/c mouse.....................49
Figure 2.16. In vivo delivery of NPSC/si_TNF-α decreased serum TNF-α production
from LPS-induced inflammation. .....................................................................................50
Figure 3.1. Prevention of cancer cell phagocytosis by CD47:SIRP-α interaction............55
Figure 3.2. Engineering Cas9 by introducing an E20-tag at the N-terminus and nuclear
localization signal (NLS) at the C-terminus......................................................................58
Figure 3.3. (a) Flow cytometry plots of PE anti-mouse F4/80 antibody-stained and
unstained RAW 264.7 cells, PE anti-mouse F4/80 antibody-stained and unstained ()SIRP-α RAW 264.7cells, GFP+/GFP- U2OS cells, coculture of PE anti-mouse F4/80
antibody-stained RAW 264.7 cells and U2OSGFP+ cells and coculture of PE anti-mouse
F4/80 antibody-stained (-)SIRP-α-RAW 264.7 cells and U2OS-GFP+ cells....................60
Figure 3.4. Assessment of phagocytosis of U2OS-GFP+ cells by (a) RAW264.7 cells and
(b) (-)SIRP-α-RAW264.7 cells...…………………………………………………….......61
Figure 4.1. Macrophage contributions to cancer and its metastasis............………..........72
Figure 4.2. Detailed scheme of three cell surface modification methods including stepby-step reaction conditions................................................................................................74
Figure 4.3. Approaches for chemical modification of macrophages......…………..........76
Figure 4.4. Cellular fluorescence over time......................................................................78
Figure 4.5. Specific cellular labeling in the presence of both linkers and dyes, which may
be applied to different macrophage types..........................................................................79
Figure 4.6. Macrophage polarization following chemical modification......…………….80
Figure 4.7. Macrophage phagocytosis following chemical modification.........................80
Figure 4.8. Motility and chemotaxis retained by functionalized macrophages.…….......81
Figure 4.9. Similar behavior of modified suspended macrophages to one another and
non-labeled cells exposed to CSF-1...............…...........…...…................………..............83
Figure 4.10. Modified macrophage homing and interaction with cancer cells.................84
Figure 4.11. Macrophage biodistribution in an immune-competent mouse model of
breast cancer...................…….............…..................……..........................……...............85

xviii

Figure 5.1. Schematic representation of macrophage mediated delivery of bioorthogonal
nanozymes (NZs) for prodrug activation selectively at tumor cells..................................97
Figure 5.2. MALDI-MS for TTMA AuNPs.....................................................................98
Figure 5.3. DLS measurements of AuNPs and NZs, indicating no aggregation before or
after catalyst encapsulation................................................................................................98
Figure 5.4. Cellular uptake of a) Au (ng/well) and b) Pd (ng/well) in macrophages (RAW
264.7 at 20,000 cells/well) after 24 h, 48 h and 72 h incubation with NZs with increasing
concentration......................................................................................................................99
Figure 5.5. Confocal images of activation of profluorophore by RAW_NZ after 24, 48
and 72 h after preparation of RAW_NZ............................................................................99
Figure 5.6. Chemotaxis capabilities are retained by RAW_NZ as determined by
transwell membrane assay...............................................................................................100
Figure 5.7. a) Pro-5FU activation by RAW_NZ.............................................................102
Figure 5.8. Viability of cells treated with pro-5FU and 5FU at various concentrations as
determined by Alamar blue assay....................................................................................103
Figure 5.9. Viability of RAW 264.7 cells treated with pro-5FU and NZ as determined by
Alamar Blue assay...........................................................................................................103
Figure 5.10. Comparison study of viability of HeLa cells after activating pro-5FU of
different concentrations by free nanozymes (NZ) vs by RAW_NZ as determined by Alamar
blue assay.........................................................................................................................104
Figure 6.1. Schematic of selective uptake of decorated nanozyme leading to
macrophage-specific antibiotic generation..…................................................................109
Figure 6.2. Zeta potential of NPs, pre- and post- functionalization with mannose........110
Figure 6.3. DLS number data of Man-NZ……..............................................................110
Figure 6.4. TEM image of Man-NZ…….…...................................................................111
Figure 6.5. Increase in fluorescence following activation of 20 μM pro-resorufin into
resorufin over time by 50 nM Man-NZ with 5 mM glutathione as a cofactor................112
Figure 6.6. ICP-MS analysis of gold accumulation in RAW 264.7 macrophages and
HepG2 hepatocytes following incubation with of Man-NZ............................................113
Figure 6.7. Cytotoxicity of Man-NZ on RAW 264.7 macrophages...............................113
Figure 6.8. Confocal images of RAW 264.7 macrophages incubated with pro-resorufin
and/or Man-NZ................................................................................................................114

xix

Figure 6.9. Cytotoxicity of pro-ciprofloxacin and ciprofloxacin on RAW 264.7
macrophages....................................................................................................................116
Figure 6.10. a.) Salmonella counts decrease substantially after 24 hr treatment with prociprofloxacin and Man-NZ in a Salmonella culture model as determined by colony
counting............................................................................................................................116
Figure 6.11. a.) Schematic of transwell bacterial coculture assay. Salmonella infected
macrophages are cultured adjacent to non-toxic Bio-K+ cultures; pro-ciprofloxacin is then
added to the top of the well.........................……………………………….....................117
Figure 7.1. Illustration of pyrimido[5,4-b]indole (PBI1)-mediated macrophage
activation..........................................................................................................................128
Figure 7.2. Effects of PBI1 on cell morphology and M1 marker expression.................135
Figure 7.3. PBI1 Synthesis Scheme................................................................................136
Figure 7.4. RT-PCR analysis of M1 related genes in primary, immortalized macrophages
(PIMs) following PBI1 treatment....................................................................................137
Figure 7.5. Toxicity of PBI1 as evaluated by Alamar Blue Ass Toxicity of PBI1 as
evaluated by Alamar Blue Assay RAW 264.7 macrophages were treated with increasing
concentrations of PBI1; subsequent cellular viability was assessed using Alamar blue
reagent..............................................................................................................................137
Figure 7.6. ELISA analysis of IL-6 secretion following treatment RAW 264.7
macrophages were treated with increasing amounts of PBI; subsequent cytokine secretion
was assessed via ELISA...................................................................................................138
Figure 7.7. Supernatant NO2- levels are increased following LPS or PBI1 treatment as
measured by Griess assay.………………………………………………………….…..140
Figure 7.8. Effects of PBI1 on phagocytosis of Daudi (B-cell lymphoma) cells...........140
Figure 7.9. Representative flow cytometry scatter plots for analysis of macrophage
phagocytosis.....................................................................................................................141
Figure 8.1. Schematic illustration of phenotyping macrophage activation states using
array-based sensor............................................................................................................150
Figure 8.2. Optical properties of PONI-C3-Gu-Py..........................................................151
Figure 8.3. Fluorescence titrations and quenching………………………………….....152
Figure 8.4. Hydrodynamic size of PONI-C3-Gu-Py polymer (a) and polymer-GFP
assembly (b) in 10mM HEPEs buffer..............................................................................153
Figure 8.5. TEM images of PONI-C3-Gu-Py polymer (a) and polymer-EGFP assembly
(b) in 10 mM HEPEs buffer.............................................................................................153
Figure 8.6. Macrophage activation confirmed by RT-PCR............................................155
xx

Figure 8.7. RT-PCR quantification of M2 state in IL-10 activated RAW 264.7
macrophages....................................................................................................................155
Figure 8.8. Discrimination of stimulated RAW 264.7 m Discrimination of RAW 264.7
macrophages activated by M1 or M2 subtype stimuli using sensor complexes..............157
Figure 8.9. RT-PCR quantification of M1-associated genes in primary bone marrowderived macrophages, according to treatment group.......................................................159
Figure 8.10. RT-PCR quantification of M2 genes in primary bone marrow-derived
macrophages, according to treatment group....................................................................159
Figure 8.11. Discrimination of M1 and M2 subtypes of bone marrow-derived
macrophages..……..........................................................................................................160
Figure 8.12. RT-PCR quantification macrophages exposed to conditioned media from
different cancer cells........................................................................................................162
Figure 8.13. Discrimination of macrophage cells cultured under exposure to conditioned
media from different cancer cell types for 48 h.………..................................................162

xxi

CHAPTER 1
CREATING NOVEL MATERIALS FOR MACROPHAGE MODULATION
1.1 Macrophage overview
1.1.1 The macrophage cell type
Macrophages, cells of the innate immune system, are one of the most crucial cell
types for mammalian organismal health. Macrophages are plastic, stimuli-responsive cells
that play a wide range of roles including, pathogen detection/removal, tissue repair, red
blood cycle recycling and lipid regulation, among others. 1 In the last few decades, there
has been significant interest in not only better understanding the relationship between
macrophage states and health outcomes, but in developing tools to interact with
macrophages to change those outcomes.
Macrophages were first discovered by Ilya Metchnikoff in 1884, which resulted in
his Nobel prize in Physiology or Medicine in 1908.1 Macrophages are phagocytic (capable
of engulfing other cells) cells of leukocyte lineage.1 Macrophages are one of primary cell
types utilized by the innate immune system, which is the portion of the immune system
mobilized first in response to external challenges.2 Generally, macrophages are divided
into two separate categories, circulating macrophages and tissue resident macrophages. 3
Circulating macrophages are derived from monocytes produced by bone marrow and
circulate throughout the body via the bloodstream (Figure 1.1). 3 These macrophages are
capable of accumulating at many different sites of the body when required and are often
associated with blood recycling and injury response. 3 Tissue-resident macrophages are
derived from neonatal development and primarily remain in the specific organ where they
originated.3 Tissue-resident macrophages are found in almost all organs including the heart,
brain, liver, spleen, skin, and lungs, among others.
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3

These macrophages are typically

slightly different from one another, so that each macrophage is specialized to perform
functions related to the organ in which it resides.3 Naturally, tissue-resident macrophages
mostly respond only to challenges or stimuli that are present in their home organ. Because
of the ubiquitous nature of macrophages throughout the body, they are in position to
respond to many different circumstances.

Figure 1.1. Illustration of the life cycle of tissue and circulating macrophages. Adapted
from reference 1.
1.1.2. Macrophage polarization
Macrophages are unusual as a cell type because, unlike many others that are
specialized to perform a particular role, they are capable of performing a large number of
diverse functions. The key to this high level of diversity is a process called macrophage
polarization,4 where macrophages respond to external signals to initiate downstream
effects that change cell phenotype and function.4 Macrophage express a range of cell
surface receptors that are evolutionarily conserved to recognize and bind to molecules and
proteins that are related to challenges associated with macrophage stimuli, such as the
presence of bacteria.4 Polarization allows macrophages to develop functionality that is
optimal to respond to the environment or stimulus the cell has detected. Traditionally,
polarization has been demarcated into two distinct states, M1 and M2. 5 The M1 state is
considered to be the “pro-inflammatory” state and is associated primarily with bacterial
response, immune activation, and pathogen removal. 6 The M2 state covers a range of
2

possible stimuli, but is generally associated with wound repair and an “anti-inflammatory”
response.7 Recently, it has become clear that this categorization is an oversimplication. In
reality, a spectrum of activation states exist within macrophages, and there are more
possible roles for macrophages to fulfill outside of the general pro/anti-inflammatory
states.7 However, the M1/M2 terminology is still frequently found in the literature and is
useful as shorthand for describing the general roles and characteristics of an activated
macrophage in a particular context. Polarization is extremely important in crucial
macrophage roles such as pathogen response and tissue repair, which rely on polarization
to resolve correctly.8 On this account, macrophage polarization is also an area of great
interest for research toward manipulating macrophage behavior.
1.1.3. Disease implications
Due to the vital roles that macrophages play in immune responses and homeostasis,
macrophage dysregulation can result in serious health issues. This is reflected in the
number of illnesses that are caused by or partly attributed to failures in macrophage
function. Diseases such as cancer,9 infection,10 diabetes,11 and atherosclerosis12 are among
those involving incorrectly functioning macrophages (Figure 1.2). Interestingly, these
disorders are generally not caused by a lack of macrophage activity, but rather macrophage
overactivation or presentation of characteristics that actively contribute to the disease
environment.13 Because of this trend, the ability to control macrophage behavior becomes
intensely attractive as one would expect that altering the aberrant macrophage activity
towards the correct behavior would have significant therapeutic benefits.
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Figure 1.2. Macrophage polarization state and common diseases affected by polarization
state. Adapted from reference 4.
1.2. Controlling macrophage behavior and phenotype
1.2.1. Important macrophage functions
In order to perform their intended functions, macrophages have developed a unique
biological toolset that can be utilized in different applications. While each of these
functions have a specific purpose, each function generally acts as a one “link” in a chain
of processes. Their combination forms a complete immune response from the
macrophages, which may influence the broader response from the rest of immune system. 2
Understanding some of the key capabilities of macrophages is crucial in understanding
their role in organismal health.
1.2.2. Macrophage surface receptors
Macrophages have evolved a wide range of surface receptors that are designed to
recognize a range of external signals, both familiar and foreign, as a means of determining
the state of their environment.14 These receptors have two main functions, to capture
antigens/pathogens for further processing and to initiate downstream pathways related to
the antigen captured.15 Commonly utilized macrophage surface receptors include; Toll-like
receptor 4 (TLR4) for lipopolysaccharide (LPS), 16 which is found on most bacterial cell
surfaces, mannose receptor or CD206 for mannose,17 which is found on bacteria, IFN-γ
4

receptor (IFN-γR) for IFN-γ, which is a common inflammatory cytokine 18, and IL-4
receptor (IL-4R) for IL-4, which is a common anti-inflammatory cytokine. 19 By expressing
a range of receptors on their cell surfaces, macrophages can easily recognize their
environment by coming into contact and binding with antigens present. Macrophages can
also detect antigen/cytokine gradients through surface receptors and respond by moving in
the direction of the gradient.20 This allows the macrophages to relocate to the origin of
immune challenge. This ability to accumulate at sites of disease, via chemokine induced
migration, has been capitalized upon to fashion macrophages into targeted delivery
vehicles for therapeutic agents.21,22 Once there, further activation of the surface receptors
initiates the desired response from the accumulated macrophages.
1.2.3. Macrophage phagocytosis
The process of phagocytosis, in which macrophages entirely engulf bound entities,
is frequently utilized by macrophages in various contexts. In phagocytosis, macrophages
utilize actin polymerization to greatly stretch and expand their cell membranes. 23 This
allows them to surround and engulf entities that range from nanometer size particles to
micrometer size cells that are larger than the macrophages themselves (Figure 1.3). 23 Once
engulfed, macrophages frequently generate proteins and reactive oxygen species to break
down the entrapped entity.23 Once broken down, the components of the former entity act
as antigens and can be presented to other cells of the immune system to drive a larger
immune response.23 Phagocytosis is extremely important for pathogen removal and blood
homeostasis.23 Phagocytosis of invading bacteria is one of the body’s first defenses against
infection, by removing and killing many of the invading bacteria and allowing
macrophages to start activation of the adaptive immune system response. 23 Phagocytosis is
also how dying red blood cells (RBCs) are removed from the blood-stream. 23 Once the
5

RBCs are broken down, the components are recycled into the generation of new RBCs.
Phagocytosis is necessary for proper disease response, so many pathogenic entities will
develop methods for circumventing or stopping phagocytosis. 24 Proper utilization of
phagocytosis by macrophages is important for overall health of the host organism.

Figure 1.3. Depiction of a macrophage phagocytosing an apoptotic cell and the pathways
involved. Adapted from reference 18.
1.2.4. Macrophage repolarization
After surface receptor recognition and/or phagocytosis of antigens, downstream
activation of conserved pathways results in macrophage polarization. Macrophage
polarization is marked by profound changes in cellular morphology and protein expression
patterns. Macrophage polarization state is extremely important for macrophage function
and an incorrect state in the wrong context often contributes significantly to disease.
Fortunately, polarization states are not only generally transient, but it is possible to force
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macrophages to change polarization state with the correct stimulation. 25 This is known as
“repolarization,” which not only happens naturally in the body to resolve immune response,
but can be artificially induced.25 Traditional approaches towards inducing repolarization
clinically involved dosing purified cytokines or natural product small molecules believed
to induce or prevent immune reactions. However, these methods are generally ineffective
due to broad, unspecific toxicity or a lack of bioavailability. 26,27 Because of the
implications, repolarization is a common avenue explored for creating next generation
therapies for a variety of diseases.25
1.3.

Chemical methods for macrophage manipulation

1.3.1. Small molecule agonists/antagonists
It was realized decades ago that macrophages are important for many diseases, and
thus pharmaceutical companies have attempted to develop drugs targeting macrophages.
The most traditional way of developing therapeutics is through creating small molecule
agonist/antagonists. With these drugs, a small molecule is designed to bind to a specific
protein target of therapeutic interest. For agonists, the activity of the protein is increased,
while for antagonists the activity is decreased. The general strategy is to activate proteins
that diminish diseases state, or to deactivate proteins that contribute to it. For macrophage
therapies, traditional strategies have focused on generating small molecules that target the
external surface receptors, such the TLR series or other cytokine-related receptors. 28 This
is due to the fact that many diseases are related to mis-activation or mis-signaling of
macrophages and those receptors are the origin site of activation signals. Additionally,
since they are on the exterior surface, these receptors are more accessible, as they are not
enclosed by the cell membrane. One of the most successful examples of a small molecule
drug targeting macrophages is imiquimod, which is an FDA-approved TLR7 agonist for
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topical treatment of genital warts and basal carcinoma.29 However, there are some serious
limitations to this strategy. For macrophage-specific drugs, solubility is a major issue. 30
Many of the antigens that the macrophage specific receptors bind to are highly
hydrophobic, such as LPS. Hence, many of the drugs designed to bind to the same receptors
are also hydrophobic. This results in reduced solubility, which limits the application in in
vivo systems. For example, as one of the only macrophage activating drugs, imiquimod is
only approved for topical skin use partially due to its low solubility in circulation. 31
Another problem with most small molecule drugs is the lack of targeting capability. While
the drugs are designed to be specific for a particular receptor, the molecules are not tissue
or macrophage-type specific. This is problematic in two ways: the drug does not
accumulate at the site of disease, which results in reduced therapeutic activity, and offtarget drug effects result in toxicity. The second problem is particularly important as
allowing immune stimulating drugs to freely interact with the immune system at large is
extremely dangerous. This unintentional activation can lead to conditions such as cytokine
storms and autoimmune disorders, which result in severe illnesses or even death. 32 Because
of these downsides, there has been limited success in using traditional small molecule drugs
for macrophage modulation.
1.3.2. Covalently linked cell surface conjugation
In addition to traditional direct usage, there are alternative therapeutic strategies for
utilizing small molecules with macrophages. A relatively new strategy involves covalently
binding small molecules to the surface of macrophages. 33 This approach takes advantage
of the innate homing ability of macrophages to bring molecules of interest to sites of
disease.33 As stated previously, macrophages have the ability to respond to chemokine
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gradients and accumulate at sites of diseases, such as tumor and infection sites. 33 By stably
attaching molecules to the surface of macrophages, the cells will carry the molecule to the
site of accumulation (Figure 1.4). Attaching therapeutic molecules results in a targeted
therapy, which is lacking in traditional drug dosing. Additionally, attaching imaging agents
to macrophages has been utilized to created specific imaging tools for sites of diseases
recognized by macrophages.33 Currently, no approved strategies utilizing covalently bound
macrophages exist, but there is growing interest in the strategy.

Figure 1.4. Different chemical methods for conjugating molecules directly to the
macrophage surface. Adapted from reference 33.

1.4.
Nanomaterials for macrophage manipulation
1.4.1. General properties of nanomaterials
The field of nanomaterials, those 1-1000 nanometers in size, has been steadily
growing since the late 1980’s.34 Since then, an incredible diversity of nanomaterials has
been produced via enormous advances in fabrication. Nanoparticles with various cores
have been made, including gold,35 silver,36 silica,37 carbon,38 iron oxide,39 and others. They
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have also been made in a variety of shapes including spheres, stars, flowers, rods, and
others.39 Combining the excellent control over nanoparticle size and morphology with the
ability to functionalize their surfaces with various organic molecules results in
nanomaterials with useful physical and chemical properties. This has led to nanoparticles
being utilized in industries as far ranging as construction, automotive, and cosmetic. 40,41,42
Due to this controllable and high level of function, there has been considerable interest in
using nanomaterial as “nanomedicines” for next generation disease therapy.
1.4.2. Inorganic particles
Inorganic nanomaterials, consisting of an inorganic core, have unique physical
properties that make them useful for a range of biological applications. Nanomaterials are
similar in size to many biological entities of interest including proteins, organelles, and
certain DNA/RNA structures. This similarity in size allows for the creation of
nanomaterials designed to optimally interact with or mimic these biological structures for
therapeutic use.43 The high surface to volume ratio gives ample surface area for the
nanoparticle to be functionalized and interact with biological entities of interest. 43
Functionalizing the surface with charged molecules creates a highly charged particle and
results in multivalent interactions, as the closely spaced charged headgroups work together
in an additive way when interacting with other charged species. 43 This can result in strong
repulsive or attractive interactions, which can be used to bind biological entities or to
assemble nanoparticles into larger structures.43 These properties are unique to nanometersized particles and are difficult to replicate with small molecules. 43
In addition to the general properties of nanoparticles, the inorganic core of different
inorganic nanoparticles often adds a considerable depth of function to the nanomaterial.
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Common inorganic nanoparticles for biological applications include gold, silver, and iron
oxide. Iron oxide and silver are frequently used for specific applications on account of their
magnetic and antimicrobial properties, respectively. 35,38 One of the most common materials
for biological applications is gold (Figure 1.5). Gold nanoparticles have several properties
that are attractive for biological use. Gold forms stable thiol bonds, which make it easier to
functionalize with a range of organic molecules as long as they contain thiol groups. 43 Gold
is considered bioinert, meaning that it does not normally react with biological entities,
making it relatively non-toxic.43 Gold nanoparticles also exhibit optical properties through
surface plasmon resonance, allowing them to absorb light, quench fluorescence, and
produce heat, which has multiple anti-tumor cell and imaging applications. 43,44 Finally,
gold is not typically found in biological environments, which makes it easy to determine
particle biodistribution of gold-based materials using simple analytical chemistry
techniques.45 The high potential of inorganic nanoparticles is demonstrated in the
thousands of publications detailing their usage as nanomedicines. However, currently there
is little use of inorganic nanoparticles in a clinical setting. Difficulties in translation are
generally on account of lack of understanding of biological fate, and lack of reproducibility
and standardization in reported inorganic nanomedicine vehicles. 46 Better understanding
and methods to meet these challenges will open the door to an array of new therapies.

Figure 1.5. Different surface functionalizations of gold particles result in different
interactions with biological environments. Adapted from reference 43.
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1.4.3. Polymer materials
In addition to inorganic nanoparticles, there is significant interest in creating
polymer-based medicines. Polymer materials have a long history of use in manufacturing
for consumer and industrial products.47 Modern polymer synthetic methods make it
possible to create polymers with a high level of control in terms of polymer length,
monomer incorporation ratio, and final material size. Incorporation of monomers with
significantly different chemistries allows for a polymer material with a range of capabilities
that potentially include fluorescence, cytotoxicity, charge, hydrophobic pockets, and
others.48 Unlike inorganic particles, polymers can be soft and deformable, which allows
for a range of dynamic interactions with biological entities (Figure 1.6).49 This flexibility
also allows polymers to encapsulate therapeutic entities, then release them under specific
conditions.50 Additionally, the synthesis of polymers is easier to scale for manufacturing
than comparable inorganic nanoparticles, which makes the translation into real world
technologies more feasible. However, many polymer systems are plagued by off-target
toxicity and stability issues.51 To an extent, polymers struggle with the same limitations as
small molecule drugs in that polymer materials frequently lack the specialized physical
properties of inorganic nanoparticle cores: it is more difficult to determine biodistribution
of materials that primarily consist of common organic elements.
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Figure 1.6. Example of a degradable polymer-drug micelle vehicle for specific drug
accumulation at a tumor site. Adapted from reference 49.
1.5 Dissertation overview
With the unmet need in macrophage modulation, the array of functionality provided
by nanomaterials and novel chemical methods paves the way for a new generation of
nanomedicines. In this thesis, I describe the synthesis and application of numerous
chemical and nanomaterial strategies that interact with macrophages to alter their behavior
in a therapeutic manner.
A relatively new class of therapeutics that has recently garnered significant
academic and clinical interest is short interfering RNA (siRNA). siRNA, a short double
stranded sequence of RNA, temporarily knocks down the expression of a particular protein
in a specific and non-toxic manner. As a therapeutic, siRNA has the capability to efficiently
knockdown nearly any disease related protein, including macrophage-related ones. The
main limiting factor in its therapeutic potential is that siRNA needs to be in the cytosol of
the targeted cell to be active, and siRNA cannot cross cell membranes independently. In
13

Chapter 2, I describe the synthesis and application of a gold nanoparticle-stabilized
nanocapsule vehicle for siRNA delivery. This cationic self-asssembled vehicle is capable
of delivering siRNA directly to the cytosol of cells, without being limited by endocytotic
entrapment. With the vehicle, siRNA targeting the common inflammatory cytokine TNFα was delivered to macrophages in vivo as a treatment for acute inflammatory disease.
Similarly to siRNA, CRISPR-Cas9 systems also represent an exciting new class of
therapeutics. The CRISPR complex has the capability to permanently edit the genome of
the targeted cell to which it has been introduced. This has immense therapeutic
possibilities: disease-promoting genes can be deleted from afflicted cells or genetic errors
that drive disease can be corrected. However, as with siRNA, effective cytosolic delivery
is necessary for activity and the protein complex cannot enter alone. In Chapter 3, I describe
a gold nanocomposite system for delivering active Cas9 complexes into macrophages to
improve their ability to remove immunoevasive cancer cells. Specifically, the introduced
Cas9 edited out the SIRP-α surface receptor on macrophages, which interacts with cancer
cells over-expressing CD47, stoping phagocytosis from occurring and preventing
macrophages from removing the tumor cell. The CRISPR-based editing of macrophages
results in a next generation therapy for tumor elimination.
Macrophages’ tumor cell killing ability is complemented by their ability to home
to and accumulate at tumor sites. In Chapter 4, I took advantage of this homing ability to
create tumor imaging agents by stably conjugating fluorescent dyes to the surfaces of
macrophages. Multiple chemical methods were utilized to decorate the cells with
fluorophores, which then demonstrated accumulation in an in vivo model. Direct loading
of therapeutic agents into macrophages can also be utilized for targeted therapy. In Chapter
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5, I utilize macrophages as targeted delivery vehicles for nanoparticle-based catalytic
“nanozyme” agents. This strategy utilizes a common tactic, pro-drug activation, for
reducing the broad toxicity of chemotherapeutics. In this approach, a blocking group is
added to an active drug molecule with a labile linker to create a molecule with reduced
activity, a “pro-drug.” This pro-drug is then deprotected by a catalyst at the site of interest
to yield the active molecule. This targeted activation limits activity to the disease site,
limiting off-target effects that cause toxicity. For this project, pro-chemotherapeutics are
activated by nanoparticles carrying hydrophobic metal catalysts, materials known as
“nanozymes.” These nanozymes are loaded into macrophages, which accumulate at tumor
sites, causing targeted drug activation and therapy.
The controllable nature of activation and tunable surface chemistry of nanozymes
provides an avenue for targeted therapy of multiple diseases. In Chapter 6, nanozymes
targeted for macrophage uptake via mannose decoration are utilized to kill intracellular
pathogenic bacteria. Certain bacteria, such as Salmonella tyhphimurium, require
macrophage internalization to survive in and infect a host. By utilizing nanozymes that are
specifically internalized by macrophages, pro-antibiotics are activated at the exact site of
infection, resulting in a highly specific and effective therapy.
Aside from targeting therapeutic agents towards macrophages, creating agents to
specifically modify macrophage behavior also has significant therapeutic benefits. In
Chapter 7, I synthesized and evaluated the anti-cancer effects of a new small molecule
TLR4 agonist, referred to as PBI1. Macrophages treated with PBI1 exhibit characteristics
of classical M1 inflammatory polarization state, even if previously polarized to an M2 antiinflammatory phenotype. In the immune-activating state, macrophages demonstrated
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increased ability to phagocytose tumor cells and produce cytotoxic agents that would be
invaluable in eliminating immunoevasive cancers.
Macrophage polarization state is extremely important in determining the effects of
agents or particular biological contexts. However, the current state of the art for
determining polarization state of macrophages are slow, tedious, and expensive
biochemical methods that often yield conflicting results. In Chapter 8, I describe the
application of a PONI-C3-guanidine polymer-GFP sensor array complex for rapid highthroughput detection of macrophage polarization state. With this sensor array, I was able
to successfully discriminate macrophages in over 9 unique activation states using multiple
macrophage types in a matter of minutes via a simple multiwell plate reader assay with
over 90% accuracy. The ability to rapidly and easily identify macrophage activation state
would be a major benefit to both academic and clinical applications.
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CHAPTER 2
NANOPARTICLE-STABILIZED CAPSULES FOR SIRNA DELIVERY
Reprinted (adapted) with permission from “Hardie, J.; Jiang, Y.; Tetrault, E. R.; Ghazi, P.
C.; Tonga, G. T.; Farkas, M. E.; Rotello, V. M. Nanotech. 2016, 27, 1-6.” Copyright (2016)
IOPscience and “Jiang, Y.; Hardie, J.; Liu, Y.; Ray, M.; Luo, X.; Das, R.; Landis, R. F.;
Farkas, M. E.; Rotello, V. M. J. Contr. Rel. 2018, 283, 234-240.” Copyright (2018)
Elsevier

2.1. Simultaneous cytosolic delivery of a chemotherapeutic and siRNA using
nanoparticle-stabilized nanocapsules
2.1.1. Introduction
Breast cancer is the most common type of cancer affecting women worldwide;
approximately 1 in 8 women will develop invasive breast cancer at some point during their
lifetime.1 Traditional therapies for breast cancer include chemo- and radio-therapies—
treatments that often lose effectiveness over time and have substantial off-target effects.
There has been a significant drive in research to discover innovative methods for treating
breast cancer in safer, more robust and successful ways.
Over the past decade there has been a considerable effort to capitalize on the
potential of small interfering RNA (siRNA) to act as an anti-cancer therapy. 2–4 siRNA can
be introduced into cells to induce the endogenous RNA interference (RNAi) mechanism,
by which the mRNA of specific proteins is degraded, resulting in the corresponding
knockdown.5 By introducing siRNA targeted at the messenger RNA (mRNA) of the
proteins that promote cancer survival and expansion, the progression of the cancer may be
inhibited or even reversed outright.6
Due to the high specificity and low toxicity of siRNA, there have been numerous
investigations toward its use as an alternative to traditional cancer treatments. 7–10 Because
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siRNA is both large and strongly negatively charged, a delivery platform is required to
introduce exogenous siRNA into cells for induced RNAi. 11 Many different vehicles have
been synthesized for this purpose; however, the majority of these rely on endocytosis to
enter cells, and therefore require an endosomal escape strategy for siRNA to reach the
cytoplasm, where RNAi occurs.2–4 Without endosomal escape, the siRNA remains trapped,
decreasing agent efficacy. There are several different strategies that have been developed
for the release, including the proton sponge effect, endosome pore formation, and photoactivated endosome disruption.12 While these methods differ in their specific mechanisms,
they typically involve the rupture of the endosomal membrane caused by a chemical or
physical force. However, the escape efficiency of the delivered cargo is often poor,
resulting in an inevitable decrease in potency for vehicles relying on endocytosis.
Additionally, strategies for endosomal escape often show undesirable, non-specific cellular
toxicity.
Nanoparticle-stabilized capsules (NPSCs) provide a potential solution to the issue
of the endosomal sequestration of siRNA.25 NPSCs consist of a linoleic acid oil core coated
in arginine-functionalized gold nanoparticles (Arg-AuNP) that are electrostatically
associated with negatively charged biomolecules such as siRNA (Figure 2.1). Instead of
relying on endocytosis to enter cells, NPSCs use an entirely different mechanism,
circumventing endosomal entrapment.25 Evidence suggests that the linoleic acid oil core of
the NPSC causes the vehicle to utilize a cholesterol-dependent ‘membrane fusion’
mechanism: the oil core fuses with the lipid portion of the cell membrane upon contact,
resulting in the direct entry of the associated cargoes into the cytosol of the treated cells. 25
By entering the cells via this alternative mechanism, NPSCs avoid the need to employ a
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means for endosomal escape, decreasing dosages and giving them enhanced promise as
efficient, non-toxic co-delivery vehicles.
Building on the capabilities of siRNA, therapies have been designed that combine
the targeted knockdown capabilities of siRNA with the more broadly cytotoxic power of
small molecule drugs to create a ‘1-2 punch.’2 A variety of platforms have been developed
for the simultaneous delivery of siRNA and drugs, including polymers, 13 liposomes,14 and
mesoporous silica nanoparticles.15 In general, these nanoparticles encapsulate the siRNA
via electrostatic interactions, with anticancer drugs loaded by either non-covalent
encapsulation or covalent conjugation.16 These co-delivery strategies have resulted in
improved cancer therapies by countering biological compensation and by accessing
multiple context-specific targets.
While co-delivery vehicles have shown promise, they not only face all of the
challenges that are encountered by individual siRNA or small-molecule drug delivery, but
also other unique issues.17–22
The syntheses of vehicles that can tolerate both aqueous and hydrophobic cargoes
can be cumbersome and unwieldy.21 Furthermore, endocytosis remains the primary method
of uptake for these vehicles, which results in the endosomal entrapment of both cargoes,
reducing the total concentration of the successfully delivered therapeutic. 23 Hydrophobic
small molecule drugs pose an additional challenge since they are not compatible with the
aqueous environment of the body, and exhibit unfavorable pharmacokinetic and
pharmacodynamic features.21 Because of their hydrophobicity, these molecules have
retention and excretion characteristics that are significantly different from those of aqueous
molecules. The challenging pharmacokinetics of these drugs also present an issue for co21

delivery, as vehicle modifications meeting the requirements for hydrophobic drug
incorporation may alter the release profile.21 Because of these challenges, there has been
little effort made towards developing potentially powerful drugs that do not have favorable
solubility profiles; this trend can be reversed by developing effective delivery vehicles for
hydrophobic drugs.24

Figure 2.1. Schematic presentation of NPSC-mediated co-delivery of both siSurv and
tamoxifen for enhanced cancer therapy.
We have previously reported the use of nanoparticle-stabilized capsules for the
independent delivery of proteins, siRNA, and drugs.25–27 The outer positively charged shell
of the ‘nanocapsule’ structure allows interaction with the negatively charged molecules,
such as siRNA and certain proteins, while the inner oil core facilitates the encapsulation of
hydrophobic chemotherapeutics. Here, we combine their capacities to associate with
siRNA electrostatically and solubilize the hydrophobic drugs in the oil layer to generate
the first NPSC dual-delivery agents. By co-loading NPSCs with siRNA and anti-cancer
drugs concomitantly we reduced the number of doses required to treat the cells with
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multiple therapeutics; we also anticipate that the dual-loaded entities will have a greater
anti-cancer therapeutic effect than individual treatments alone.
The therapeutic combination chosen for NPSC codelivery is survivin-targeted
siRNA (siSurv) and tamoxifen. One of the core elements of this strategy is the delivery of
siRNA targeted to the cancer-related protein survivin. Survivin is an inhibitor of apoptosis
protein (IAP) that is overexpressed in nearly every type of cancer. 18 The delivery of siSurv
decreases survivin expression, thus preventing the caspase-inhibiting action of the
functional survivin protein, enabling apoptosis.28 Tamoxifen (TM) is a highly hydrophobic
cytostatic and cytotoxic chemotherapeutic used clinically for the treatment of estrogen
receptor positive breast cancers.19, 29 It has been shown that cancer cells that only receive a
single treatment of tamoxifen alone can evade apoptosis by over-expressing survivin, while
those that are treated with siSurv alone do not have the sufficient impetus to undergo
apoptosis following survivin knockdown.30 For this reason, we concomitantly deliver the
two via NPSCs to yield increased breast cancer cell death by both halting the growth of
cancer cells— thereby driving them towards apoptosis—and removing their ability to avoid
it, in a single treatment.
In this paper, we demonstrate that NPSCs are highly effective in the simultaneous
delivery of anti-survivin siRNA and tamoxifen to MCF7 human breast cancer cells. We
confirm the NPSC-mediated delivery of both to the cytoplasm, and ensure decreased
survivin mRNA levels following treatment with siSurv. To demonstrate the enhanced
anticancer efficiency of the dual loaded siRNA, we used cell viability assays and apoptotic
staining. As a result, we find that not only does NPSC encapsulation increase the
effectiveness of tamoxifen treatment, but that the siRNA/drug combination is more
23

effective in inducing cancer cell death than individual treatments alone. These results
illustrate that the NPSC vehicle holds promise as an effective treatment vector for cancer
by facilitating the effective co-delivery of various therapeutics.
2.1.2. Methods
2.1.2.1. General methods
All standard reagents and chemicals used were purchased from Fisher Scientific or
Sigma-Aldrich, except where noted. The chloroauric acid used for gold nanoparticle
synthesis was bought from Strem Chemicals Inc. (Newburyport, MA). Validated siSurv
was purchased from Sigma-Aldrich. Scrambled siRNA and FAM-labeled scrambled
siRNA were purchased from Invitrogen (Carlsbad, CA). Transmission electron microscopy
(TEM) was performed on a JEOL-2010 microscope with an accelerating voltage of 200
kV. Particle size was measured using a Malvern Zetasizer (Nano series, Malvern
Instruments Inc., USA) with a He-Ne laser (633 nm) and a backscattering angle of 173°.
Confocal microscopy images were obtained on an Eclipse Ti-E microscope (Nikon, Tokyo,
Japan) using a 63X or 10X objective.
2.1.2.2. NPSC, drug and siRNA complexation
The arginine-functionalized AuNPs (Arg-AuNP) and NPSCs were synthesized
according to our previous report.25–27 Briefly, tamoxifen was dissolved into linoleic acid at
120 mg ml−1. Then, 1 μl of linoleic acid was mixed with 500 μl of phosphate buffer (5 mM,
pH = 7.4) containing 1 μM Arg-AuNP and agitated by an amalgamator at 5000 rpm for
100 s to form emulsions. Then, 10 μl of the emulsion was added to 90 μl of the 5 mM
phosphate buffer containing 2.5 μM Arg-AuNP and incubated for 10 min at room
temperature to afford the NPSC/drug/siRNA complex.

24

2.1.2.3. Cell culture
The MCF7 cells were purchased from American Type Culture Collection (ATCC,
Manassas, VA). The cells were cultured at 37 °C under humidified atmosphere with 5%
CO2. High glucose DMEM (4.5 g l−1) with 10% fetal bovine serum (FBS), 1% antibiotic
(100 U ml−1 penicillin and 100 μg ml−1 streptomycin) were used for culturing the cells.
2.1.2.4. Fluorescently labeled siRNA and oil delivery
For confocal laser scanning microscopy (CLSM) imaging of the cellular uptake of
the NPSC/siRNA complex, the MCF7 cells (8.0×104 cells) were seeded in each well of a
four chamber Lab-Tek II chambered coverglass system (Nunc, NY) one day prior to the
experiment. On the day of delivery, the culture medium was replaced with Opti-MEM
containing 40 nM NPSC/FAM-siRNA/Nile Red; the cells were subsequently incubated for
2 h at 37 °C. After 2 h, the media was removed, and the cells were washed once with cold
phosphate buffer saline (PBS); fluorescence imaging was performed in PBS using an
Eclipse Ti-E microscope.
2.1.2.5. NPSC/siSurv delivery for the evaluation of survivin expression
The MCF7 cells (2×104 cells/well) were seeded in a 24-well plate for 24 h prior to
delivery. On the day of transfection, the cells were washed with PBS three times, followed
by the addition of various siSurv or scrambled siRNA formulations in Opti-MEM, which
were incubated with the cells for 3 h. The Opti-MEM was replaced with fresh culture
media, and the cells were incubated for an additional 48 h prior to further analysis.
2.1.2.6. RNA extraction
Approximately 1.5 μg of RNA was harvested using the PureLink RNA Mini Kit
(Ambion) following the manufacturer’s instructions. Superscript IV reverse transcriptase
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was used for the conversion of approximately 150 ng of RNA to cDNA, along with
RNaseOut, 10mM dNTPs, and 50 μM random hexamers (Thermo Fisher Scientific), also
following the manufacturer’s instructions.
2.1.2.7. Real-time polymerase chain reaction (RT-PCR)
RT-PCR was performed on cDNA as prepared above using a CFX Connect realtime system with iTaq universal SYBR Green Supermix (Biorad). All DNA primers were
purchased from Integrated DNA Technologies (Caralville, Iowa). The following sequences
were used: GAPDH Forward (5ʹ-CTTCTTTTGCGTCGCCAGCC-3ʹ), Reverse (5ʹATTCCGTTGACTCCGACCTTC-3ʹ);

Survivin

Forward

(5ʹ-

GACGACCCCATAGAGGAACA-3ʹ), Reverse (5ʹ-CTTGACAGAAAGGAAAGCGCA3ʹ). The samples were incubated as follows: the samples were first activated at 50 °C for 2
min then 95 °C for 2 min. Then denaturing occurred at 95 °C for 5 min followed by
annealing at 60 °C. The denature/anneal process was repeated over 40 cycles. At the
conclusion, a melting analysis was performed holding at 95 °C for 10 min, then 60 °C for
5 min and then back to 95 °C for 5 min. Relative survivin expression was determined by
comparing the Ct value of survivin to that of GAPDH, used as a housekeeping gene, by the
2ΔΔCt method.31 Three biological replicates were performed for each control group and
three technical replicates were used for each biological replicate.
2.1.2.8. Serum stability gel electrophoresis assay
NPSC complexes containing 300 pmol siRNA were incubated in 5 mM PB
containing 10% FBS at 37 °C for 2, 4 and 7 h. At those time points, 1 μl 50 mM SDS was
added and the solution was heated to 60 °C for 5 min to denature the nucleases in the FBS.
The siRNA was then released from the complexes by the addition of 1 μl of 25 mgml −1
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heparin solution. The solutions were then added to a 1% w/v agarose gel (40mM Tris-HCl,
1% v/v acetic acid, 1 mM EDTA) which was then subjected to electrophoresis at 120 v for
15 min.
2.1.2.9. Cytotoxicity of NPSC/siRNA complex
The MCF7 cells (2×104 cells/well) were seeded in a 24-well plate 24 h prior to the
experiment. On the day of the experiment, the cells were washed with PBS and treated with
varied concentrations of NPSC and siRNA/tamoxifen complexes in OptiMem (prepared in
a similar way to the NPSC/siSurv complex solution described above) for 3 h. The treatment
media was replaced with fresh culture media, and the cells were incubated for an additional
48 h. For cells treated with free tamoxifen, the tamoxifen was dissolved in DMSO and
added directly to the cell solutions. The cell viability was determined using the Alamar
Blue assay reagent (Invitrogen, CA) using a SpectraMax M2 plate reader exciting at 560
nm and detecting emission at 590 nm. Three biological replicates were performed for
viability determination.
2.1.2.10 Apoptosis assay
The MCF7 cells (2.0×104 cells) were seeded in each well of a four chamber LabTek II chambered coverglass system (Nunc, NY) a day before the experiment. On the day
of the experiment, the cells were washed with cold PBS and treated with various
concentrations of NPSC and siRNA/tamoxifen complexes in OptiMEM for 3 h, followed
by replacement of the media. For cells treated with free tamoxifen, tamoxifen was
dissolved in DMSO and added directly to the cell solutions. The cells were incubated for
an additional 48 h, after which the media was replaced with a fresh growth media
containing 1 mM YO-PRO-1 (ThermoFisher Scientific) apoptotic staining reagent, and
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incubated for 30 min at 37 °C. After removing the medium, the cells were washed and
replaced with cold phosphate buffer saline (PBS) for fluorescence imaging under an
Eclipse Ti-E microscope.

Figure 2.2. A) Dynamic light scattering (DLS) measurements of size (number average) of
NPSC/drug (red line), NPSC/siRNA (blue line), and NPSC/siRNA/drug complexes (black
line). B) TEM images of NPSC/siRNA/drug complexes.

2.1.3. Results and discussion
Prior to the co-delivery experiments, the NPSCs were fabricated and characterized.
NPSCs were prepared as described previously.25–27 Previous work has optimized the
formulation of the NPSCs, so essentially all the gold nanoparticles in the solution are
incorporated into the NPSC complex.26 In order to determine the quality of the NPSCs
synthesized, TEM images and DLS measurements were obtained to determine the relative
size and morphology of the fabricated capsules (Figure 2.2). These measurements
demonstrated a consistent spherical morphology and a stable size of approximately 150 nm
in diameter, with no population of unbound nanoparticle. Additionally, DLS and serum
stability assays were utilized to demonstrate the relative stability and siRNA protection
capabilities of the NPSCs in serum conditions. These assays demonstrated that the NPSCs
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were able to stay intact in the serum for a significant period of time (Figures 2.3 and 2.4).
Having confirmed the successful fabrication of NPSCs, we determined whether they could
deliver siRNA and a hydrophobic small molecule simultaneously into the cytosol. We have
previously reported that NPSCs can efficiently deliver drugs or siRNA individually into
the cytosol of treated cells.25–27 To confirm co-delivery, a FAM-labeled scramble sequence
siRNA (FAM-siRNA) was incorporated onto the surface of the NPSCs that had Nile Red
dissolved in the interior oil core. Using confocal laser scanning microscopy (CLSM)
(Figure 2.5) to monitor uptake, we observed significant and diffuse green and red
fluorescence throughout the cytosol following treatment. This pattern suggests that the
fluorophore has free access to the entire cytosol, since an endocytotic route would lead to
endosomal entrapment,25 which should be apparent via a ‘punctuate’ fluorescence signal
and is not observed.25 Additionally, there is significant overlap of the red and green
fluorescence signals, providing evidence for the co-localization of both cargoes. To
confirm the ability of NPSCs to effectively deliver siRNA for the knockdown of survivin,
a real-time polymerase chain reaction (RT-PCR) was used to determine the change in
mRNA expression following treatment (Figure 2.6). Both the NPSCs loaded with siSurv
alone and the NPSCs loaded with tamoxifen and siSurv resulted in an approximately 70%
decrease in survivin mRNA levels. Concurrently, the control groups that did not receive
siSurv treatment showed minimal survivin mRNA change compared to the untreated
control. This data is evidence of the ability of NPSCs to efficiently deliver siRNA into the
cytosol and elicit the occurrence of specific RNAi.
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Figure 2.3. Dynamic light scattering (DLS) measurements of size (number average) of
NPSCs in 5 mM PB or 10% serum at various time points.

Figure 2.4. Agarose gel electrophoresis assay of NPSC serum stability. siRNA or
NPSC/siRNA complex were incubated in either 5 mM phosphate buffer (PB) or 10% FBS
at 37°C for the indicated amount of time.
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Figure 2.5. Confocal microscopy images of the MCF-7 cells following 2 h treatment
with NPSC/FAM-siRNA/Nile red complex. Scale bar: 20 μm.

Figure 2.6. RT-PCR of normalized survivin mRNA levels in MCF7 cells 48 h after
treatment. Cell control (non-treated), NPSC/Scr (Scr: 40 nM), NPSC/Scr/TM (Scr: 40 nM,
and TM: 2.6 μM), NPSC/Surv (Surv: 40 nM), NPSC/Surv/TM (Surv: 40 nM, and TM: 2.6
μM), and free TM (10 μM).
We next investigated the therapeutic potential of siRNA and tamoxifen co-delivery
using NPSCs. To evaluate the efficacy of this combination, an Alamar Blue cell viability
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assay was performed (Figure 2.7). As shown, the NPSCs with both siSurv and tamoxifen
reduce cell viability more than either of the individual treatments at any concentration
level. With 40 nM siRNA and 2.6 μM tamoxifen, the combination outperforms either
individual treatment by a minimum of 30% more decrease in cell viability, resulting in an
80% decrease overall. Loading either siSurv or tamoxifen individually into the NPSCs
shows a dose-dependent decrease in cell viability. Treatment with 40 nM siSurv/NPSC
resulted in a 50% decrease in cell viability, while 2.6 μm tamoxifen/NPSC treatment
caused a 27% decrease in cell viability. This result suggests that not only is the combination
of tamoxifen and siSurv efficient at killing breast cancer cells, but that NPSCs are an
effective platform for codelivery. Interestingly, the NPSC delivery of tamoxifen results in
a greater decrease in cell viability than free tamoxifen even at much higher doses. Because
NPSCs show nearly undetectable toxicity at high doses, this may be the result of active
tamoxifen delivery into the cell membrane via the unique membrane fusion entry
mechanism of the capsules versus the passive diffusion that occurs with free tamoxifen. 19
This is another major benefit of the NPSC system, as the increased potency reduces the
required concentration for a therapeutic effect, decreasing the risk of the side effects that
are common with chemotherapeutics. The apparent increase in cell death following codelivery was further confirmed by the staining of apoptotic nuclei with YOPRO-1 (Figure
2.8), where cells treated with NPSCs carrying both chemotherapeutic cargoes displayed a
major increase in fluorescent nuclei versus controls. This experiment provides evidence
that this treatment strategy will have a wide therapeutic window that is beneficial for longterm cancer treatments.
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Figure 2.7. Alamar blue evaluation of MCF7 cell viability. Cells were treated with
NPSC/Scr, NPSC/Scr/TM, NPSC/Surv, NPSCs/Surv/TM complexes, and free TM at
indicated siRNA and drug concentrations.

Figure 2.8. Confocal microscopy images of MCF-7 cells after 48 hours treatment with
NPSC/Surv/TM (siSurv: 35 nM, and TM: 2.3 μM), NPSC/Scr (siScr: 35 nM),
NPSC/Surv (siSurv: 35 nM), and NPSC/TM (TM: 2.3 μM) complex. Apoptotic cells
were stained with YOPRO-1 (green fluorescence). Scale bar: 100 μm.2.1.4. Conclusion
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2.1.4. Conclusion
We have reported the fabrication and development of a combined siRNA and
hydrophobic anti-cancer drug delivery platform using NPSCs. NPSCs composed of ArgAuNP and linoleic acid provide an ideal combination of chemical functionalities and
interacting forces to effectively bind and encapsulate anti-survivin siRNA and tamoxifen,
and are able to deliver them efficiently to the cytosol in a non-endocytotic manner. Not
only did the co-delivery of both therapeutics result in the increased efficacy of cancer cell
death, incorporation of tamoxifen in the NPSCs resulted in higher cell death than tamoxifen
alone— a fact that could be attributed to the active delivery of tamoxifen in aqueous media
by the capsules. NPSC-mediated co-delivery is highly promising in terms of being able to
maximize the usefulness of different therapies and reduce the probability of the adverse
side effects that are currently common in most cancer therapies. 21 The NPSC platform can
be extended to a variety of combination therapies involving different small molecule drugs
and biologics in order to produce advanced cancer therapies. Future work will develop the
NPSC platform as a therapeutic vehicle, further utilizing the co-delivery capabilities of the
vehicle to deliver different cargo combinations, providing new therapeutic approaches for
different disease models.
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2.2. Nanocapsule-mediated cytosolic siRNA delivery for anti-inflammatory
treatment
2.2.1. Introduction
Inflammation is a complex biological reaction of the immune system in response to
microbial, autoimmune, metabolic or physical insults.1-2 Uncontrolled inflammation,
however, is responsible for numerous autoimmune disorders. 3-4 Macrophages play a
critical role in the production of inflammation by secreting proinflammatory cytokines. 5
Suppressing cytokine expression has proven to be beneficial for the treatment of
inflammatory diseases.6 For example, up-regulation of tumor necrosis factor-α (TNF-α) is
frequently involved in autoimmune disorders. TNF-α monoclonal antibodies or
recombinant TNF-α receptors have been used to interfere with the inflammation cascade. 7
RNA interference (RNAi) is an alternative approach to modulate the immune system, with
potential to treat immune disorders by knocking down pro-inflammatory cytokines using
small interfering RNA (siRNA).8 Cytosolic siRNA delivery, however, remains a challenge
to realizing RNAi-based immunotherapy.9 Though a number of nanocarriers have recently
been developed for siRNA delivery relying on endocytosis of siRNA to enter cells,
endosomal escape is quite inefficient, which decreases RNAi efficiency. Recently, we have
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reported that nanoparticle-stabilized nanocapsules (NPSCs) are capable of direct cytosolic
siRNA delivery, avoiding siRNA endosomal entrapment. 10 The NPSC/siRNA assembly
relies on stabilization through interaction between the cationic gold nanoparticle shell and
hydrophobic/anionic “oil” component. These capsules are also stabilized through lateral
electrostatic interactions at the NPSC surface between NPs and siRNA, resulting in
nanocapsules as small as 150 nm, preventing siRNA degradation and delivering siRNA
directly to the cytosol, bypassing endocytosis.

Figure 2.9. Schematic of nanoparticle stabilized nanocapsule/siRNA-mediated in vivo
TNF-α silencing in lipopolysaccharide-induced inflammation. The anti-inflammatory
nanocapsule was prepared by assembling TNF-α targeted siRNA with arginine
functionalized gold nanoparticles, with the ensemble self-assembled onto the surface of
fatty acid nanodroplets to form a NPSC/siRNA nanocomplex.
In this study, we report NPSCs for siRNA delivery to macrophages, and modulation
of cellular immune response in vitro and in vivo (Figure 2.9). In vitro studies showed
NPSCs deliver siRNA to the cytosol of RAW 264.7 cells with transfection efficiency up to
90%. Delivery of TNF-α targeted siRNA knocked down TNF-α expression of RAW cells
stimulated with lipopolysaccharide (LPS). In vivo bio-distribution studies show that >80%
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of systematically administrated NPSC/siRNA accumulated in the spleen, with siRNA
targeting GAPDH resulting in effective gene knockdown. TNF-α targeted NPSC/siRNA
dosing lowers TNF-α expression after LPS challenge, with higher efficiency than other in
vivo siRNA studies, which utilize concentrations 5-10 fold higher for effective gene
knockdown.11 The efficacy of NPSCs for immune system delivery presents a promising
approach for the treatment of inflammatory disease.
2.2.2. Materials and Methods
2.2.2.1 General
All reagents or chemicals used were purchased from Fisher Scientific or SigmaAldrich. Chloroauric acid used for gold nanoparticle synthesis was bought from Strem
Chemicals Inc. (Newburyport, MA). si_GADPH and si_TNF-α with the following
sequence,

5’-CAAGAGAGGCCCUAUCCCA[dT][dT]-3’(sense

GUCUCAGCCUCUUCUCAUUCCUGct-3’
synthesized

by

Sigma-Aldrich.

(sense

Scramble

strand),
siRNA

strand);

and

respectively,
(sense

strand:

5'were
5’-

UUCUCCGAACGUGUCACGU-3') and Cy3-labeled scramble siRNA, were both
purchased from Life Technologies (Carlsbad, CA). Confocal microscopy images were
obtained on an Eclipse Ti-E microscope using a 40X objective. Flow cytometry analysis
was performed on a BD LSR-II flow cytometer equipped with FACSDiva (BDSciences,
USA) by counting 10000 events.
2.2.2.2. NPSC/siRNA preparation
The arginine-functionalized AuNP (Arg-AuNPs) and NPSCs were synthesized
according to our previous report.10 Briefly, 1 μL of linoleic acid was mixed with 500 μL of
phosphate buffer (5 mM, pH = 7.4) containing 1 μM Arg-AuNPs and agitated by an
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amalgamator at 5000 rpm for 100 s to form emulsions. Then, 10 μL of the emulsion was
added into 90 μL of 5 mM phosphate buffer containing pre-mixed 2.5 μM Arg-AuNPs and
1 μM siRNA and incubated for 10 min. at room temperature to afford NPSC/siRNA
complex.
2.2.2.3. Cytotoxicity of NPSC/siRNA complex
For the Alamar Blue assay, RAW 264.7 cells (2.0 x 10 5 cells) were seeded in a 48well plate 24 h prior to the experiment. At the day of experiment, cells were washed by
cold PBS and treated with varied concentration of NPSCs and scramble siRNA complexes
for 2 h, followed by an incubation of additional 24 h with fresh culture medium. The cell
viability was determined using Alamar Blue assay reagent (Invitrogen, CA) according to
manufacturer’s instructions. Three biological replicates were performed for viability
determination.
2.2.2.4. Fluorescently labeled siRNA delivery
For confocal laser scanning microscopy (CLSM) imaging of the cellular uptake of
NPSC/siRNA complex, RAW 264.7 cells (4.0 x 10 5 cells) were seeded in each well of a 4
chamber Lab-Tek II chambered coverglass system (Nunc, NY) one day prior to the
experiment. At the day of delivery, the culture medium was removed and replaced with
Opti-MEM containing 40 nM NPSC/Cy3-siRNA, followed by 1 h of incubation at 37 ºC.
After removing medium, the cells were washed once with cold phosphate buffer saline
(PBS), fluorescence imaging was performed in PBS using an Eclipse Ti-E microscope. For
timelapse imagery, RAW 264.7 cells (2.5 x 10 5) were plated into a 35 mm petri dish
(MatTek) one day prior to the experiment. At the day of delivery, the culture medium was
removed, the cells were washed once with cold PBS and replaced with DMEM containing
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100 nm NPSC/Cy3-siRNA. Cells were imaged following transfection every 30 seconds for
two hours using an Eclipse Ti-E microscope. For the inhibitor assay, RAW 264.7 cells (7.5
x 104) were seeded in each well of a 4 chamber Lab-Tek II chambered coverglass system
one day prior to the experiment. At the day of delivery, the culture medium was removed
and replaced with media containing the appropriate inhibitor. The following concentrations
were utilized, wortmannin: 150 ng/mL, chlorpromazine: 1.5 μg/mL, and MβCD: 7.5
mg/mL. The cells were incubated at 37 ºC for one hour and then the media was replaced
with DMEM containing 40 nM NPSC/FAM siRNA, followed by another 1 h of incubation
at 37 ºC. The media was then replaced with PBS and fluorescence imaging was performed
using an Eclipse Ti-E microscope. For flow cytometry analysis, RAW 264.7 cells (4.0 x
105 cells) were seeded in a 24-well plate for 24 h prior to delivery, and the cells were
washed with PBS for three times before siRNA delivery. At the day of transfection, various
concentrations of siRNA formulations were added to cells and incubated for 2 h in OptiMEM. The cells were harvested and resuspended in PBS for flow cytometry analysis on
FACS LSR II (BD Biosciences). Cells suspensions were analyzed under the same
parameter setting, and at least 10000 events were analyzed for each sample.
2.2.2.5. In vitro TNF-α knockdown
RAW 264.7 cells (2.0 x 105 cells/well) were cultured in a 48-well plate for 24 h
prior to the experiment. At the day of experiment, cells were washed by cold PBS and
treated with PBS, NPSC/si_TNF-α complexes at the indicated si_TNF-α concentration,
NPSC/si_Scr (40 nM), and free si_TNF-α (40 nM) for 24 hours, followed by 3 hours LPS
stimulation (1 μg/mL). At the end of incubation, culture media was collected for TNF-α
level measurement by ELISA (R&D Systems, MN, USA). The silencing efficiency was
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denoted as the percentage of TNF-α levels of the control cells without nanoparticle
treatment. Experiments were performed in triplicate.
2.2.2.6. Animal care
All animal experiments were conducted in accordance with the guidelines of
Institutional Animal Care and Use Committee (IACUC) at University of Massachusetts
Amherst. Female BALB/c mice at least 6 weeks of age used for biodistribution and
GAPDH knockdown study, and TNF-α knockdown study were purchased from The
Jackson Laboratory (Bar Harbor, ME), and generously provided by Prof. Michelle Farkas
(University of Massachusetts Amherst), respectively. All mice were allowed to rest at least
one week in the animal facilities before any procedure was performed. Food and water
intake were assessed.
2.2.2.7. In vivo gene silencing
After one week of acclimatization, Female BALB/c mice at least 6 weeks of age,
received lateral tail vein injections of PBS (negative control), or NPSCs containing either
non-targeting siRNA (NPSC/si_SCr), or anti-GAPDH siRNA (NPSC/si_GADPH), or antiTNF-α siRNA (NPSC/si_ TNF-α) diluted in PBS at a volume of 0.01 ml/g. For
biodistribution and GADPH knockdown study, BALB/c mice were i.v. injected twice with
NPSC/siRNA complexes at a siRNA dose of 0.14 mg/kg at a 2 day interval, blood and
organs were collected and harvested 3 days after final injection. Blood was centrifuged in
serum separator tubes at 5,000 r.p.m. for 10 min, and the supernatant serum was carefully
collected for TNF-α and IFN-γ analysis by ELISA (R&D Systems, MN, USA). Serum total
bilirubin, alkaline phosphatase, aspartate aminotransferase, and alanine aminotransferase
were measured using commercial kits (Teco Diagnostics, Anaheim, CA). For TNF-α
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knockdown study, BALB/c mice were i.v. injected twice with NPSC/siRNA complexes at
a siRNA dose of 0.28 mg/kg at a 6 hour interval, followed by LPS (10 μg/kg or 5 mg/kg,
i.p.) 24 hours later. Serum TNF-α was measured by ELISA 1.5 hours after administration
of LPS.
2.2.2.8. Real Time Polymerase Chain Reaction (RT-PCR) analysis
Once mice were sacrificed, organs including spleen, liver, lung, kidney, and heart
were harvested, cut into small pieces, washed with saline, and homogenized with Trizol
reagent. RNA extraction was performed. Briefly, approximately 1.5 μg of RNA was
isolated using the Pure Link RNA Mini kit (Ambion) following the manufacturer’s
instructions. Superscript IV reverse transcriptase was used for conversion of approximately
150 ng of RNA to cDNA, along with RNaseOut, 10 mM dNTPs, and 50 μm random
hexamers (ThermoFisher Scientific), also following manufacturer’s instructions. RT-PCR
was performed on cDNA as prepared above using a CFX Connect Real Time System with
iTaq Universal SYBR Green Supermix (Biorad). All DNA primers were purchased from
Integrated DNA Technologies (Caralville, Iowa). The following sequences were used:
GAPDH

Forward

(5’-ACCACAGTCCATGCCATCAC-3’),

Reverse

(5’-

TCCACCACCCTGTTGCTGTA-3’); β-actin Forward (5’-GATCAGCAAGCAGGA
GTACGA-3’), Reverse (5’-AAAACGCAGCTCAGTAACAGTC-3’). Three biological
replicates were performed for each control group and three technical replicates were used
for each biological replicate. All GAPDH mRNA measurement was normalized to β-actin,
with the NPSC/si_GAPDH values presented relative to the NPSC/si_Scr controls.
2.2.2.9. ICP-MS sample preparation and conditions
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Each harvested organ was weighed and transferred to metal ion-free tubes, followed
by overnight digestion using a 3:1 (v/v) mixture of HNO3 (68%) and H2O2 (30%). On the
next day, ~ 0.5 mL of fresh aqua regia was added, the sample was then diluted to 10 mL
with de-ionized water.14 A series of standard solutions (gold concentration: 20, 10, 5, 2, 1,
0.5, 0.2, 0 ppb) was prepared for each experiment. The ICP-MS analyses were performed
on a Perkin-Elmer NexION 300X ICP mass spectrometer. 197Au was measured under
standard mode. Operating conditions are listed as below: nebulizer flow rate: 0.95-1 L/min;
rf power: 1600 W; plasma Ar flow rate: 18 L/min; dwell time: 50 ms.
2.2.3. Results and Discussion
2.2.3.1. NPSCs deliver fluorescent siRNA to RAW 264.7 macrophages
We explored siRNA delivery to RAW 264.7 cells, and studied gene knockdown
efficiency following TNF-α targeted siRNA delivery. We treated RAW 264.7 cells with
Cy3 labeled siRNA-loaded NPSCs to track cellular localization. Both confocal laser
scanning microscopy (CLSM) imaging and flow cytometry analysis (Figures 2.10a and
2.10b) confirmed that NPSC/Cy3-siRNA complex was efficiently internalized by RAW
264.7 cells. Diffusion of Cy3 red fluorescence in the cytosol was observed for cells treated
with 40 nM NPSC/Cy3-siRNA, indicating cytosolic siRNA delivery via a non-endocytic
route associated with NPSC delivery (Figure 2.10a). 10 NPSCs were also used to deliver
FAM-siRNA and the rate of uptake was analyzed by time-lapse CLSM. Imaging every 30
seconds demonstrated that the siRNA is dispersed completely through the cytosol nearly
instantaneously. The rapid transfection rate and absence of punctate fluorescence provide
evidence of a non-endocytotic entry route of NPSC/siRNA into RAW 264.7 cells. This
non-endocytotic uptake mechanism was also confirmed by delivery of FAM-siRNA into
RAW 264.7 cells pretreated with endocytosis inhibitors (wortmannin and chlorpromazine)
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and membrane fusion inhibitor, methyl-β-cyclodextrin (MβCD). We have found that
siRNA delivery was not inhibited by endocytosis inhibition, however, membrane fusion
inhibition using MβCD significantly decreased siRNA transfection efficacy (Figure 2.11).
By bypassing endosomal entrapment, siRNA transfection efficiency of RAW 264.7 cells
was as high as 90% (40 nM siRNA, Figure 2.2.2b).

Figure 2.10. In vitro siRNA delivery into RAW 264.7 cells. a) Confocal microscopy
images of RAW 264.7 cells treated with 40 nM Cy3-labeled siRNA delivered with NPSCs.
b) Flow cytometry plots of Cy3-siRNA positive RAW 264.7 cells. RAW 264.7 cells treated
with PBS (top), or 40 nM NPSC/Cy3-siRNA (bottom) for 2 hours were harvested for flow
cytometry analysis. c) In vitro delivery of NPSC/si_TNF-α decreased TNF-α production
from LPS stimulation. RAW 264.7 cells were treated with PBS, NPSC/si_TNF-α
complexes at indicated si_TNF-α concentration, NPSC/si_Scr (50 nM), and free si_TNFα (50 nM) for 24 hours, followed by 3 hours LPS stimulation (1 μg/mL). Supernatant TNFα was measured by ELISA.
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Figure 2.11. CLSM imaging of NPSC/FAM-siRNA delivery into RAW 264.7 cells pretreated with chloropromazine (CPM), wortmannin, and methyl-cyclo-β-dextrin (MCβD).
2.2.3.2. RNAi mediated knockdown of TNF-α expression in vitro
We next investigated the efficacy of NPSC-facilitated siRNA delivery to
knockdown TNF-α expression. The secretion of TNF-α from RAW 264.7 cells challenged
with LPS (1 μg/mL) was used as the determinant for silencing efficiency. 12
NPSCs/si_TNF-α (50 nM siRNA) treatment resulted in a 90% decrease in TNF-α secretion,
with suppression occurring in a concentration dependent manner (Figure 2.2.2c). si_TNFα alone or NPSCs containing scrambled siRNA had no effect on suppressing TNF-α
secretion.
2.2.3.3. NPSC delivery of siRNA in vivo
We next investigated NPSC/siRNA delivery in vivo. To characterize tissue
distribution and efficacy of RNAi of NPSC/siRNA in vivo, we chose glyceraldehyde 3phosphate dehydrogenase (GAPDH) as a target.13 NPSCs loaded with siRNA targeting
GAPDH (si_GAPDH) were injected intravenously into BALB/c mice twice, with a 2 day
interval in between, at a dose of 0.14 mg/kg siRNA each. Tissues were harvested 3 days
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after the second injection for analysis. Two parallel analyses were performed to assess in
vivo distribution of NPSC/siRNA, one using inductively coupled plasma mass
spectrometry (ICP-MS) to determine gold accumulation in different tissues, 14 and the other
using reverse transcription polymerase chain reaction (RT-PCR) to quantify GAPDH
mRNA following the injections of different formulations. 15 Quantifying the concentration
of gold in different tissues (μg of Au/g of organ) revealed that gold concentration
accumulated in spleen were nearly 6-fold higher than in liver, and 20-fold higher than that
were accumulated in other tissues, including kidney, lung, and heart (Figure 2.12a). The
combination of vehicle accumulation in the spleen and direct cytosolic delivery provided
potent silencing in the spleen after systematic injection of NPSC/si_GAPDH. The efficacy
of in vivo GAPDH silencing in different tissues was analyzed by quantifying GAPDH
mRNA, with β-actin expression as an internal comparison. The systematic injection of
si_GAPDH NPs into BALB/c mice at a total siRNA dose of 0.28 mg/kg, resulted in 80%
decrease of GAPDH mRNA in spleen (Figure 2.12b) compared to mice injected with
scramble NPSCs/siRNA. In contrast, no GAPDH silencing was observed in other organs,
including the liver. Importantly, no significant bodyweight change was noted for mice
injected with NPSC compared to those with PBS injection (Figure 2.13). Moreover, testing
clinical chemistry parameters demonstrated that NPSCs have low liver toxicity and low
immune response for in vivo siRNA delivery (Figure 2.14).18 There was no significant
change of TNF-α and IFN-γ levels in serum (Figure 2.15), demonstrating that NPSCs did
not induce an innate immune response. Due to the high stability of AuNPs in vitro, there
is potential concern about toxicity from over-accumulation in vivo. However, there is
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evidence in recent literature that 2 nm AuNPs are rapidly degraded in the spleen and are
cleared by the renal system, ameliorating this possible toxicity. 19,20

Figure 2.12. In vivo distribution and gene silencing of NPSC/siRNA. a) Biodistribution of
gold after intravenous injection of NPSC/siRNA. Gold content was analyzed by ICP-MS
(n = 3). b) In vivo delivery of NPSC/si_GAPDH decreased splenic GAPDH mRNA levels.
BALB/c mice were i.v. injected twice with NPSC/siRNA complexes at a siRNA dose of
0.14 mg/kg at a 2 day interval, and organs were harvested 3 days after final injection.
NPSC/si_GAPDH values are presented relative to the NPSC/si_Scr control (n = 3).
Finally, we studied whether splenic NPSC/siRNA delivery could regulate TNF-α
secretion and modulate immune response in a LPS-challenged mouse model. 21 BALB/c
mice were i.v. injected with PBS, NPSC/si_TNF-α or NPSC/si_Scr twice at a total siRNA
dose of 0.56 mg/kg, 24 hours prior to LPS administration. 21c Mice were sacrificed 1.5 h
post LPS treatment and serum was processed for a TNF-α ELISA assay. NPSC/si_TNF-α
treated mice displayed 60% reduced serum TNF-α secretion compared to PBS and
NPSC/si_Scr treated mice (LPS: 5 mg/kg, Figure 2.16). We observed effective TNF-α gene
knockdown at a 9-fold lower dose of siRNA than prior systems, 21c demonstrating the
efficacy of NPSC/si_TNF-α for in vivo RNAi. There was no significant difference in serum
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TNF-α level between PBS and NPSC/si_Scr injected mice, indicating that NPSCs are
biocompatible, and attenuation of LPS-induced inflammation in vivo resulted only from
RNAi. At a concentration of 5 mg/kg LPS, the generation of TNF-α was significant and
robust, but there was no noticeable production of blood TNF-α at a lower concentration
LPS treatment (10 μg/kg, Figure 2.16). Our results indicate that LPS induced inflammation
and TNF-α secretion can be suppressed by in vivo delivery of NPSCs/siRNA targeting
TNF-α. Given the high accumulation of NPSC/siRNA in spleen, we speculated the potent
systematic TNF-α knockdown resulted from siRNA delivery to splenic macrophages,
which led to TNF-α depletion in a LPS-induced mouse inflammation model.

Figure 2.13. Average mouse weight changes during the course of treatment with PBS,
NPSC/si_Scr, and NPSC/si_GAPDH (n = 3, mean ± standard deviation).
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Figure 2.14. Clinical chemistry parameters. Parameters were evaluated for negative
control (PBS), NPSC/si_Scr, and NPSC/si_GAPDH injected BALB/c mice. The mice were
injected twice with NPSC/siRNA complexes at a siRNA dose of 0.14 mg/kg at 2 day
interval. Blood was drawn 3 days post-final injection. There were no statistically
significant changes in any of the clinical chemistry parameters for any of the treated groups
compared to controls. Normal ranges for clinical chemistry parameters are: total bilirubin
(0 – 0.9 mg/dL), alkaline phosphatase (ALP: 44 – 147 U/L), aspartate aminotransferase
(AST: 54 – 298 U/L), and alanine aminotransferase (ALT: 17 – 77 U/L). Error bars
represent standard deviation (n = 3, mean ± standard deviation).

Figure 2.15. No significant changes of serum a) TNF-α, or b) IFN-γ levels following the
injection of PBS, NPSC/si_Scr, and NPSC/si_GAPDH to BALB/c mouse. The TNF-α and
IFN-γ level were measured using ELISA, and normalized to the PBS treated group (n = 3,
mean ± standard deviation).
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Figure 2.16. In vivo delivery of NPSC/si_TNF-α decreased serum TNF-α production from
LPS-induced inflammation. BALB/c mice were i.v. injected twice with NPSC/siRNA at a
siRNA dose of 0.28 mg/kg in 6 hour intervals, followed by LPS administration (10 μg/kg,
or 5 mg/mouse, i.p.) 24 hours later. Serum TNF-α was measured by ELISA 1.5 hours after
LPS dosing (n = 3). * = p < 0.05 through unpaired t-test；**= p < 0.005 through unpaired
t-test between control group and siRNA group.

2.2.4. Conclusion
NPSCs are an effective platform for spleen-directed siRNA delivery and
immunomodulation in vivo. The direct cytosolic delivery of siRNA, coupled with the
splenic-directed ability, contributes to potent RNAi in vivo, enabling silencing of
proinflammatory cytokines with a total siRNA dose as low as 0.56 mg/kg. The ability to
dose at levels significantly lower than prior studies decreases off-target effects, overcoming
a critical barrier in in vivo siRNA delivery. The NPSC system provides a means to enhance
the potential for therapeutic siRNA in the treatment of autoimmune disorders and other
inflammatory conditions.
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CHAPTER 3
CRISPRED MACROPHAGES FOR CELL-BASED CANCER IMMUNOTHERAPY
Reprinted (adapted) with permission from“Ray, M.; Lee, Y. W.; Hardie, J.; Mout, R.;
Tonga, G. Y.; Farkas, M. E.; Rotello, V. M. Bioconjugate Chem. 2018, 29, 445-450.”
Copyright (2018) American Chemical Society
3.1 Introduction
The immune system plays a critical role in preventing tumor initiation and growth;
evasion of this system is required for cancer progression.1 One such mechanism is the
generation of “don’t eat me” signals by the cancer cells, preventing phagocytosis by
macrophages.2 The avoidance signal of perhaps greatest interest is CD47, 3 a cell surface
protein overexpressed by most cancer cells. Interaction between cancer cell CD47
receptors and macrophage signal regulatory protein-α (SIRP-α) is sufficient to bypass
phagocytosis even if phagocytic signals are present (Figure 3.1). CD47:SIRP-α binding
leads to activation of SIRP-α via phosphorylation of its immune receptor tyrosine-based
inhibition motifs on the cytoplasmic tail,4 resulting in binding and activation of Src
homology phosphatase-1 (SHP-1) and SHP-2.5 As a result, phagocytosis is blocked by
preventing accumulation of myosin-IIA at the phagocytic synapse. This inhibitory
mechanism of CD47:SIRP-α binding is evident in a wide range of cancer-initiated
malignancies making it a promising therapeutic target. 6
Recently, strategies have been developed to block the interaction of CD47 with
SIRP-α. Use of an anti-CD47 monoclonal antibody has shown efficacy in preclinical
studies with different human cancers both in vitro and in mouse xenotransplantation
models.2,7−11 An engineered SIRP-α variant, CV1,12 has been used as an antibody adjuvant
and shown to facilitate macrophage-mediated phagocytosis in tumor models with increased
tumor penetration and low toxicity. However, overexpression of CD47 by cancer cells
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leads to a large antigen sink in the employment of antibody-based strategies that both
reduces bioavailability and increases the potential for toxicity to normal cells. 7,13 An
alternative to blocking CD47 is the targeting of SIRP-α. Studies have shown that antiSIRP-α antibodies significantly enhanced antibody mediated killing of tumor cells by
phagocytes in vitro. Nevertheless, due to their large size, penetration of the antibodies into
solid tumors was a major limitation for therapeutic efficacy. SIRP-α-targeting agents must
have sufficient tumor penetration to interact with and block tumor infiltrating
macrophages,14,15 to be a viable therapeutic approach.16
Recently, we have developed nanomaterial platforms for the delivery of biologics.
These scaffolds can simultaneously transport proteins and nucleic acids directly to the
cytosol through a membrane fusion mechanism. In our approach, we have delivered the
complete CRISPR/Cas9 machinery (Figure 3.1b) by engineering Cas9 protein to facilitate
association with cationic arginine-coated gold nanoparticles (ArgNPs). 17 This strategy has
demonstrated ∼90% delivery efficiency along with ∼30% gene editing efficiency. Here,
we use the same system to knock out SIRP-α in macrophages to turn off this “don’t eat
me” signal and enable phagocytosis of cancer cells (Figure 3.1c), thus providing a strategy
for cancer immunotherapy.18,19
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Figure 3.1. (a) Prevention of cancer cell phagocytosis by CD47:SIRP-α interaction. (b)
Genomic editing using CRISPR-Cas9 machinery. (c) Cell based immunotherapy through
elimination of CD47:SIRP-α interaction by knocking out SIRP-α using nanoparticlemediated delivery of CRISPRCas9E20/sgRNA and resulting phagocytosis of cancer cell
by (-)SIRP-α macrophage.
3.2. Results and Discussion
3.2.1. Delivery of CRISPR-Cas9 protein and subsequent knockout of SIRP-α gene
Recently, the CRISPR-Cas9 nuclease system has emerged as a powerful tool for
genome editing.20 It is a two-component system consisting of sgRNA and Cas9 nuclease
(generally derived from Streptococcus pyogenes, or SpCas9) for generating sequencespecific targeted mutations in the genome.21 This targeted modification of the genome is
permanent and can be passaged to offspring cells. In our previous research, 17,22 we have
demonstrated CRISPR/Cas9 mediated gene editing by engineering Cas9 protein to
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facilitate association with cationic ArgNPs. We inserted a peptide tag containing glutamic
acids (E-tags) at the N terminus of Cas9 protein derived from S. pyogenes (SpCas9) and
appended a nuclear localization signal (NLS) tag23 at the C terminus to enhance nuclear
accumulation (Figure 2a-d). When E-tagged SpCas9 was mixed with ArgNPs, selfassembled superstructures were generated via carboxylate−guanidinium binding. We
found that E20-tag provided the most efficient delivery of SpCas9 into the cytosol and
nucleus in multiple cell lines, including the RAW 264.7 model macrophage cell line.
Therefore, we engineered SpCas9, first, by introducing an E20 tag at the N-terminus of the
protein so that the protein could self-assemble with cationic ArgNPs.
After engineering and purifying Cas9E20 protein, we fabricated nanoassemblies
with Cas9E20-sgRNA (Cas9E20-ribonucleoprotein, hereafter referred to as Cas9E20RNP) and ArgNPs. These nanoassemblies were incubated with RAW 264.7 cells in cell
culture media. Delivery efficiency was monitored by using Cas9E20 labeled with
fluorescein isothiocyanate (FITC), and imaging via confocal laser scanning microscopy
(CLSM) after 3 h of incubation. Cas9E20 was readily delivered to cytosol via membrane
fusion mechanism24 and accumulated in the nucleus, stained with Hoechst 33342 (Figure
3.2f), a prerequisite for gene editing. We further demonstrated the intracellular release
dynamics of Cas9E20-RNP by performing time lapse video imaging. We recorded images
at 30 s intervals for 1 h following addition of the nanoassemblies into the RAW264.7 cell
culture media. Real time tracking of a delivery event showed almost instantaneous release
of Cas9E20 in the cytosol with subsequent transport of the protein to the nucleus,
presumably due to active nuclear transport of NLStagged Cas9E20. This remarkably fast
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intracellular delivery is consistent with prior studies showing that the protein payload was
directly released from the cell membrane without being trapped in the endosomes.
After efficient intracellular delivery of Cas9E20 was demonstrated, we identified
the target gene sequence and generated the appropriate sgRNA25 for the transmembrane
region of SIRP-α in RAW264.7 cells (Figure 3.2e). We subsequently assembled Cas9E20RNP with ArgNPs and delivered these nanoassemblies into RAW264.7 cells. The
nanoassemblies were incubated with the RAW 264.7 cells for 3 h in serum-free media.
Genome editing efficiency was evaluated after 48 h, using indel analysis (Figure 3.2g). We
observed 27% indel efficiency, fully competitive with other gene delivery based editing
approaches. Cells treated with only Cas9E20-RNP and untreated cells did not show any
gene editing. Once the RAW 264.7 cells were edited using Cas9E20-RNP and ArgNP
nanoassemblies, the knockouts were isolated by dilution (single cell isolation).
To further assess the expression level of SIRP-α in (-)SIRP-α-RAW 264.7 cells
(after single cell isolation), we labeled both RAW 264.7 and (-)SIRP-α-RAW 264.7 cells
with APC antimouse SIRP-α-antibody. Labeling with APC anti-mouse SIRP-α antibody
caused an increase in fluorescence intensity of the RAW 264.7 cells as shown by flow
cytometry data (Figure 3.2h). The fluorescence intensity of the RAW 264.7 cells shifted to
the right (green histogram) compared to that of the (-)SIRP-α-RAW 264.7 cells (purple
histogram) due to the increased level of SIRP-α expression in RAW 264.7 cells compared
to (-)SIRP-α-RAW 264.7 cells. This result clearly proved that ArgNPs facilitated delivery
of Cas9E20-RNP in RAW 264.7 cells, and indeed knocked-out SIRP-α.
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Figure 3.2. (a) Engineering Cas9 by introducing an E20-tag at the N-terminus and nuclear
localization signal (NLS) at the C-terminus. (b) Chemical structure of ArgNPs. (c)
Schematic showing formation of nanoassembly by Cas9E20-RNP and ArgNPs. (d)
Delivery of Cas9E20 via membrane fusion mechanism. Fusion of nanoassemblies to the
cell membrane facilitates direct release of the protein payload into cytoplasm, bypassing
endosomes. (e) Endogenous SIRP-α gene locus showing the CRISPR-Cas9 target site. (f)
Cytoplasmic/nuclear delivery of FITC-labeled SpCas9E20 into RAW 264.7 cells (cell
nuclei stained with Hoechst 33342). (g) Delivery of Cas9E20-RNP to target SIRP-α gene
in RAW 264.7 cells resulted in efficient gene editing, as determined by indel (insertion and
deletion) assay: Lane 1, Cas9E20-RNP:ArgNPs; Lane 2, cells only; and Lane 3, Marker
(the bottom one is 200 bp and each increase in fragment size is 100 bp). Indel efficiency is
given in percentages. (h) Fluorescence histogram from flow cytometry analysis on (-)SIRPα-RAW 264.7 cells (purple), and RAW2 64.7 cells (green).

3.2.2. SIRP-α knockout RAW 264.7 macrophages promote phagocytosis of cancer
cells
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Next, the phagocytic ability of the SIRP-α knockout RAW 264.7 ((-)SIRP-α-RAW
264.7) cells was tested against cancer cells. Here, we chose human osteosarcoma cells
expressing and not expressing GFP (U2OS-GFP+ and U2OS-GPF-, respectively) as a
cancer cell model. We separately cocultured RAW 264.7 and (-)SIRP-α-RAW 264.7 cells
(both labeled with PE anti-mouse F4/80 antibody) with U2OS-GFP+ cells for 4 h at 37 °C.
(-)SIRP-α-RAW 264.7 cells showed a 4-fold increase in phagocytosis of U2OS-GFP+ cells
compared to nonedited RAW 264.7 cells, as measured by flow cytometry (Figure 3.3a,b).
This demonstrates that the U2OS cells were being recognized and engulfed by the (-)SIRPα-RAW 264.7 cells at a higher rate, revealing the efficacy of the strategy.
To confirm the internalization of the U2OS cells within the macrophages, we
labeled U2OS-GFP- cells with pHrodo GreenAM Intracellular pH Indicator.26 This dye is
non-fluorescent at neutral pH; however, it becomes fluorescent as phagolysosomes are
formed in acidic environments. The brightly fluorescent cells (green) confirmed the
internalization of the U2OS cells by the modified macrophages as well as formation of
phagolysosomes (Figure 3.3c). Fluorescent cells are not seen when U2OS cells are not
internalized by the macrophages (Figure 3.3c, right image). To provide further
confirmation, we used an imaging flow-cytometer that provided an image of each cell
passing through the system. Using this method, we observed the internalization of the
U2OS cells by (-)SIRP-α-RAW 264.7 cells with an internalization score of 2.822 (Figure
3.3d). Unmodified RAW 264.7 cells, on the other hand, had an internalization score of
1.134 (Figure 3.4). The images clearly exhibited that the PE-F4/80 stained (-)SIRP-α-RAW
264.7 cells contained U2OS-GFP+ cells. No cancer cells bound to, but not internalized by,
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macrophages were detected with this imaging technology due to the setting of gates on
single cells. These results collectively demonstrated the efficiency of our method.

Figure 3.3. (a) Flow cytometry plots of PE anti-mouse F4/80 antibody-stained and
unstained RAW 264.7 cells, PE anti-mouse F4/80 antibody-stained and unstained (-)SIRPα RAW 264.7cells, GFP+/GFP- U2OS cells, coculture of PE anti-mouse F4/80 antibodystained RAW 264.7 cells and U2OSGFP+ cells and coculture of PE anti-mouse F4/80
antibody-stained (-)SIRP-α-RAW 264.7 cells and U2OS-GFP+ cells. (b) Percentage of
phagocytosis of U2OS-GFP+ by (-)SIRP-α-RAW 264.7 cells and RAW 264.7 cells. (c)
Confocal images showing phagocytosis or no phagocytosis of U2OS cells; U2OS cells
(green) labeled with pHrodo Green AM Intracellular pH Indicator. Scale bar: 20 μm. (d)
Representative images U2OS-GFP+ cells internalized by PE-F4/80 labeled (-)SIRP-αRAW 264.7 cells measured by Imaging flow cytometry. The negative control (no
internalization) is a representative PE-F4/80 labeled (-)SIRP-α-RAW 264.7 cell without
internalized U2OS-GFP+ cells. Scale bar: 10 μm.
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Figure 3.4: Assessment of phagocytosis of U2OS-GFP+ cells by (a) RAW264.7 cells and
(b) (-)SIRP-α-RAW264.7 cells. Single cell populations were gated by PE positive events
and high PE aspect ratios. Using the internalization wizard of IDEAS software, an index
of internalization was calculated. The histogram plot illustrates the U2OS-GFP+ cells
internalized by the (a) RAW264.7 cells within the R6 gate and (b) (-)SIRP-α-RAW264.7
cells within the R5 gate. Ch02: U2OS-GFP+ cells, Ch03: PE-F4/80 labelled RAW264.7
cells or PE-F4/80 labelled (-)SIRP-α-RAW264.7 cells.

3.3. Methods
3.3.1. Engineering Cas9
Glutamic acid tag (E-tag) was inserted to the N-terminus of SpCas9 via sitedirected mutagenesis (SDM). Briefly, the following primers were used for the insertion of
E-tag (inserted nucleotides are underlined in the primer sequences) into the N-terminus of
SpCas9 using pET28b-Cas9 expression vector (Addgene plasmid ID: 47327) as the
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template. The C-terminus of Cas9 contained a nuclear localization signal (NLS) and a
6xHis tag. Cas9E10-F: 5’-ATGGAGGAAGAAGAGGAAGAGGAGGAGGAAGAGATGGACAAGAAGTACTCCATTGGGCTCGAT-3’ Cas9E10-R: 5’-GGTATATCTCCTTCTTAAAGTTAAACAAAATTATTTCTAGAGGGG-3’ Cas9E15-F: (Cas9E10 as
template) 5’-ATGGAAGAGGAGGAAGAAGAGGAAGAAGAGGAAGAGGAGGAGGAAGAGA-TGGAC-3’ Cas9E15-R: 5’-GGTATATCTCCTTCTTAAAGTTAAACAAAATTATTTCTAGAGGGG-3’ Cas9E20-F: (Cas9E15 as template) 5’-ATGGAAGAAGAGGAGGAAGAAGAGGAGGAAGAAGAGGAAGAAGAGGAAG-AGGAGGAG3’ Cas9E20-R: 5’-GGTATATCTCCTTCTTAAAGTTAAACAAAATTATTTCTAGAGGGG-3’.
3.3.2. Expression and purification of Cas9E20
Recombinant proteins (Cas9E20) were expressed in the E. coli BL21 Rosetta strain
using a standard protein expression protocol. Briefly, protein expression was carried out in
2xYT media with an induction condition of 0.75 mM IPTG and 160C for 16 h. Next, the
cells were harvested and the pellets were lysed by using 1% Triton-X-100/DNase-I. TritonX-100 treatment was performed for ~30 min followed by DNase-I treatment for 15 min.
Lysed cells were then centrifuged at 14,000 rpm for 30 min. The supernatant was collected
and to it an additional 150 mM salt was added. Proteins were purified using HisPur cobalt
columns. Proteins were finally preserved in PBS buffer containing 300 mM NaCl. The
purity of native proteins was determined using 8% SDS-PAGE gel.
3.3.3. sgRNA design and synthesis.
sgRNAs were transcribed in vitro from dsDNA template (containing the
protospacer and the tracrRNA sequences) using an AmpliScribe-T7- Flash Transcription
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kit according to manufacturer’s protocol. dsDNA was PCR amplified from a template
plasmid carrying the tracrRNA sequence. The following primers were used for the PCR
amplification:

Forward-sgRNA

SIRP-α:

5’-GAAATTAATACGACTCACTATA-

GGcaatgcttgcatattctgtgGTTTTAGAGCTAGAAATAGC-3’

A

Reverse-sgRNA:

5’-

AAAAAAGCACCGACTCGGTGCCACT-3’. In vitro transcribed sgRNAs were purified
using an RNA purification kit (Zymo research RNA Clean & Concentrator).
3.3.4. Nanoparticle synthesis and characterization.
Arginine-functionalized gold nanoparticles (ArgNPs) were prepared according to
our previous methods.27 The arginine-functionalized thiol ligands were synthesized first.
Following this, ArgNPs were prepared by conventional place-exchange reaction of 2-nm
sized 1-pentanethiolprotected gold nanoparticles (Au-C5) with HS-C11-TEG-NHArginine (Arginine ligand). The resulting ArgNPs were dissolved in distilled water,
purified by dialysis, and the characterization of the ArgNPs was performed as per previous
reports.27 It is noteworthy that the complete synthesis of a batch of ArgNPs may take
approximately 1- 2 weeks, however they can be synthesized in large batches that may be
stable and used for years for delivery purposes.
3.3.5. Nanoassembly fabrication.
Cas9E20-RNP:ArgNPs nanoassemblies were prepared through a simple mixing
procedure. Cas9E20 and sgRNAs (1:1 molar ratio)5 were assembled in 1x PBS for 30 min
at room temperature first, then ArgNPs (50 µM stock in 5 mM PB, pH 7.4) were added to
100 µL of 1x PBS in another vial, followed by adding the preassembled Cas9E20-RNP at
appropriate working molar ratio (usually at 2:1 ratio (ArgNP, 125 nM)/(Cas9E20-RNP, 62
nM)). The working molar ratio was determined by screening different ratios in the
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subsequent delivery experiments. The nanoassemblies were incubated at room temperature
for another 10 min. DMEM was added to the nanoassemblies to give the final volume of
1000 µL. The nanoassemblies were directly added to cells, which had been plated the
previous day and grown overnight in confocal dishes for delivery experiments.
3.3.6. Cell culture.
RAW 264.7 cells were grown in high glucose DMEM media (with 10% FBS, and
1% antibiotics) overnight at 37 ºC in 5% CO2. Cells were washed with 1x PBS (twice)
before incubation with nanoassemblies. All U2OS cells were cultured in high glucose
DMEM media (with 10% FBS, 1% antibiotics, 1% Non-essential amino acids, 1% LGlutamine and 1% sodium pyruvate) at 37 °C under 5% CO 2.
3.3.7. Delivery
Assembled Cas9E20-RNP:ArgNPs nanoassemblies (pre-assembled in 100 µL PBS
for 10 min, plus 900 µL DMEM media) were immediately transferred to each dish of
confluent cells. Cells were then incubated at 37 °C and 5% CO 2 for 3 h. At this point cells
were washed with PBS buffer and incubated with Hoechst 33342 (1µg/ml in PBS) for 15
min. The cells were then washed with PBS and immediately imaged via confocal
microscopy for investigation of delivery efficiency (Zeiss LSM 510 Meta microscope, or
Nikon A1 laser scanning microscope). It is noteworthy that the nanoassemblies can be
incubated with cells for a longer period of time (~24h) without affecting cell
growth/viability. Furthermore, the use of serum containing media may affect the delivery
efficiency.
3.3.8. Time lapse video imaging.
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30x104 RAW 264.7 cells were grown in a confocal dish (glass bottom culture
dishes, MatTek). Live-delivery imaging was performed using Nikon A1 confocal laser
scanning microscope. Briefly, immediately following the addition of nanoassemblies to the
cultured RAW cells in a live-cell imaging chamber containing humidified 5% CO 2 at 37
°C, the images were acquired at every 30s interval for 3 h using a 60x oil immersion lens.
3.3.9. Indel analysis.
3 h after Cas9E20-RNP delivery, cells were washed and replaced with DMEM
media (with 10% FBS, and 1% antibiotics), then allowed to grow for another 48 h. At this
point cells were harvested to extract genomic DNA using QuickExtract genomic DNA
isolation kit (Epicentre biotechnologies). Indel assays were performed using T7
endonuclease-I according to a standard protocol.
3.3.10. Single cell isolation
After indel analysis, the cells were detached from the plate and counted. Serial
dilutions were performed to obtain a final concentration of 0.5 cells per 100 µL to minimize
the probability of having multiple cells in a single well. The cells were grown in a 96-well
plate until they were confluent. Cells from each of the wells were separately assessed for
gene editing via indel analysis to select SIRP-α - colonies.
3.3.11. Antibody staining and flow cytometry assay
10x104 RAW 264.7/(-)SIRP-αRAW 264.7 cells were first labelled with APC anti
mouse CD172a (BD Pharmingen) for 30 min at 40 ºC according to the manufacturer’s
protocol. After 30 min, the RAW 264.7/(-)SIRP-α-RAW 264.7 cells were thoroughly
washed thrice with PBS until no excess CD172a antibody was present. The cells were then
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resuspended in 100 µL FACS buffer (1% FBS in PBS). Data were acquired using a BD
LSR Fortessa 5 Laser Cell Analyzer and analyzed using FlowJo software.
3.3.12. In vitro phagocytosis assay
30x104 RAW 264.7/(-)SIRP-α-RAW 264.7 cells were first labelled with PE antimouse F4/80 Antibody for 30 min at 40 °C according to the manufacturer’s protocol
(BioLegend). After 30 min, the RAW 264.7/SIRP-αRAW 264.7 cells were thoroughly
washed thrice with PBS until no excess F4/80 antibody was present. For the in vitro
phagocytosis assay, 30x104 RAW 264.7/SIRP-αRAW 264.7 cells labelled with PE antimouse F4/80 antibody were incubated with 15x104 U2OS-GFP+ cells in 200 µL DMEM
media (with 10% FBS, and 1% antibiotics) for 4 h at 37 °C under 5% CO 2. After 4 h, the
cells were washed again thoroughly with PBS thrice to remove any DMEM media. The
cells were then resuspended in 100 µL FACS buffer (1% FBS in PBS) and analyzed in a
BD LSR Fortessa 5 Laser Cell Analyzer. The percentage of phagocytosis was calculated
as the percentage of U2OS-GFP+ cells within F4/80+ RAW 264.7 cells gate using FlowJo.
For the microscopy-based pHrodo assay, 30x104 RAW 264.7/(-)SIRP-α-RAW 264.7 cells
were grown in a confocal dish (glass bottom culture dishes, MatTek) in high glucose
DMEM media (with 10% FBS, and 1% antibiotics) overnight at 37 °C under 5% CO 2.The
next day, U2OS-GFP- cells were washed and labelled with pHrodo Green AM Intracellular
pH Indicator. They were then added to the confocal dish with RAW 264.7/(-)SIRP-α-RAW
264.7 cells. After incubation for 4 h at 37 °C, RAW 264.7/(-)SIRP-αRAW 264.7 cells were
washed and imaged with Nikon A1 confocal laser scanning microscope. The U2OS-GFPcells were labelled with 100 ng/ml of pHrodo Green AM Intracellular pH Indicator
(Thermo Fisher Scientific) according to the manufacturer’s protocol. pHrodo dyes are non-

66

fluorescent at neutral pH and become fluorescent in acidic environments such as
phagolysosomes.
3.3.13. Image-based assessment of phagocytosis by flow cytometry.
Cells were labelled and co-cultured (80x104 RAW 264.7/(-)SIRP-α-RAW 264.7
cells and 40x104 U2OS-GFP+ cells) as described for the detection of internalization. Data
were collected using an auto-sampler on an Amnis ImageStream Mark II Imaging Flow
Cytometer, equipped with a 40x objective. 10,000 events were collected for each sample.
Recorded data were saved as a raw image file and analyzed with the selecting
internalization wizard of IDEAS 6.1 image data analysis software.
3.3.14. Experimental design of CRISPR-Cas9 mediated gene editing
CRISPR-Cas9 protein can create targeted double-stranded break (DSB) in DNA
sequences. This DSB can be repaired by the host cell repair mechanism via nonhomologous end joining (NHEJ) by randomly inserting or deleting (indel) nucleotides at
the DSB site of DNA. When the coding region of the DNA is repaired by NHEJ
mechanism, the indels created will generate a reading frame shift. This mutated sequence
generally produces a truncated non-functional protein. Therefore, we aimed to achieve
CRISPR-Cas9 mediated knockout of the transmembrane domain of the macrophage SIRPα gene. Our hypothesis was that the truncated protein generated by CRISPR-Cas9 mediated
editing would be functionally inactive, and unable to interact with cancer cell CD47. As a
result, the anti-phagocytic “don’t eat me” signal would be turned off. We subsequently
identified the target gene sequence of the transmembrane region of the SIRP-α gene in
RAW 264.7 cells (the model macrophage cell line used in this work) using Broad Institute’s
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Design sgRNAs for CRISPRko (http://portals.broadinstitute.org/gpp/public/analysistools/sgrna-design). sgRNA targeting SIRP-α was transcribed in vitro.
3.3.15. Analysis by IDEAS 6.1 image data analysis software
Single-stained samples were used as controls to compensate for between-channel
images on a pixel-by-pixel basis. For data analysis, cells were gated on the basis of their
aspect ratio to differentiate the single cells from aggregates. For assaying internalization,
the singlet population was gated (because this represented almost 90% of the cells imaged),
and only the PEstained singlet population was considered to exclude unstained cells. The
internalization score is defined as the ratio of signal intensity (U2OS-GFP+) inside the cell
to the intensity of the entire cell for a specific florescent signal (PE labelled RAW 264.7/
(-)SIRP-α-RAW 264.7 cells), with higher internalization scores indicating higher
internalization. Internalization wizard has been used for this purpose.
3.4 Conclusion
In summary, we have created an integrated nanotechnology/biology approach to
engineer macrophages in vitro into therapeutic tools to fight cancer. We have utilized a
protein based approach to deliver CRISPR-Cas9 into macrophages to knockout the SIRPα gene that governs macrophage interactions with CD47 on cancer cells to prevent
phagocytosis. Knocking out SIRP-α weaponizes the macrophages, greatly enhancing their
ability to phagocytose tumor cells, providing a new immunotherapeutic strategy for cancer
therapy.
3.5 References
1. Chao, M. P.; Weissman, I. L.; Majeti, R. Curr. Opin. Immunol. 2012 24, 225−232.

68

2. Willingham, S. B.; Volkmer, J.-P.; Gentles, A. J.; Sahoo, D.; Dalerba, P.; Mitra, S. S.;
Wang, J.; Contreras-Trujillo, H.;, Martin, R.; Cohen, J. D.. et al. Proc. Natl. Acad. Sci. U.
S. A. 2012 109, 6662−6667.
3. Fehervari, Z. Nat. Immunol. 2015 16, 1113−1113.
4. Slee, J.; Christian, A.; Levy, R.; Stachelek, S. Polymers 2014 6, 2526.
5. Inagaki, K.; Yamao, T.; Noguchi, T.; Matozaki, T.; Fukunaga, K.; Takada, T.;
Hosooka, T.; Akira, S.; Kasuga, M. EMBO J. 2000 19, 6721−6731.
6. Barclay, A. N.; Van den Berg, T. K. Annu. Rev. Immunol. 2014 32, 25−50.
7. Zhao, X. W.; van Beek, E. M.; Schornagel, K.; Van der Maaden, H.; Van Houdt, M.;
Otten, M. A.; Finetti, P.; Van Egmond, M.; Matozaki, T.; Kraal, G.; et al. Proc. Natl.
Acad. Sci. U. S. A. 2011 108, 18342−18347.
8. Chao, M. P.; Alizadeh, A. A.; Tang, C.; Jan, M.; Weissman-Tsukamoto, R.; Zhao, F.;
Park, C. Y.; Weissman, I. L.; Majeti, R. Cancer Res. 2011 71, 1374−1384.
9. Chao, M. P.; Alizadeh, A. A.; Tang, C.; Myklebust, J. H.; Varghese, B.; Gill, S.; Jan,
M.; Cha, A. C.; Chan, C. K.; Tan, B. T.; et al. Cell 2010 142, 699−713.
10. Chao, M. P.; Tang, C.; Pachynski, R. K.; Chin, R.; Majeti, R.; Weissman, I. L. Blood
2011 118, 4890−4901.
11. Edris, B.; Weiskopf, K.; Volkmer, A. K.; Volkmer, J.-P.; Willingham, S. B.;
Contreras-Trujillo, H.; Liu, J.; Majeti, R.; West, R. B.; Fletcher, J. A.; et al. Proc. Natl.
Acad. Sci. U. S. A. 2012 109, 6656−6661.
12. Weiskopf, K.; Ring, A. M.; Ho, C. C. M.; Volkmer, J.-P.; Levin, A. M.; Volkmer, A.
K.; Özkan, E.; Fernhoff, N. B.; van de Rijn, M.; Weissman, I. L.; Garcia, K. C. Science
2013 341, 88−91.
13. Ho, C. C. M.; Guo, N.; Sockolosky, J. T.; Ring, A. M.; Weiskopf, K.; Özkan, E.;
Mori, Y.; Weissman, I. L.; Garcia, K. C. J. Biol. Chem. 2015 290, 12650−12663.
14. Panni, R. Z.; Linehan, D. C.; DeNardo, D. G. Immunotherapy 2013 5, 1075.
15. Mitchem, J. B.; Brennan, D. J.; Knolhoff, B. L.; Belt, B. A.; Zhu, Y.; Sanford, D. E.;
Belaygorod, L.; Carpenter, D.; Collins, L.; Piwnica-Worms, D.; et al. Cancer Res. 2013
73, 1128−1141.
16. Chames, P.; Van Regenmortel, M.; Weiss, E.; Baty, D. Br. J. Pharmacol. 2009 157,
220−233.
17. Mout, R.; Ray, M.; Yesilbag Tonga, G.; Lee, Y.-W.; Tay, T.; Sasaki, K.; Rotello, V.
M. ACS Nano 2017 11, 2452−2458.
69

18. Varela-Rohena, A.; Carpenito, C.; Perez, E. E.; Richardson, M.; Parry, R. V.; Milone,
M.; Scholler, J.; Hao, X.; Mexas, A.; Carroll, R. G.; June, C. H.; Riley, J. L. Immunol.
Res. 2008 42, 166−181.
19. Rossig, C.; Brenner, M. K. Mol. Ther. 2004 10, 5−18.
20. Zhang, F. Hum. Gene Ther. 2015 26, 409−410.
21. Ran, F. A.; Hsu, P. D.; Wright, J.; Agarwala, V.; Scott, D. A.; Zhang, F. Nat. Protoc.
2013 8, 2281−2308.
22. Mout, R.; Ray, M.; Lee, Y.-W.; Scaletti, F.; Rotello, V. M. Bioconjugate Chem. 2017
28, 880−884.
23. Ray, M.; Tang, R.; Jiang, Z.; Rotello, V. M. Bioconjugate Chem. 2015 26, 1004−
1007.
24. Tang, R.; Kim, C. S.; Solfiell, D. J.; Rana, S.; Mout, R.; Velázquez-Delgado, E. M.;
Chompoosor, A.; Jeong, Y.; Yan, B.; Zhu, Z.-J.; Kim, C.; Hardy, J. A.; Rotello, V. M.
ACS Nano 2013 7, 6667−6673.
25. Sano, S.-I.; Ohnishi, H.; Kubota, M. Biochem. J. 1999 344, 667−675.
26. Chen, J.; Zhong, M.-C.; Guo, H.; Davidson, D.; Mishel, S.; Lu, Y.; Rhee, I.; PérezQuintero, L.-A.; Zhang, S.; Cruz-Munoz, M.-E.; Wu, et al. Nature 2017 544, 493−497.
27. Jiang, Y.; et. al. Angew. Chem. Int. Ed. 2015, 54, 506–510.

70

CHAPTER 4
SURFACE-MODIFIED MACROPHAGES FACILITATE TRACKING OF BREAST
CANCER-IMMUNE INTERACTIONS
Reprinted (adapted) with permission from“Joshi, B.; Hardie, J.; Mingroni, M. A.;
Basabrain, A. O.; Paracha, A.; Farkas, M. E. ACS Chem. Bio. 2018, 13, 2339-2346.”
Copyright (2018) American Chemical Society

4.1 Introduction
With implications toward the development of new treatments and understanding
the nature of the disease, the intersection between cancer and the immune system has
become a very busy place. While the immune system is responsible for detecting and
removing abnormal cells, many cancers can produce signals and/or undergo
transformations to avoid this fate.1 Macrophages are immune cells that play a major role in
facilitating cancer progression (Figure 4.1), leading to the correlation of their presence with
disease severity in many cancer types.2 In fact, macrophages represent the most abundant
leukocyte within the tumor environment, comprising in some instances up to 50% of the
tumor mass.3 Tumor associated macrophages (TAMs) have been shown to generate factors
that promote tumor angiogenesis,4 silence the immune response to tumors,2 and contribute
to the epithelial to mesenchymal transition (EMT), 5 a metastatic process where epithelial
cells undergo changes that result in an enhanced migratory capability, increased
invasiveness, and elevated resistance to apoptosis ascribed to mesenchymal (i.e., stem celllike) phenotypes via remodeling of the tumor environment and association with tumor
cells.6 They have also been implicated in the metastasis-enabling processes of intra- and
extra-vasation of migratory tumor cells7 and can affect the efficacy of anticancer
therapeutics.8 TAMs are not only important in the initial stages of metastasis but have been
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shown to contribute to the establishment and survival of metastases at sites away from the
primary tumor.9−11 TAMs have been associated with a variety of tumor types, including
breast, prostate, glioma, lymphoma, bladder, lung, cervical, and melanoma. 12

Figure 4.1. Macrophage contributions to cancer and its metastasis.
On account of their roles in cancer progression and metastasis, TAMs have become
a target of interest for developing new treatments.13 But because macrophages and their
monocyte precursors are actively recruited to cancerous tissues, 14 they have also become
candidates for use as imaging and therapeutic agent delivery vehicles. 15 A number of tumor
types secrete the major macrophage chemoattractants macrophage colony stimulating
factor (M-CSF, also known as colony stimulating factor 1, or CSF-1) 16 and monocyte
chemoattractant protein like chemokine (C−C motif) ligand 2 (CCL2).17 Once in the tumor
microenvironment, TAMs can traffic into difficult-to-reach hypoxic regions, 14 areas that
are problematic to target with other therapeutic delivery systems. 18 Engineered
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macrophages are therefore being developed as tools for the diagnosis and treatment of
various diseases, from delivering theranostic (therapeutic and diagnostic) agents to
tumors19 to administering antiretroviral therapeutics to HIV infected mice. 20 For cancerbased applications, the specific interactions of macrophages with tumor tissue have been
exploited to facilitate imaging of tumors and metastases and the delivery of various
therapeutics. This has enabled enhanced contrast of tumor boundaries and imaging of
metastases, as well as the delivery of nanoparticle-conjugated small molecule and
photothermal therapeutics to tumors, showing efficacy in vitro and in vivo.19,21−24
The challenge in using nanoparticles as a therapeutic strategy, however, is that their
phagocytosis and release are difficult to control, despite modifications to particle surfaces
to alter their characteristics.25 Furthermore, because small molecules cannot be engulfed
and released in the same manner without additional modifications, 26 these platforms are
limited to the use of nanoparticle agents. Separately, transgenic animals expressing GFP, 27
CFP,28 and RFP29 have been produced and employed in imaging studies of cancer−host
cell interactions,30 including in longitudinal studies.31 In these cases, tumor cells derived
from a fluorescent animal can be distinguished from host cells in or from another animal
bearing a different reporter.32,33 While cells derived from these systems can be used in the
context of imaging, they must be obtained from genetically modified animals, and only
fluorescence-detecting platforms may be used. To circumvent various issues associated
with macrophage engulfment and release, and to provide a more flexible strategy for
imaging, delivery, and studies of macrophage associations with cancer, we have
investigated the direct modification of macrophage cell surfaces with small molecules.
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The cell membrane contains a diverse array of biomolecules, many of which can
be

chemically

manipulated34

to

allow

selective

noncovalent35

and

covalent

bioconjugations.36 Successful membrane modification involves linkage of the target
molecule to the cell surface under physiological conditions, without inhibiting the normal
functioning of the cell. In this report, we demonstrate that fluorescent probes can be
appended to macrophages to monitor chemosensing, tracking, and interactions with cancer
cells. Using either N-hydroxysuccinimide coupling chemistry 37 or metabolic incorporation
of unnatural azido-sugars,38 we show that modified macrophages chemotax to a similar
extent as unmodified cells and, more importantly, continue to associate with cancer cells
in vitro and accumulate in tumors in vivo. This work sets the stage for further use of this
platform as a diagnostic tool but also as a delivery agent for therapeutics and molecular
probes to study the tumor microenvironment.

Figure 4.2. Detailed scheme of three cell surface modification methods including step-bystep reaction conditions.

4.2. Results and discussion
4.2.1. Modification of macrophages to install fluorescent molecules
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To determine whether macrophages (i.e., RAW 264.7 cells) are amenable to surface
modifications, three different approaches were used (Figure 4.2, 4.3A). In the first method,
the cell surface is biotinylated by reacting exposed primary amines with sulfosuccinimidyl6(biotinamido)hexanoate

(Sulfo-NHS-LC-Biotin),

prior

to

binding

fluorescein

isothiocyanate (FITC)-labeled avidin.39 Cellular labeling was confirmed by fluorescent
confocal microscopy (Figure 4.2, Figure 4.3B). We also attached the dye moiety directly
to the cells, forgoing the display of large avidin proteins on the cell surface, via Nhydroxysuccidimide (NHS)-dye conjugation. With Sulfo-NHS-Cyanine5 (NHSCy5), we
observed significant cellular modification (Figure 4.2, Figure 4.3C). As a third approach,
we used metabolic labeling and “click” chemistry, which also utilizes small molecules, but
modifies incorporated unnatural azido-glycans as opposed to amino acids. 38 Cells were
metabolically

labeled

with

azidoacetylmannosamine

(ManNAz)

or

azidoacetylglucosamine (GlcNAz), and subsequent Staudinger ligation was performed
using Phosphine-Dylight 650 (Phos-Dy680). Confocal microscopy images illustrate the
extent of labeling (Figure 4.2, Figure 4.3D).
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Figure 4.3. Approaches for chemical modification of macrophages. (A) Three methods
used to modify the model macrophage cell line RAW 264.7 are an attachment of NHSbiotin followed by noncovalent interaction with fluorophore-conjugated avidin
(Biotin/Avidin-dye), amide formation through direct linkage of NHS-fluorophores with
cell surface lysines (NHS-dye), and bioorthogonal Staudinger ligation between phosphine
conjugates and metabolically incorporated azido sugars (N3/Phos-dye). Confocal
microscopy images show suspended RAW 264.7 cells labeled with (B) avidin-FITC, (C)
NHS-Cy5, and (D) phosphine-Dylight 650. Corresponding cellular dye distributions via
fluorescence intensities are shown adjacent to the respective image. Modified sites are
generally located at the membrane or endosomally throughout the cell (yellow line).
Magnification = 60x, scale bar = 25 μm.
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All three conjugation approaches resulted in significant cellular modification with
a majority of the dye intensities located at the cell membranes. As expected, fluorescence
intensity decreases concomitantly with macrophage proliferation (doubling time is ∼15 h;
Figure 4.4) and the signal remains over several cell divisions. Following modifications,
cells could be stored and were viable for up to 1 week without any manipulation, with the
exception of metabolically installed ManNAz conjugates, which showed slightly
diminished viabilities (data not shown). With the two-step strategies (biotin−avidin and
metabolic labeling), we have found that the appendage of the fluorophores largely depends
on the presence of the linker. For example, incorporation of avidin-FITC is not observed
unless cells have been biotinylated (Figure 4.5A). Likewise, minimal uptake of PhosDy680 is detected in cells that have not incorporated the azido sugar (Figure 4.5B).
Modifications did not affect macrophage polarization state (Figure 4.6), and cells largely
retained their abilities to phagocytose entities (Figure 4.7). The employment of these three
strategies is also useful for the modification of cells with other molecules; a wide array of
NHS-, (strept)avidin-, and phosphine-linked molecules are commercially available or can
be synthesized. Of particular interest for in vivo imaging applications is the installation of
near-infrared dyes to facilitate tissue penetration. We have also found the surface
functionalization methods to be versatile and amenable to use with other macrophage types,
including J774.2 (murine monocyte macrophages) and bone marrow derived primary
macrophages (Figure 4.5C).
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Figure 4.4. Cellular fluorescence over time. The results are shown as percentage difference
in fluorescence from time = 0, which has been normalized to 100% for each modification
type. Error is shown as standard deviation of the mean.
4.2.2. Macrophage migration and chemotaxis
Critical to the employment of functionalized macrophages as agents for the
visualization of macrophage interactions with cancer cells, delivery of therapeutics to
tumor

sites,

or

localization

of

chemical

probes

to

understand

oncogenic

microenvironments, is the retention of chemotactic properties. For this reason, it is
important to assess motility following chemical modification. Because the biotin/avidindye modification results in the potential for steric hindrance on account of the resulting
display of avidin proteins (monomer is approximately 16.5 kDa), the majority of studies
described here were conducted using macrophages that were conjugated in this manner.
Wound healing/scratch assays were used to visualize cellular motility. 40 A single
“scratch” was generated through a monolayer of cells, and the ability of the cells to migrate
and fill the scratch was tracked over time via fluorescence microscopy. We compared
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nonmodified cells with those appended with biotin/avidin-FITC (Figure 4.8A) and noted
that the two were strikingly similar. Macrophage response to chemotactic signals was
determined via Boyden chamber assay.41 Here, labeled and nonlabeled macrophages were
compared in their abilities to migrate through a membrane in response to a chemoattractant
(CSF-1 was used in all instances; Figure 4.8B). These experiments show that not only do
cells survive chemical modification but they continue to migrate toward a chemoattractant.
Furthermore, even the presence of large avidin proteins on the cell surface does not hinder
cellular sensing and trafficking abilities.

Figure 4.5. Specific cellular labeling in the presence of both linkers and dyes, which may
be applied to different macrophage types. (A) Suspended cells are only labeled in the
presence of both biotin and avidin; no fluorescence is observed where cells are incubated
with only avidin. (B) Significant fluorescence is observed in suspended cells metabolically
labeled with azidomannose followed by reaction with Dylight 650; in the absence of
azidomannose, minimal fluorescence was seen. Magnification = 60x, scale bar = 25 μm.
(C) The biotin−avidin strategy is used to label J774.2 (monocyte-derived, magnification =
63x, scale bar = 20 μm) and primary (harvested and differentiated from bone marrow,
magnification = 20x, scale bar = 50 μm) macrophages in suspension.
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Figure 4.6. Macrophage polarization following chemical modification. Data for M1
markers (TNF-α and iNOS) are shown here. M2 markers (Ym1 and Arg1) did not amplify
in any of the samples shown. While NHS-Cy5 shows slightly increased levels of M1
markers, these are minimal compared to those accompanying M1 polarization. NT = Not
Treated, and a DMSO control group is included to account for treatment of the
metabolically incorporated azido-sugars. Error bars indicate standard deviation of the
mean.

Figure 4.7. Macrophage phagocytosis following chemical modification. Biotinstreptavidin labeling and NHS coupling methods show reduced phagocytic efficacy.
However, metabolic labeling methods had increased zymosan internalization possibly due
to membrane permeabilization. Each group is the result of three separate measurements.
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Having determined that the biotin/avidin-dye modification method has minimal
effects on cellular chemotaxis, we evaluated the effects of other labeling strategies. Boyden
chamber assays were used to determine the effects of direct NHS-dye incorporation and
metabolic-Staudinger ligation methods (using both GlcNaz and ManNaz for azide
incorporation) on migration toward CSF-1 chemoattractant (Figure 4.9). Similarly to
biotin/avidin, the use of these other strategies resulted in minimal change to migration
ability in comparison with nonmodified cells exposed to CSF-1 in the positive control
group. As a result, we conclude that each method assessed largely preserves the ability of
macrophages to track and follow chemoattractant signals produced by cancer cells and may
be amenable to use in further studies on macrophage-oncogenic interactions.

Figure 4.8. Motility capabilities retained by functionalized macrophages. (A) Assessment
of adherent macrophage motility via wound healing assay. At time 0, a pipette tip-induced
scratch was generated in both nonmodified and Avidin-FITC labeled RAW 264.7 cells.
Migration after 24 h was observed; both set behaved similarly. Dashed line indicates
highest cell density border; scale bar is 200 μm. (B) Boyden chamber assay to determine
migration changes following suspended modification. Modified cells migrate similarly to
nontreated cells. Nonmodified cells were tracked in starved media with and without the
CSF chemoattractant and compared to Avidin-FITC modified cells exposed to CSF. Nine
panels of cells were counted per treatment (n = 9, from three biological replicates,
represented by differently colored diamonds). Boxes represent the interquartile range (25th
to 75th percentile). The line bisecting the box represents the median. The small square in
the center is the mean, and whiskers indicate the 5th and 95th percentiles. *P ≤ 0.0001.
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4.2.3. Macrophage association with in vitro models of breast cancer.
After establishing that the migratory aptitude of macrophages is not altered upon
modification, we investigated the association between these modified cell lines and cancer
cells. Breast cancer is a heterogeneous disease generally classified into five subtypes based
on genetic profile: luminal A (estrogen receptor (ER) positive, low grade), luminal B (ER
positive, high grade), human epidermal growth factor receptor 2 (HER2) enriched, basallike (ER negative, HER2 negative, progesterone receptor (PR) negative; often referred to
as triple negative), and claudin-low (triple negative with low expression of cell−cell
junction proteins).42 These disease types are not only associated with the presence and/or
absence of cellular markers but with varying levels of aggression and patient outcomes. At
different ends of the spectrum, luminal A is generally considered highly treatable and has
high rates of survival, while triple negative types are extremely aggressive with few
treatments available, resulting in far worse prognoses. Knowing that macrophages are
strong contributors to cancer progression,5,10 that patients with higher levels of tumor
associated macrophages have worse prognoses,3 and that CSF-1 both is a macrophage
chemoattractant and has been correlated with breast cancer mortality, 43 we wished to
determine whether particular cancer subtypes have an enhanced capability to recruit and
interact with macrophages.
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Figure 4.9. Similar behavior of modified suspended macrophages to one another and
nonlabeled cells exposed to CSF-1. Box and whisker plot of counted cell groups (n = 9
from three biological replicates, represented by differently colored diamonds) from
Boyden chamber assay comparing migratory behaviors. Boxes represent the interquartile
range (25th to 75th percentile). The line bisecting the box represents the median. The small
square in the center is the mean, and whiskers indicate the 5th and 95th percentiles. We
compare nonlabeled cells not exposed to and exposed to Colony Stimulating Factor-1
(CSF, controls), versus surface-labeled cells exposed to CSF (NHS-Cy5, cells
metabolically labeled with N-azidoglucose (GlcNaz) or -mannose (ManNaz) conjugated to
phos-DY650). As a control for the metabolically labeled cells, we have also included a
DMSO-treated control. *P ≤ 0.0001.
We present here the results from initial studies addressing the association of
macrophages with cancer cells representing different subtypes and degrees of aggression,
facilitated by chemically modified macrophages. While it has been observed that
macrophage infiltration occurs to a lesser extent in luminal A versus other tumor
subtypes,44 interactions between cancer cells and macrophages have not been assessed. We
utilize MCF7 (luminal A), SKBR3 (HER2+), and MDA-MB-231 (triple negative, claudinlow) cell lines in concert with RAW 264.7 macrophages at approximately a 2:1 ratio.
Previous work has demonstrated the cross-species interaction of murine macrophages with
human cancer cell lines.45 Indeed, across multiple experiments the macrophages show the
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most vivid associations with the most aggressive cell line, MDA-MB-231 (Figure 4.10).
Fluorescence microscopy was similarly used to evaluate macrophage interactions with
MCF7 and SKBR3 cells. While macrophages associated with both of these breast cancer
cell lines as well, the interactions were not nearly as dramatic. Whereas the macrophages
appear to “pick up” and move the MDA-MB-231 cells, they seem to pull the MCF7 cells,
which remain attached to the surface. The SKBR3 cells appear unperturbed by the
macrophages, which hover in the vicinity and appear to make contact, but do not show any
effect. Single-cell type experiments are provided for reference. Future work toward this
end involves studying associations of macrophages with additional cell types and the use
of three-dimensional cell culture tissue models.

Figure 4.10. Modified macrophage homing and interaction with cancer cells. Time-lapse
fluorescence microscopy images show migration and association of FITC-avidin labeled
(in suspension) RAW 264.7 macrophages with MDA-MB-231 cancer cells at a 1:2 ratio
across 0, 4, 8, and 12 h. Green = avidin-FITC macrophages; blue = MDA-MB-231 cells
labeled with cell tracker dye. Scale bars indicate 100 μm.
4.2.4. Chemically modified macrophages show tumor homing capabilities in a mouse
model of cancer
In vivo biodistribution studies of functionalized macrophages were performed to
determine the applicability of our platform to studying the interactions between
macrophages and tumors and metastases in mouse models of cancer. Because of the
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immune relevant nature of this work, it is critical to use animals with intact immune
systems. For this reason, we used female BALB/c mice orthotopically implanted with
isogenic 4T1 (mouse mammary carcinoma) cells;46 RAW 264.7 macrophage cells also
possess the same genetic background. 4T1 cells are highly tumorigenic and invasive. They
have been widely used as a clinically relevant triple-negative breast cancer model and are
considered to represent stage IV human breast cancer. 47 Once tumors were palpable,
macrophage cells were modified using the biotin/avidin-dye method to append Dy680 to
the cell surface. These cells were intravenously injected into the mice (n= 3) via tail veins.
Because the mouse breed possesses autofluorescent hair, the removal of which can result
in additional stress and inflammation and is not always effective in removing all signal,
macrophage biodistribution was assessed ex vivo following euthanasia at 4 and 24 h
following injection (Figure 4.11).

Figure 4.11. Macrophage biodistribution in an immune-competent mouse model of breast
cancer. 4T1 cells (mouse mimic of stage IV human breast cancer) were orthotopically
implanted into BALB/c mice. Macrophages were labeled via suspended methods with
biotin/avidin-Dy680 immediately prior to intravenous injection via tail vein. Following
euthanasia at 4 and 24 h after injection, fluorescent imaging of organs was performed ex
vivo using IVIS-CT.
At the 4 h time-point, significant signal is observed in the liver, followed by the
spleen, lungs, and tumor, with some signal in the brain. It is also noted that significant
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signal appears in the tail, which may be the result of macrophage accumulation near the
site of injection due to the presence of a wound or inability to leave the tail vein. After 24
h, signal remains in the tumor, liver, and spleen. Considering that the macrophage surfaces
are significantly modified with foreign entities (Figure 4.2), the accumulation of
macrophages in the liver is not surprising. The hepatic route is a major pathway for
elimination of a variety of drugs, nanoparticles, and other entities that are too large for
renal (kidney) excretion. It is in fact encouraging that in general, macrophages that are not
localized to the tumor are also not accumulating in other tissues but rather are likely being
excreted. In the future, we will assess the biodistribution of macrophages modified with
smaller functionalities. Also, in further work, we seek to use imaging modalities that will
facilitate in vivo tracking of the macrophages (e.g., PET or MRI) and study their tracking
to and accumulation at metastatic sites.
4.3 Conclusion
We have been able to demonstrate that macrophages can be functionalized via three
different approaches, retaining viability and their inherent migratory and chemotactic
properties in vitro and in vivo. While earlier work utilizing macrophages as delivery
vehicles was constrained to the phagocytosis and release of nanoparticle-based agents, we
have shown that surface modification is also feasible, and small molecules may be used.
By using this strategy we can now employ macrophage conjugates as delivery vehicles for
in vivo imaging, therapeutic, and chemical-sensing agents for the diagnosis, treatment, and
study of cancer. Furthermore, many groups are broadly interested in the chemical
modification of cells toward a variety of applications-this work also serves to answer some
fundamental questions regarding the biological effects of these alterations.

86

4.4. Methods
4.4.1. Reagents and cell lines
All reagents were purchased from Thermo-Fisher Scientific except where
otherwise noted. Immortalized cell lines were obtained from the ATCC and maintained
under ATCC recommended conditions. Primary macrophages were isolated and
differentiated from bone marrow of BALB/c mice, as previously reported. 48 Following
differentiation, cells were used within 7 days.
4.4.2. Biotin-(strept)avidin modification of macrophages.
Cells were labeled in either an adherent or suspended manner. For adherent
labeling, culture medium was removed and cells rinsed twice with phosphate-buffered
saline (PBS). Cells were then incubated in 2 mM Sulfo-NHS-LC-Biotin for 30 min at
ambient temperature and then washed twice with 100 mM glycine, once with PBS, and
then incubated in 2.5 μg/mL Avidin-FITC or Streptavidin-Dylight for 30 min at 37 °C/5%
CO2. Cells were rinsed once more with PBS before use. For suspended labeling, cells were
harvested via trypsinization, centrifugation, and resuspension, followed by counting. For 6
× 106 cells, the cell pellet was rinsed twice with 1 mL of PBS, centrifuging and removing
supernatant for each wash. Cells were resuspended in 2 mL of 2 mM Sulfo-NHS-LC-Biotin
and incubated for 30 min at ambient temperature. Cells were then centrifuged at 1500 rpm
for 5 min, and the pellet was washed twice with 2 mL of 100 mM glycine and once with 1
mL of PBS. Cells were resuspended in 2 mL of 2.5 μg/mL FITC-Avidin or StreptavidinDylight 680 for 30 min at 37 °C and 5% CO2. Cells were centrifuged at 1500 rpm for 5
min, and the pellet was rinsed once with 1 mL of PBS before use. Images of cells were
acquired using a Nikon Point Scanning C2+ confocal microscope with excitation at 488
and 650 nm.
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4.4.3. Direct NHS-Ester Modification of Macrophages.
Cells were labeled in either an adherent or suspended manner. For adherent
labeling, culture medium was removed and cells rinsed twice with phosphate-buffered
saline (PBS). Cells were then incubated in 100 μM Sulfo-NHS-Cyanine5 (Lumiprobe) for
1 h at 37 °C and 5% CO2, and then washed twice with 100 mM glycine, once with PBS.
Cells were rinsed once more with PBS before use. For suspended labeling, the cell
monolayer was treated with 0.25% trypsin for detachment, centrifuged, resuspended, and
counted. For 4 × 106 cells, the pellet was rinsed twice with 1 mL of PBS, centrifuging and
removing supernatant for each wash. Then, cells were suspended in 400 μL of 100 μM
Sulfo-NHS-Cyanine5 (Lumiprobe) and incubated for 1 h at 37 °C and 5% CO 2. Cells were
centrifuged at 1500 rpm for 5 min, and the pellet was rinsed twice with 2 mL of 100 mM
glycine and once with 1 mL of PBS before use. Images of cells were acquired using a
Nikon Point Scanning C2+ confocal microscope with excitation at 488 and 650 nm.
4.4.4. Metabolic labeling/staudinger ligation modification of macrophages.
Labeling of cells via this method largely followed previously established
protocols.28 In both suspended and adherent modifications, cells were cultured in complete
DMEM media supplemented with 40 μM ManNAz or GlcNaz (0.4% DMSO v/v), for 72 h
at 37 °C and 5% CO2. For adherent labeling, culture medium was removed and cells rinsed
twice with phosphate-buffered saline (PBS). Cells were then incubated in Dylight 650Phosphine (1% DMSO v/v) and incubated for 3 h at 37 °C and 5% CO 2 and then washed
twice with PBS. Cells were rinsed once more with PBS before use. For suspended
modification, cells were detached using a cell scraper. For 4 × 106 cells, following
additional centrifugation, the pellet was rinsed with 1 mL of 2% fetal bovine serum (FBS)
in Hank’s Buffered Saline Solution (HBSS), and then resuspended in 400 μL of 100 μM
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Dylight 650-Phosphine (1% DMSO v/v) and incubated for 3 h at 37 °C and 5% CO 2. Cells
were centrifuged at 1500 rpm for 5 min, and the pellet was rinsed twice with 1 mL of 2%
FBS in HBSS and once with 1 mL of PBS before use. Images of cells were acquired using
a Nikon Point Scanning C2+ confocal microscope with excitation at 488 and 650 nm. For
experiments employing a DMSO control, populations of cells were treated with DMSO for
analogous times at the same concentrations (0.4% for 72 h and 1% for 3 h).
4.4.5. Wound healing/scratch assay
For the wound healing assay, RAW 264.7 cells were plated at high density (5 × 10 6
cells per well) in a six-well plate and incubated for 6 h at 37 °C and 5% CO2 to adhere.
The cells were labeled with avidin-FITC according to the protocol above. A sterile 200 μL
pipet tip was used to make a single scratch through the monolayer. The cells were rinsed
once with PBS and then incubated in phenol-red free complete DMEM media. Scratch
width was monitored using a Zeiss Axio Observer Z1 microscope.
4.4.6. Chemotaxis/boyden chamber assay
Boyden chamber cell migration assays were largely performed as previously
described.31 A transwell insert (8 μm pore, 6.5 mm, PET membrane; Corning Life
Sciences) was coated with 10 μg/mL of fibronectin (Sigma-Aldrich), allowed to rest for 4
h at ambient temperature, rinsed with PBS, and left to dry overnight. The inserts were
placed into 24-well plates containing 650 μL of starved (FBS-free) media supplemented
with and without 40 ng/mL rCSF-1, depending on chemoattractant conditions. In parallel,
cells were cultured for 24 h in starved media and then either labeled according to the
respective protocol or left untreated. For azido-sugar metabolic labeling, cells were
cultured in complete media containing the azido-sugar for 48 h, followed by replacement

89

with starved media containing azido-sugar for 24 h. For each cell sample, 100 μL
containing 1 × 105 cells was added into the transwell insert and incubated for 12 h at 37 °C
and 5% CO2. Nonmigratory cells were removed with a Q-tip, and migratory cells at the
bottom of the insert were fixed in 4% formaldehyde and stained with a 0.1% crystal violet
solution in 25% methanol. Membranes were removed from the inset, mounted onto coverglass, and visualized using a Zeiss Axio Observer Z1 with an Axio Cam 506 Color
attachment. Using a 20x objective, cells were counted from three fields of view per
membrane, with three membranes per condition (n = 9). Box and whisker plots were
generated using OriginPro 2017, and statistical significance was determined using the
student’s t test (two tailed distribution and two sample unequal variance).
4.4.7. Coculture assays
MCF7, SKBR3, and MDA-MB-231 cells were plated on 24-well tissue culture
plates at 1 × 105 cells per well and incubated overnight (∼20 h). MDA-MB-231 cells were
labeled with CellTracker Blue CMAC dye (Invitrogen) according to the manufacturer’s
protocol. RAW 264.7 cells were avidin-FITC labeled in suspension, and 1 × 10 5 cells were
added to each cancer-cell containing well. Accounting for cancer cell growth, the ratio of
cancer to macrophage cells was approximately 2:1. Time lapse microscopy was used to
monitor cell behavior at 15 min intervals over 12 h using a Zeiss Spinning Disk Observer
SD confocal microscope with excitation at 405 and 488 nm.
4.4.8. Generation of in vivo tumor models and macrophage biodistribution studies
Six to eight-week-old BALB/cAnNCrl mice (Charles River Laboratories) were
orthotopically implanted with 5 × 104 4T1 murine breast cancer cells, similarly to previous
studies.36 Briefly, mice were anesthetized with 400 mg/kg tribromoethanol, the ventral
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thoracic-inguinal region was shaved, and an incision was made to expose the fourth
mammary fat pad. The veins leading to the fat pad were cauterized and the fat pad was
removed using forceps. The 4T1 cells were injected into the fat pad cavity in 10 μL of PBS
using a 100 μL Hamilton syringe. A total of 1 mg/kg of bupivacaine was administered to
the surgical site, and the wound was closed using wound clips. Following closure, 1 mg/kg
meloxicam was administered subcutaneously. Mice to be used for imaging were placed on
an alfalfa-free diet. Once palpable tumors formed, 1 × 107 RAW 264.7 cells were labeled
with avidin-DY680 using the suspension method described above. Cells were then
suspended in 100 μL of PBS and were injected into tumor-bearing mice intravenously
through the tail vein. At 4 and 24 h following injection, mice were euthanized, and organs,
blood, and tumors collected. Tissues were imaged using an In Vivo Imaging System (IVIS;
PerkinElmer) available at UMass Amherst. All procedures involving the use of animals
were conducted under a protocol approved by the Institutional Animal Care and Use
Committee (IACUC) at UMass Amherst.
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CHAPTER 5
MACROPHAGE-ENCAPSULATED BIOORTHOGONAL NANOZYMES: TOOLS
FOR TARGETED CANCER THERAPY
5.1 Summary
Targeted drug delivery is a prominent strategy for avoiding the widespread toxicity
typically associated with conventional cancer chemotherapies. The successful application
of targeting has been shown to result in improved survival time and patient quality of life. 1
Macrophages are innate immune cells that are inherently attracted to specific tissue
environments, including hypoxic, ischemic, and necrotic areas associated with tumors and
their cores.2 Concurrently, many cancers secrete macrophage chemoattractants, whose
gradients the cells migrate across, resulting in active recruitment of cells to cancerous
regions.3 This characteristic makes macrophages particularly attractive as cell-based
delivery vehicles for accessing solid tumors, which are normally difficult to reach by using
conventional targeting strategies.4
Previous approaches have utilized macrophages loaded with nanoparticle-drug
conjugates or free drugs for anti-cancer therapeutic delivery. 4a,5 In several cases, the cellmediated delivery resulted in greater efficacy than free materials, and reduced off-target
toxicity.6 However, the direct loading approach is challenging due to the ceiling for amount
of loadable payload and lack of controlled release pathways. Cells are limited in the amount
of drug they can carry, and there are no cellular means to regulate the rate, extent, and site
of discharge. The loaded cytotoxic drugs can also affect or kill the carrier cell prior to
reaching the desired target site. To a certain extent, these issues can be addressed by
utilizing macrophages bearing stimuli-responsive nanoparticles, which control the release
of therapeutics.7 In these approaches, external stimuli such as thermal energy, light, or
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ultrasound can be used to trigger release of drug molecules from nanoparticles specifically
at the tumor site. While this type of strategy is promising, limited therapeutic loading
remains a hurdle. Also, efficiency is affected by tissue penetration depth of stimuli, and
localized damage to the surrounding healthy tissues is a concern.
Bioorthogonal catalysis8 has the potential to overcome limitations associated with
payload loading of and release from macrophages and other cell-based delivery agents.
Internalized catalysts can be transported by cells to the desired tissue/organ, where they
continuously generate active therapeutics from inactive prodrugs at the targeted location. 9
In our study, we engineered macrophages as a delivery vehicle for transition metal catalyst
(TMC)-bearing gold nanoparticle (AuNP) nanozymes (NZs). In these NZs, catalysts are
embedded in the AuNPs, providing solublization and protection. The TMCs can then
activate profluorophores/prodrugs via bioorthogonal cleavage reactions in the cellular
environment.10 Here, we deliver NZs into macrophages, converting them into stable
‘factories’ for localized activation of fluorophores and therapeutics. We tested the efficacy
of these NZ-loaded macrophages (RAW_NZ) in a co-culture model with HeLa (human
cervical cancer) cells. Significant cancer cell toxicity was achieved in the presence of
nanozyme-bearing macrophages, even at the lowest concentration of the prodrug
administered. In addition to cancer cell killing abilities, we assessed the migratory behavior
of engineered versus non-modified macrophages towards the Colony Stimulating Factor-1
(CSF) chemoattractant.11 In chemotaxis assays, both cell populations exhibited similar
behaviors, demonstrating that the macrophages retained their targeting abilities. Taken
together, this strategy combines the targeting ability of cell-based drug delivery with
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bioorthogonal activation of a chemotherapeutic prodrug, providing a new approach for next
generation drug delivery systems.

Figure 5.1. Schematic representation of macrophage mediated delivery of bioorthogonal
nanozymes (NZs) for prodrug activation selectively at tumor cells.
For the NZ platform, 2 nm AuNPs functionalized with a ligand containing a
cationic terminal group (TTMA) were employed to facilitate a high degree of cellular
uptake.12 The AuNP ligand monolayer contains a crucial hydrophobic alkane chain for
catalyst encapsulation and a tetra(ethylene glycol) spacer to provide biocompatibility
(Figure 5.1). These particles were synthesized from pentane-thiol capped 2 nm core AuNPs
using a place exchange reaction (synthesis and characterization of NPs is described in
Figures 5.1-5.2).13 Nanozymes were generated by immobilizing a hydrophobic palladium
TMC (1,1′ bis(diphenylphosphino) ferrocene)palladium(II)dichloride 14 in the hydrophobic
portion of AuNP monolayer.14 The catalyst was dissolved in acetone and added to an
aqueous solution of AuNPs in a 1:1 ratio by volume. Acetone was evaporated slowly and
any excess catalyst was filtered away to provide the desired nanozyme. There was no
aggregation observed before or after encapsulation of TMCs, as confirmed by dynamic
light scattering (DLS) (Figure 5.3). Quantification by inductively coupled plasma mass
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spectrometry (ICP-MS) (Table 5.1) indicated that on average, 37 ± 1 catalysts were present
per AuNP in the NZs.

Figure 5.2. MALDI-MS for TTMA AuNPs

Figure 5.3. DLS measurements of AuNPs and NZs, indicating no aggregation before or
after catalyst encapsulation

NZ

Au(ng)

Pd(ng)

Pd(ng)/AuNP(pmol) Pd(pmol)/AuNP(pmol) Pd/AuNP

62.3

5.3

3.9

36.6

65.9

5.5

4

37.6

63.2

5.5

4.1

38.5

37 ± 0.5

Table 5.1. Quantification of encapsulated catalysts in the 2 nm TTMA-AuNP.
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NZs were internalized by macrophages (RAW 264.7) in vitro to generate RAW_NZ
(Figure 5.1). The quantification by ICP-MS showed that both Au (Figure 5.4a) and Pd
(Figure 5.4b) were efficiently uptaken and amounts of both metals increased consistently
with NZ concentration. We also assessed the amounts of Au and Pd in macrophages
following prolonged incubation periods of 48 h and 72 h. These results were similar to
those observed for the 24 h incubation time (Figure 5.4), establishing the long-term
retention of NZs inside macrophages.15 Also, we performed confocal imaging to
demonstrate profluorophore activation by RAW_NZ after 24, 48 and 72 h after preparing
RAW_NZ (Figure 5.5). Similar levels of fluorescence generation were observed even after
72 h. These results demonstrated stability of NZs inside macrophages for a prolonged time
period.

Figure 5.4. Cellular uptake of a) Au (ng/well) and b) Pd (ng/well) in macrophages (RAW
264.7 at 20,000 cells/well) after 24 h, 48 h and 72 h incubation with NZs with increasing
concentration. The data shown are averages of triplicates; error bars indicate standard
deviations.

Figure 5.5. Confocal images of activation of profluorophore by RAW_NZ after 24, 48 and
72 h after preparation of RAW_NZ. The scale bars are 15 μm.
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We next investigated the effects of nanozyme internalization on macrophage
responses to chemotactic signals, critical to their tumor targeting capabilities. 4a Colony
Stimulating Factor-1 (CSF-1) was used as the chemoattractant, and migration was
evaluated by transwell membrane assay (Figure 5.6). We compared the abilities of
macrophages with NZ (RAW_NZ) and without NZ (RAW 264.7) to traffic through a
membrane in response to CSF-1. Macrophages were stained with crystal violet at the
conclusion of the experiment to visualize and quantify the migrated cells. No significant
difference was observed in the behavior of macrophages with and without NZs as observed
under wide-field fluorescence microscope (Figure 5.6a) and after quantification (Figure
5.6b), indicating that the NZs retain their chemoattractant capabilities.

Figure 5.6. Chemotaxis capabilities are retained by RAW_NZ as determined by transwell
membrane assay. a) Confocal imaging of migrated macrophages with NZs (RAW_NZ) and
without NZs (RAW 264.7) in presence and absence of chemoattractant Colony-Stimulating
Factor-1 (CSF-1). All cells were stained with crystal violet to facilitate detection. Scale bar
= 100 µm. b) Quantification of migrated RAW 264.7 cells and RAW_NZ in presence and
absence of CSF-1. Nine panels of cells were counted per treatment (n = 9, from three
biological replicates). Box constitutes the interquartile range (25th to 75th percentile), the
intersecting line designates the median, the small square in the center represents the mean,
and the bottom and top whiskers specify the 5th and 95th percentiles, respectively.
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After establishing the high stability of RAW_NZs and their ability to retain inherent
chemotaxis capabilities of macrophages, we next investigated their therapeutic activation
in a co-culture model with HeLa cells (Figure 5.7). For this study, propargyl-protected 5fluorouracil (pro-5FU) was chosen as a model prodrug (Figure 5.7a), due to the broad
application of its active counterpart (5FU).16 The caged propargyl group blocks the active
site of 5FU, reducing its cytotoxicity before activation by the NZs (Figure 5.8). 10c Once
added to solution containing NZ, the hydrophobic prodrug diffuses towards the
hydrophobic layer of the NZ ligand monolayer containing the catalyst. Once there, the
catalyst deprotects the prodrug, restoring efficacy.
For the co-culture experiment, RAW_NZ cells were seeded on a glass slide, which
was then immersed in a well seeded with HeLa cells (Figure 5.7b). The co-incubated cell
lines were incubated with prodrug at different concentrations, of up to 1 mM for 24 hours.
The glass slide with RAW_NZ was removed before performing Alamar blue assay
separately on HeLa cells and macrophages to differentiate the viability of the cells by type.
In the presence of RAW_NZ, the viability of both HeLa (Figure 5.7c) and RAW 264.7
(Figure 5.8) cells was substantially reduced with increasing concentrations of prodrug,
indicating successful therapeutic activation by NZ. HeLa cells that received increasing
concentrations of prodrug, but were not co-cultured with RAW_NZ did not show any
reduction in cell viability, indicating successful protection of the active site of 5FU (Figure
5.6c). The same trend was mirrored in the case of RAW 264.7 cells that were not modified
with NZs (Figure 5.9), consistent with the inability of macrophages to eliminate tumor
cells.17 Diminished viability of RAW 264.7 cells was observed only occurred in treatments
where NZ and prodrug were both present. Most likely, after the prodrug is activated, the
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carrier cell is killed, which allows the activated drug to escape and kill surrounding target
cells. In therapeutic settings, carrier cell death is not an issue so long as it occurs after the
target tissue has been reached. Also, we investigated toxicity and catalytic activity of free
nanozymes and AuNPs finding both of them non-toxic to cancer cells in absence of
prodrug. Nanozymes showed toxicity only in presence of prodrug, whereas, AuNPs
remained non-toxic in all prodrug concentrations (Figure 5.10). Both HeLa (Figure 5.6)
and RAW 264.7 (Figure 5.9) cells were treated with 5FU as a positive control.

Figure 5.7. a) Pro-5FU activation by RAW_NZ. b) Graphical scheme of co-culture
experiment to evaluate therapeutic efficacy of RAW_NZ in HeLa cells. c) Viability of
HeLa cells after pro-5FU (prodrug) activation by RAW_NZ in the co-culture experiment.
The data are average of triplicates and the error bars indicate standard deviations.
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Figure 5.8. Viability of cells treated with pro-5FU and 5FU at various concentrations as
determined by Alamar blue assay.

Figure 5.9. Viability of RAW 264.7 cells treated with pro-5FU and NZ as determined by
Alamar Blue assay.
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Figure 5.10. Comparison study of viability of HeLa cells after activating pro-5FU of
different concentrations by free nanozymes (NZ) vs by RAW_NZ as determined by Alamar
blue assay.
In summary, we have developed a macrophage-mediated delivery platform for
bioorthogonal nanozymes to generate therapeutic molecules at desired sites. Macrophages
bearing internalized nanozymes demonstrated high therapeutic activation in a co-culture
model with cancer cells. The macrophages retained the nanozymes for prolonged
incubation periods and also demonstrated similar chemotactic behaviors to their nonmodified counterparts, illustrating their potential for use in in vivo applications. Coupling
the chemotactic ability of macrophages with the ability to generate therapeutic and imaging
agents at tumor sites presents a strong advantage relative to current standard chemotherapy
and cell-based therapeutic delivery techniques. Future studies are underway exploring the
use of this platform for specific drug activation in in vivo tumor models.
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CHAPTER 6
TARGETING OF INVADING PATHOGENIC BACTERIA USING
BIOORTHOGONAL NANOZYMES
6.1 Introduction
Salmonella is a Gram-negative intracellular pathogen that causes systemic
infections such as typhoid fever and gastroenteritis. Around 1.3 billion cases of
Salmonella-related illness and 370,000 deaths have been reported every year worldwide. 1
Salmonella infections remain extremely common in the developing world, frequently
affecting the young with a mortality rate of upwards of 30%. 1 As one of the most common
sources of foodborne illness, Salmonella pathogens remain a threat to public health
internationally.1 One of the major problems with treating Salmonella infections is the fact
that Salmonella invades and resides within a host’s own macrophages. These intracellular
infections, where bacteria invade, deactivate and reproduce within host cells, are difficult
to combat.2 The ability of these pathogens to localize in host cells protects the pathogens
from both host defenses and exogenous antimicrobial therapy. The result of this
intracellular infection mechanism is both acute life-threatening infections and long-term
colonization and recurring chronic infections that are difficult to treat. 3
Treatment of intracellular infections remains a critical challenge despite the variety
of antibiotics available in the market. Traditional treatment strategies are ineffective
against intracellular bacteria, as most antibiotics are not designed to penetrate the
mammalian cell wall prior to entering the bacteria and/or are degraded by enzymes in the
host cell cytosol.4,5 The high doses of antibiotics required to kill intracellular pathogens
magnifies their off-target effects on the microbiome. Dosing broad spectrum antibiotics
eliminates beneficial bacteria in the gut microbiome, attenuating the positive role the
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microbiome plays in fighting infections,6 while generating resistant strains that lead to
reduced drug efficacy.7 Moreover, loss of a healthy microbiome leads to a range of
gastrointestinal problems and C. difficile infection.7,8 These challenges are all exacerbated
by the lack of investment in antibiotics, makings it unlikely that a new drug effective
against intracellular infections is likely to appear soon. 9
A key challenge in treating intracellular infections is localization of therapeutic
activity to the affected host cells. Bioorthogonal catalysis provides a strategy for ondemand generation of therapeutics at the disease sites. Nanoparticle-encapsulated catalysts
(nanozymes) provide a versatile platform for bioorthogonal catalysis in complex
biosystems.10,11 We report here the generation of an environmentally-targeted “nanozyme”
that activates pro-antibiotics into antibiotics at the site of intracellular infections to
effectively target pathogenic bacteria. We hypothesized that functionalizing negatively
charged nanozymes with a ligand recognized by macrophages, such as mannose, 12 would
provide a nanozyme that is specifically uptaken by these cells. To achieve this end, we
synthesized mannose-functionalized gold nanoparticles (AuNPs) with encapsulated iron
tetraphenylporphyin catalyst (TPP).13 These catalyst-embedded nanoparticle nanozymes
(Man-NZ) specifically bind and are uptaken by the mannose receptor (CD206) on
macrophage cells. Once internalized, Man-NZ converts pro-ciprofloxacin into
ciprofloxacin to specifically kill pathogenic Salmonella typhimurium. Transwell co-culture
studies using macrophages with internalized Salmonella and non-pathogenic bacteria
resulted in significant reduction of internal Salmonella counts while causing minimal
toxicity to the non-pathogenic bacteria. Our nanozyme strategy combines ligand-receptor
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targeting with bioorthogonal catalysis to create an effective, site-specific intracellular
antibiotic treatment, while avoiding off-target toxicity to the beneficial bacteria biome.

Figure 6.1. Schematic of selective uptake of decorated nanozyme leading to
macrophage-specific antibiotic generation.

6.2 Results and Discussion
Negatively charged carboxylate AuNPs (2 nm core) were used to minimize nonspecific uptake of the nanozyme.14 These particles were synthesized from pentanethiol
capped 2 nm core AuNPs using a place exchange reaction as previously reported. 15 The
particles were post-functionalized with mannose to give the particles macrophage-targeting
functionality. Zeta potential measurements were consistent with these modifications,
changing from -42.7 mV to -7.9 mV after mannose was conjugated (Figure 6.2).
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Furthermore, homogenous hydrodynamic diameter and spherical nature of the AuNP was
demonstrated by DLS and TEM characterization (Figure 6.3 and 6.4). Catalyst
encapsulation into the AuNP monolayer and the resulting nanozyme activity was
demonstrated using ICP-MS analysis and pro-fluorophore activation assay, respectively
(Table 6.1 and Figure 6.5).

Figure 6.2. Zeta potential of NPs, pre- and post-functionalization with mannose.

Figure 6.3. DLS number data of Man-NZ.
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Figure 6.4. TEM image of Man-NZ.

Au(ng)
NZ

Fe(ng)

Fe(pmol)/AuNP(pmol) Fe/AuNP

2937.043 260.671

46.967

3551.401 267.447

39.852

3705.077 361.747

51.668

46.152 ± 4.857

Table 6.1. ICP-MS determination of embedded TPP catalyst concentration in Man-NZ.
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Figure 6.5. Increase in fluorescence following activation of 20 μM pro-resorufin into
resorufin over time by 50 nM Man-NZ with 5 mM glutathione as a cofactor.
After producing the nanozyme, the selective uptake of Man-NZ by macrophages
was quantified using ICP-MS to determine Au accumulation in the cells after incubation
(Figure 6.6). Gold quantitation revealed that Man-NZ was uptaken by macrophages in a
dose-dependent fashion. However, hepatocytes did not accumulate any significant amount
of gold even at the highest doses of Man-NZ. The lack of uptake is expected due to the
slight negative charge of the Man-NZ, as the negative charged cell membrane repells the
particle. For macrophages, the surface-bound mannose receptor recognizes the ligand’s
mannose terminal group. This recognition overcomes charge repulsion and allows for
receptor-mediated endocytosis. The balance of charge repulsion and receptor recognition
allows for selective uptake of the Man-NZ by macrophages, and not other cell types.
Furthermore, the Man-NZ was shown to be non-toxic to the macrophages, even at very
high concentrations, by Alamar blue assay (Figure 6.7).
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Figure 6.6. ICP-MS analysis of gold accumulation in RAW 264.7 macrophages and
HepG2 hepatocytes following 24 hr incubation with varying concentrations of Man-NZ.

Figure 6.7. Cytotoxicity of Man-NZ on RAW 264.7 macrophages.
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6.2.1. Activation of pro-fluorophore within macrophages
After confirming uptake of the Man-NZ, we determined the intracellular activity of
the encapsulated Fe-TPP catalyst. As a catalyst, FeTPP is designed to remove the
protecting group from pro-drugs. This happens when FeTPP reduces the protecting group
azide, which then attacks the attached carbonyl carbon, removing the group in a selfimmolative reaction.16 To confirm this intracellular deprotection, we synthesized a prodrug version of the fluorophore resorufin. This pro-resorufin had reduced fluorescence and
was added to macrophages with and without Man-NZ (Figure 6.8). With Man-NZ, the proresorufin is deprotected and converted to active resorufin with enhanced fluorescence.
Confocal imaging revealed that cells treated with Man-NZ and pro-resorufin had
noticeably more red fluorescence than with only pro-resorufin treatment. Cells treated with
only nanozyme displayed no fluorescence. This increased fluorescence indicates that the
encapsulated catalyst remains active after uptake.

Figure 6.8. Confocal images of RAW 264.7 macrophages incubated with pro-resorufin
and/or Man-NZ. Scale bar = 25 µm
After confirming the activity of the Man-NZ inside of cells, we decided to evaluate
the therapeutic efficacy of the nanozyme in an antibiotic setting. For this assessment, we
synthesized a pro-drug version of the antibiotic ciprofloxacin that is converted to the active
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form by the encapsulated TPP of Man-NZ (Figure 6.8). First, we evaluated antibiotic
unmasking in culture containing only Salmonella typhimurium (Figure 6.9). Compared to
the untreated Salmonella group, treatment with only pro-ciprofloxacin or the Man-NZ
resulted in no significant reduction of bacteria counts. However, treatment with both NZ
and pro-ciprofloxacin (1 μM) reduced Salmonella colony forming units (CFU) nearly
10,000 fold, similar to treatment with ciprofloxacin (15 nM). This level of bacterial
reduction indicates that the pro-ciprofloxacin is successfully converted to the active form,
resulting in Salmonella death.
Following confirmation of antibiotic pro-drug conversion and efficacy, we next
determined the activity of the Man-NZ+pro-ciprofloxacin combination in an intracellular
macrophage Salmonella infection model. Macrophages infected with Salmonella
typhimurium were treated in a similar fashion as the Salmonella-only experiment. Colony
counting following treatment revealed that again, treatment with only Man-NZ or prociprofloxacin did not reduce Salmonella counts significantly, but treatment of ManNZ+pro-ciprofloxacin reduced bacterial counts to a similar extent as treatment with active
ciprofloxacin. Alamar blue analysis also demonstrated that the pro-ciprofloxacin and
ciprofloxacin are not toxic to macrophages at concentrations used in this study (Figure
6.10). This result demonstrates the ability of the Man-NZ to generate active antibiotics to
kill pathogenic intracellular bacteria.
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Figure 6.9. Cytotoxicity of pro-ciprofloxacin and ciprofloxacin on RAW 264.7
macrophages.

Figure 6.10. a.) Salmonella counts decrease substantially after 24 hr treatment with prociprofloxacin and Man-NZ in a Salmonella culture model as determined by colony
counting. b.) Salmonella counts after 24 hr treatment with pro-ciprofloxacin and Man-NZ
in an intracellular macrophage Salmonella infection model as determined by colony
counting.
6.2.2. Selective killing of Salmonella in a pathogenic/non-pathogenic bacterial
coculture model
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Having confirmed the intracellular activation of antibiotic by Man-NZ, we wished
to assess the spatial targeting of the antibiotic treatment via biorthogonal activation from
the macrophage-targeted nanozyme. We created a transwell membrane model in which
bacterial strains similar to those found naturally in the human gut are cocultured with
Salmonella-infected RAW 264.7 macrophages (Figure 6.11). Colony counting after
treatment revealed that ciprofloxacin treatment resulted in significant killing of both
Salmonella and Bio-K+ strains, while pro-ciprofloxacin alonedid not alter counts of either.
However, pro-ciprofloxacin treatment of Man-NZ loaded macrophages resulted in
significant Salmonella death while minimally affecting Bio-K+. This demonstrates the
spatial specificity of the Man-NZ activation strategy: pathogenic intracellular Salmonella
is killed by via activation of pro-ciprofloxacin by macrophage-based Man-NZ, while
extracellular Bio-K+ remained nearly unharmed. This is a significant advantage over
traditional, single-molecule antibiotic therapies, such as ciprofloxacin, which frequently
results in reduction of beneficial bacteria with excessive or even standard dosing.

Figure 6.11. a.) Schematic of transwell bacterial coculture assay. Salmonella infected
macrophages are cultured adjacent to non-toxic Bio-K + cultures; pro-ciprofloxacin is then
added to the top of the well. b.) Salmonella and Bio-K+ counts after 24 hr treatment with
pro-ciprofloxacin and Man-NZ in a transwell intracellular macrophage Salmonella
infection model as determined by colony counting.
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6.3 Conclusion
In summary, we have generated macrophage-targeted bioorthogonal nanozymes to
produce antibiotics at the site of intracellular bacterial infection. Negatively-charged
nanozymes post-functionalized with a mannose terminal headgroup demonstrated high
specificity in cell uptake. Following internalization by macrophages, the nanozyme
retained the ability to convert inactive into active molecules in fluorophore and antibiotic
models. Activation of pro-ciprofloxacin inside of Salmonella-infected macrophages by
Man-NZ resulted in significant intracellular Salmonella death in an effective and spatiallyspecific manner. The ability to generate therapeutic concentrations of antibiotic inside of
cells specifically targeted by invading bacteria results in a more effective and less toxic
treatment strategy for dangerous pathogens such as Salmonella. This nanomaterial strategy
could be utilized to more effectively combat diseases ranging from typhoid to tuberculosis,
which affect millions globally every year.17
6.4 Methods
6.4.1. Materials
All chemicals and materials for experiments were obtained from Sigma Aldrich or
Fisher Scientific. Further purification was not performed unless otherwise indicated.
Chloroauric acid used for gold nanoparticle synthesis was bought from Strem Chemicals
Inc. (Newburyport, MA). RAW 264.7 cells were purchased from ATCC. Dulbecco’s
modified Eagle’s medium (DMEM) (for RAW 264.7), Eagle's Minimum Essential
Medium (for HEPG2), fetal bovine serum (Fisher Scientific) were used in cell culture.
6.4.2. Synthesis of mannose-decorated gold nanoparticles (AuNPs)
AuNPs used in this study were synthesized as reported previously. 18 Briefly, the
Brust-Schiffrin two-phase synthesis method was used to synthesize 1-pentanethiol
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protected 2 nm AuNPs. A carboxylate-terminated ligand was synthesized using previously
reported procedures. Murray place exchange method was followed to attach the ligand to
the AuNP core. 10 mg of pentanethiol-conjugated AuNPs were dissolved in 4 mL distilled
DCM and stirred for 3 days at room temperature under nitrogen environment, followed by
removal of DCM under reduced pressure. Excess ligands, pentanethiol/dodecanetiol, acetic
acid, and salts present in the AuNP solution were removed by washing with hexane thrice
and DCM twice followed by dialysis (membrane molecular weight cut-off =10,000) for 3
days. After dialysis, the particles were lyophilized to yield a solid brown colored product.
The particles were then re-dispersed in deionized water. The carboxylate AuNPs were then
post-functionalized with mannose by adding 1 mM mannose amine, 3 mM DMAP, 3 mM
NHS and 3 mM EDC in an ice bath. The reaction was allowed to proceed overnight and
then excess reactants were removed via dialysis.
6.4.3. Mass spectrometric characterization of ligands on AuNP monolayer
The surface ligand was characterized by matrix assisted laser desorption/ionization
mass spectrometry (MALDI-MS). A stock solution of matrix α-Cyano-4-hydroxycinnamic
acid (α-CHCA) was prepared in a mixture of 70% acetonitrile and 30% deionized water.
AuNPs were diluted in deionized water to a final concentration of 1 μM followed by
addition to the matrix solution in a 1:1 volume ratio. 2 μL of this mixture was spotted on
the sample carrier and allowed to dry. MALDI-MS analysis was performed using a Bruker
Autoflex III mass spectrometer.
6.4.4. Zeta potential characterization of AuNP
Zeta potential was measured in deionized water using a Malvern Zetasizer Nano
ZS instrument.
119

6.4.5. Catalyst encapsulation in AuNP monolayer to fabricate nanozyme (NZ)
The catalyst was dissolved in acetone (2 mg/mL) and mixed with AuNPs in 1:1
ratio by volume. The organic layer was slowly evaporated. The resulting mixture was
filtered using a syringe driven filter unit (pore size=0.2 μm). Any excess catalyst was
removed by multiple filtrations through a molecular-weight cutoff filter (10K), followed
by dialysis.
6.4.6. DLS and TEM characterization of AuNPs
Hydrodynamic diameter of AuNPs and NZs were measured by dynamic light
scattering (DLS) in DI water using a Malvern Zetasizer Nano ZS instrument by using a
measurement angle of 173° (backscatter). Data were analyzed by the “multiple narrow
modes” (high resolution) based on non-negative-least-squares (NNLS).
Transmission Electron Microscopy (TEM) imaging samples were prepared by
placing a droplet of AuNP and NZ solution of 1 M onto a 300-mesh Cu-grid coated with
carbon film. The samples were analyzed using a JEOL CX-100 electron microscope. These
characterization data indicated that there was no aggregation before or after catalyst
encapsulation.
6.4.7. Quantification of catalyst concentration per AuNP using ICP-MS
characterization
The ICP-MS analyses were performed on a Perkin-Elmer NexION 300X ICP mass
spectrometer. 197Au were measured under the standard mode. Operating conditions were:
nebulizer flow rate: 0.95 L/min; rf power: 1600 W; plasma Ar flow rate: 18 L/min; dwell
time: 50 ms. Standard gold solutions were prepared via serial dilutions (0, 0.2, 0.5, 1, 2, 5,
10, and 20 ppb) for the calibration curve.
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6.4.8. Mammalian and bacterial cell culture
All mammalian cells were grown in T75 cell culture flasks using standard growth
media (DMEM supplemented with 10% FBS and 1% Pen-Strep) under physiological
conditions (37 C in a humidified atmosphere of 5% CO2). Once the cells were at sufficient
density, they were washed with phosphate-buffered saline (PBS) three times followed by
0.05% trypsinization. The trypsinized cells were centrifuged and resuspended in fresh
culture media. 10 L of cell solution was mixed with trypan blue in 1:1 volume ratio and
was counted by a hemocytometer. The cell solutions were diluted in the same media to
attain the desired cell concentration for subsequent experiments.
6.4.9. Cytotoxicity
RAW 264.7 cells were seeded at a concentration of 10,000 cells/well in a 96 well
plate overnight. The next day, the cells were treated with Man-NZ at various concentrations
for 24 h. After the incubation period, the cells were washed three times with PBS to remove
dead cells and excess NZ. 10% Alamar Blue reagent (Invitrogen, CA) in serum containing
media was added to each well and incubated for 2 h further at 37 C and 5% CO2. Cell
viability was then determined by measuring the fluorescence intensity at 570 nm using a
SpectraMax M5 microplate spectrophotometer. Three biological replicates were performed
for viability determination.
6.4.10 Macrophage NZ uptake
RAW 264.7 and HEPG2 cells were seeded at a concentration of 50,000 cells/well
in a 24 well plate overnight. The next day, the cells were treated with Man-NZ at various
concentrations for 24 h. The wells were washed three times with PBS and the cells were
lysed. The cell lysates were analyzed for gold content by ICP-MS.
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6.4.11. Intracellular pro-fluorophore activation
RAW 264.7 cells were seeded at a concentration of 75,000 cells/well in a 4 well
chamber Lab-Tek II chambered coverglass system and were incubated with 500 nM ManNZ overnight. Media was then aspirated and 20 μM pro-resorufin was added in fresh media
and the cells were incubated for 2 hours. The media was then replaced with PBS and
fluorescence imaging was performed using an Eclipse Ti-E microscope.
6.4.12 Salmonella killing assays
For Salmonella only infection model, a single colony of Salmonella enterica subsp.
enterica serovar Typhimurium (ATCC 29630) was inoculated into LB broth and incubated
at 37 ºC overnight to reach stationary phase. Then 60 µL of the stationary phase solution
was diluted to 3 mL using fresh LB broth and incubated at 37 C until bacteria grew to log
phase. The resulting bacteria solution was then centrifuged, washed three times with 0.85%
NaCl, and resuspended in phosphate buffer saline (PBS). Then, a solution containing 1x10 6
CFU/mL Salmonella was prepared using LB broth. Subsequently, the test materials- 500
nM man-NZ, 1 and 0.5 µM pro-ciprofloxacin, and 15 nM ciprofloxacin- were prepared in
LB broth. 50 µL each of the bacteria and the test material were added to a 96-well
microplate and incubated at 37 C overnight with shaking. Quantitative colony counting
was then performed to determine numbers of bacteria that survived the treatment. Wells
containing bacteria solution-only served as the growth control while wells containing LB
broth-only served as the sterile control. Cultures were performed in triplicates, and at least
two independent experiments were repeated on different days.
For intracellular killing assays, RAW cells were seeded at a concentration of 17,000
cells/well in media lacking antibiotics with 500 nM Man-NZ in a 96-well plate overnight.
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Salmonella was then added to the wells to achieve 1:100 multiplicity of infection (MOI)
and incubated for 1 hour. The wells were washed with gentamycin three times and either
1 μM pro-ciprofloxacin or 15 nm ciprofloxacin was added in fresh media and incubated
overnight. After incubation, the media was removed, the mammalian cells were lysed using
0.01% Triton X, and the lysate was collected for quantitative colony counting. Three
biological replicates were performed for each group.
6.4.13. Bacterial coculture assays using transwell membrane
To model the selective killing of intracellular macrophage pathogens over the nonpathogenic gut bacteria by Man-NZ+pro-ciprofloxacin, a transwell membrane assay was
developed. The probiotic Bio-K+ (Lactobacillus sp.) was used as a model of intestinal flora.
Briefly, RAW cells were seeded overnight in a 6-well plate using DMEM media lacking
antibiotics with 500 nM Man-NZ. Intracellular Salmonella infection was performed using
the procedure mentioned above. Bio-K+ was cultured using MRS broth overnight at 37 C
with shaking to reach stationary phase. Then, a solution of Bio-K + was prepared using 1:1
MRS:DMEM media and added to a transwell membrane (0.4 µm pore size) and inserted
into a 6-well plate containing infected macrophages. Subsequently, the test materials were
prepared using 1:1 MRS:DMEM media and added to each of the wells. The plate was
incubated overnight at 37 C. The media was then collected and used for quantitative
colony counting using MRS agar to determine numbers of surviving Lactobacillus sp. The
infected macrophages were washed using PBS and lysed with 0.01% Triton X. The lysate
was recovered and plated in LB agar to quantitatively determine Salmonella survival.
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CHAPTER 7
MACROPHAGE ACTIVATION BY A SUBSTITUTED PYRIMIDO[5,4-b]INDOLE
INCREASES ANTI-CANCER ACTIVITY
Reprinted (adapted) with permission from“Hardie, J.; Mas-Rosario, J. A.; Ha, S.; Rizzo,
E. M.; Farkas, M. E. Pharm. Res. 2019, 148, 104452.”Copyright (2019) Elsevier

7.1. Introduction
Cancer is one of the leading causes of death around the world, and fighting it is a
focus of research programs globally.1 However, most cancer therapy regimens continue to
rely on non-specific chemotherapy and radiotherapy to eliminate tumors, which have
severe side effects. They are also ineffective against many cancer types and can increase
disease recurrence.1 As a result, alternative strategies are sought after, such as
immunotherapy.2 Cancer immunotherapy involves utilizing the immune system to
eliminate the disease, and is attractive on account of the immune system’s specificity and
biocompatibility compared to traditional cancer therapy. Several immunotherapies have
been approved clinically, and others have reached the clinical trial stage. 3
While immunotherapy is alluring, developing immune-based strategies is
challenging. Normally, the immune system detects and eliminates pre-oncogenic cells, 4
however, cancer cells can generate cytokines and receptors for immune evasion and
reprogramming.5 In this manner, tumorigenic cells are able to escape detection and disable
pro-inflammatory behaviors. An example of the former is overexpression of “don’t eat me”
surface marker CD47 by cancer cells, preventing phagocytosis,6 while in the latter the
tumor releases chemo-attractants and anti-inflammatory signals, such as IL-4, IL-10, CS1,
CSF1R, and MFG-E8, to reprogram immune cells to perform protumorigenic roles. 4,7
These include facilitation of angiogenesis, epithelial to mesenchymal transition (EMT),
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and microenvironment remodeling.8 Once this point is reached, the likelihood of patient
survival decreases sharply.9
Because of the immune system’s role in cancer progression, there is great interest
in the re-education of immune elements into anti-cancer entities. Polarization of
macrophages into M1 (classically activated) phenotypes is important toward refocusing the
immune system for eliminating cancer.10 In this immune-stimulating phenotype,
macrophages attack and phagocytose tumor cells. This facilitates a larger overall attack by
the immune system, resulting in tumor elimination.10 Macrophages also generate reactive
oxygen species (ROS) and present tumor antigens, which recruit T cells and B cells to the
tumor site.11 In contrast, immune-suppressing M2 (alternatively activated) phenotypes, or
tumor-associated macrophages (TAMs), contribute to tumor progression, joining the tumor
mass and microenvironment.10 TAMs release pro-tumor growth factors, such as vascular
endothelial

growth

factor

(VEGF),

promote

vascularization,

remodel

the

microenvironment, and silence the immune response. 12-14 Overall, reprogramming
macrophages into M1-like states and away from M2/TAM phenotypes has great potential
as an anti-cancer immunotherapeutic approach.15
The polarization of macrophages toward M1 phenotypes is a well studied
phenomenon, with known pathways identified. Specifically, the interferon gamma (IFN-γ)
receptor (IFNGR) and the toll-like receptor (TLR) class are understood to activate
macrophages into pro-inflammatory roles.16 The most common strategies for in vitro M1
macrophage polarization involve treatment with IFN-γ (ligand for IFNGR) and
lipopolysaccharide (LPS, a TLR4 agonist originating from bacterial cell walls). 16 While
these agonists are useful as research tools, both IFN-γ and LPS have drawbacks that make
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them non-viable therapeutically. IFN-γ is a small protein, difficult to consistently modify
and incorporate into delivery vehicles,17 while LPS is a bacterial cell wall component
consisting of a mixture of structures and may be contaminated with other bacterial
components, resulting in off-target immune effects.18 Systemic administration of these
agents results in immune overstimulation, leading to negative outcomes including septic
shock, cytokine storms, and death.18
Because of these issues, there is a need to identify alternative macrophage
activators. Additionally, therapeutic candidates should be amenable to chemical
modifications and association with targeted delivery vehicles. To date, there are few
immune-modulating compounds approved clinically. One example is the TLR7 activator
imiquimod, which is approved for the topical treatment of genital warts and basal cell
carcinoma.19 However, in terms of general anti-cancer agents, systemically delivered drugs
are desirable to provide access to a range of tumor locations and facilitate immune cell
recruitment. There have been examples of anti-inflammatory antibody blockades utilized
to reprogram macrophages for cancer therapy,7,20 but in terms of modifications, antibodies
are more difficult to alter than small organic molecules, and are also linked to
uncontrollable immune-based toxicity.21
Here, we utilize a small molecule TLR4 activator to induce the M1 phenotype and
enhance anti-oncogenic properties in macrophages (Figure 7.1). This molecule, a
pyrimido[5,4-b]indole referred to as PBI1, was previously identified among a series of
compounds that activate TLR4.22 This molecule was shown to bind to TLR4 and induce
expression of various pro-inflammatory cytokines in dendritic cells. 22 Preclinical studies
have shown that structurally similar molecules are effective immune adjuvants for
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influenza therapy,23 however, these compounds have not been evaluated in terms of
macrophage activation and anti-cancer activity. Our hypothesis is that this small molecule
TLR4 agonist can activate and polarize macrophages into an anti-cancer phenotype nearly
as well as naturally occurring cytokines or existing adjuvants. We demonstrate that PBI1
upregulates pro-inflammatory genes in macrophages and induces M1-associated
phenotypic changes and cytokine production. Macrophages treated with PBI1 demonstrate
enhanced anti-tumor activity toward B-cell lymphoma cells as determined by phagocytosis
assays. We also show that treatment of M2-like macrophages with PBI1 results in their reeducation of macrophages toward an M1-like phenotype.

Figure 7.1. Illustration of pyrimido[5,4-b]indole (PBI1)-mediated macrophage activation.
Following TLR4 stimulation, resulting M1 macrophages have enhanced levels of TNF-α
and iNOS, increased ROS generation, and phagocytosis efficiency.
7.2. Materials and methods
All reagents were purchased from Thermo-Fisher Scientific except where
otherwise noted. All DMSO utilized was cell culture grade (Sigma). Confocal microscopy
images were obtained on an Eclipse Ti-E microscope (Nikon, Tokyo, Japan) using a 63X
or 20X objective at room temperature. Images were acquired and processed using NISElements and ImageJ. Flow cytometry analysis was performed on a BD LSRFortessa 5 L
flow cytometer equipped with FACSDiva (BD Sciences, USA) at the Flow Cytometry Core
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Facility at the University of Massachusetts Amherst. RT-PCR data was generated using a
CFX Connect Real-Time PCR Detection System (Biorad, Hercules, CA). For assays
requiring absorbance measurements, a SpectraMax M2 plate reader was used (Molecular
Devices, San Jose, CA). Student’s t-test was used to analyze statistical significance
between control groups.
7.2.1. Cell culture
RAW 264.7 cells were purchased from American Type Culture Collection (ATCC,
Manassas, VA). Primary immortalized macrophages were a gift from Prof. Susan
Carpenter at the University of California, Santa Cruz. Both types of cells were cultured at
37 °C under a humidified atmosphere containing 5% CO 2. Standard growth media
consisted of high glucose Dulbecco's Modified Eagle Medium (DMEM) supplemented
with 10% fetal bovine serum (FBS) and 1% antibiotics (100 μg/ml penicillin and 100 μg/ml
streptomycin). Daudi cells were a gift from Prof. Vincent Rotello at the University of
Massachusetts Amherst and were cultured in Roswell Park Memorial Institute media
(RPMI 1640) supplemented with 10% fetal bovine serum and 1% antibiotics (100 μg/ml
penicillin and 100 μg/ml streptomycin). Under the above culture conditions, the cells were
sub-cultured approximately once every four days and only cells between passages 7 and
15 were used for all experiments.
7.2.2. Synthesis
The synthesis of PBI1 was largely performed as previously described. 22 A complete
description of procedures and analytical data may be found in the figures F1-10.
7.2.3. RT-PCR preparation
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RAW 264.7 cells were plated in 24 well plates at a density of 100,000 cells/well.
Media was aspirated and PBI1-treated cells were dosed with 20 μg/mL compound in fresh
media for 24 h. M1 treatment group cells were treated with 50 ng/mL IFN-γ for 24 h after
which LPS was added to a final concentration of 50 ng/mL for an additional 24 h. M2
group cells were treated with 50 ng/mL IL-4 for 48 h. For the M2+PBI1 group, the cells
were treated with 50 ng/mL IL-4 for 24 h. 24 h after IL-4 dosing, the media was removed
and replaced with fresh media containing 20 μg/mL PBI1 for 24 h. Each experiment
included three biological replicates per treatment condition. 20 μg/mL of PBI1 was used
for this assay and several others as PBI1 demonstrated no toxicity at this concentration.
Following treatments, RNA was extracted following the procedure below.
7.2.4. RNA extraction and cDNA conversion
Approximately 1.5 μg RNA was directly harvested from cells using the PureLink
RNA Mini Kit (Ambion) following the manufacturer's instructions. SuperScript IV
Reverse Transcriptase, RNaseOut, 10mM dNTPs, and 50 μM Random Hexamers were
used for the conversion of approximately 150 ng of RNA to cDNA (ThermoFisher,
Pittsburgh, PA), also following the manufacturer's instructions with a sample volume of 20
μL. Briefly, primers were annealed to RNA at 65 °C for 5 min. Then the annealed RNA
was combined with the reaction mixture (containing 500 units of reverse transcriptase per
sample) and amplified at 53 °C for 10 min and melted at 80 °C for 10 min. The cDNA was
frozen at -20 °C and then used for RT-PCR within 1 week. RNA and cDNA were quantified
using a NanoDrop 2000 (ThermoFisher). RNA and cDNA contamination, inhibition, and
integrity were assessed by analyzing the A260/A280 ratio, where 1.8 for DNA and 2.0 for
RNA was considered “pure.”
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7.2.5. Quantitative RT-PCR
RT-PCR was performed on cDNA as prepared above using a CFX Connect realtime system (Biorad) with iTaq Universal SYBR Green Supermix (Biorad, Hercules, CA).
All DNA primers were purchased from Integrated DNA Technologies (Caralville, Iowa).
The following primer sequences (as determined by NCBI primer-BLAST) were used: βactin (ACTB, accession number: NM_007393, amplicon length: 86 pairs, exon 6)
(forward)

GATCAGCAAGCAGGAGTACGA,

(reverse)

AAAACGCAGCGCA-

GTAACAGT; iNOS (NOS2, accession number: NM_010927.4, amplicon length: 127
pairs, exon 2,3, splice variants: 1–3) (forward) GTTCTCAGCCCAACAATACAAGA,
(reverse)

GTGGACGGGTCGATGTCAC;

NM_013693.3,

amplicon

length:

145

TNF-α
pairs,

(TNF,
exon

accession

number:

3,4)

(forward)

CCTGTAGCCCACGTCGTAG, (reverse) GGGAGTCAAGGTACAACCC. 200 nM of
each primer was mixed with 1 μl (100 ng) of cDNA, 10 μL SYBR green supermix and
H2O to a final volume of 20 μL. Analyses were performed as follows: the samples were
first activated at 50 °C for 2 min, then 95 °C for 2 min. Then denaturing occurred at 95 °C
for 30 s followed by annealing at 57 °C; the denature/anneal process was repeated over 40
cycles. Relative gene expression was determined by comparing the Ct value of the gene of
interest to that of the β-actin housekeeping gene, by the 2ΔΔCt method. 24 Three biological
replicates were performed for each treatment condition and three technical replicates were
used for each biological replicate. There was no amplification for the no-template control
(NTC). Data was analyzed using the CFX Manager 3.1 software. CQ values were generated
by using the point at which the sample fluorescence value exceeded the software’s default
threshold value. Each sample was normalized to the untreated control. β-actin was used as
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a reference gene since it is commonly used and none of the treatments were expected to
affect its expression.
7.2.6. Phagocytosis assay with flow cytometry
RAW 264.7 and Daudi cells were separately plated in 24 well plates at a density of
2×105 cells/well each. The same day, designated RAW 264.7 wells were treated with PBI1
to reach a final concentration of 5 μg/mL in 0.5% DMSO. A slightly lower concentration
was utilized in this experiment to demonstrate that profound changes in cell phenotype are
possible at low concentrations of PBI1. 24 h following treatment, RAW cells were
trypsinized using TrypLE (ThermoFisher), washed twice in PBS, and labelled with 1
μg/mL PE-F4/80 antibody (BD Biosciences, cat. No: 565410, Clone:T45-2342) for 30 min
at 4 °C. All RAW cells were resuspended in culture media and 10 μM cytochalasin D was
added to the designated samples. Simultaneously, Daudi cells were removed from the 24
well plate, washed twice with LCIS (ThermoFisher) and labelled with pHRhodo Green
according to the manufacturer’s instructions (ThermoFisher). These cells were washed
with PBS and then labelled with 10 μg/mL anti-CD47 antibody (BioXcell, cat. No:
BE0019-1, Clone: B6.H12) for 30 min at 4 °C. All of the Daudi cells (approximately
4×105) were resuspended in culture media and combined with the RAW 264.7 cells for 2
h at 37 °C. The approximate ratio of RAW:Daudi was 1:1. The samples were then washed
with PBS, resuspended in FACS buffer (1% FBS in PBS) and transferred to flow cytometry
tubes. The samples were analyzed on an LSRFortessa 5L flow cytometer (BD Biosciences)
using 488 nm and 561 nm lasers, counting 30,000 events, at the University of
Massachusetts Amherst Flow Cytometry Facility. Three samples per treatment group were
evaluated. Phagocytotic index was calculated using the following equation:
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[F4/80+pHRhodoGreen+ events]/[F4/80+pHRhodoGreen− events], normalized to the
untreated control group.
7.2.7. Griess assay
RAW 264.7 cells were plated in 24 well plates at a density of 1.5×10 5 cells/well 24
h prior to the experiment. The following day, the culture media was removed and replaced
with serum free Opti-Mem media for 2 h. Cells designated for TLR4 inhibition were pretreated with 7.2 μg/mL TAK242 (Cayman Chemical) 1 h before additional treatment. Then,
media was replaced again with 250 μL phenol red-free DMEM culture media containing
either LPS or PBI1 at the indicated concentrations, and cells were incubated for an
additional 48 h. Cell supernatant was collected from wells and centrifuged at 5000 rpm for
5 min. Then, Griess reagent (ThermoFisher) was prepared according to the manufacturer’s
instructions and 60 μl Griess reagent was combined with 60 μL cell supernatant in a clear
96 well plate. After 15 min in the dark, absorbance was read using a SpectraMax M2 plate
reader (Molecular Devices, Sunnyvale, CA) at 548 nm. Three biological replicates per
treatment condition were used. Actual NO2− concentrations were determined by comparing
absorbance values to a standard curve generated using pure NaNO 2− solutions.
7.2.8. Confocal microscopy
For acquisition of representative cell morphology images, RAW 264.7 cells were
plated in a 4 chamber Lab-Tek II chambered coverglass system (Nunc) at a density of
5×104/well and allowed to adhere overnight. Media was aspirated and cells were then
polarized with 20 μg/mL PBI1 in 0.2% DMSO in fresh media for 48 h. Afterpolarization,
cells were imaged using an Eclipse Ti-E microscope at 20x magnification. M1 cell images
were acquired similarly, using polarization conditions as outlined in the RT-PCR
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preparation section above. For acquisition of representative phagocytosis images, 5×10 4
RAW 264.7 cells were plated in a 4-chamber Lab-Tek II chambered coverglass system.
Designated wells were directly treated with PBI1 to a final concentration of 4.5 μg/mL in
0.4% DMSO for 24 h. The RAW cells were labeled with Cell Tracker Blue according to
the manufacturer’s instructions. 1×105 Daudi cells were counted, labeled with phRhodo
Green and added to the wells containing RAW cells. After 2 h incubation, wells were
imaged using an Eclipse Ti-E microscope at 63x magnification. The final ratio of RAW to
Daudi cells was approximately 2:1.
7.2.9. ELISA
RAW 264.7 cells were plated in 24 well plates at a density of 60,000 cells/well and
allowed to adhere overnight. Media was removed and PBI1-treated cells were dosed with
5, 10, and 20 μg/mL compound in 0.4% DMSO in fresh media for 48 h. M1 treatment
group cells were treated with 50 ng/mL IFN-γ for 24 h after which LPS was added to a
final concentration of 50 ng/mL for an additional 24 h. M2 group cells were treated with
50 ng/mL IL-4 for 48 h. For the M2+PBI1 group, the cells were treated with 50 ng/mL IL4 for 24 h. 24 h after IL-4 dosing, the cells were treated with 20 μg/mL PBI1 for 24 h. Each
experiment included four biological replicates per treatment condition. After treatment,
supernatant was collected from the wells and then analyzed using a Mouse IL-6 ELISA kit
and a Mouse TNF-α ELISA kit (BD Biosciences, Bedford, MA) according to the
manufacturer’s instructions.
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Figure 7.2. Effects of PBI1 treatment on cell morphology and M1 marker expression. a)
Confocal microscopy images (20x) depicting changes in cell morphology following
treatment with 20 μg/ml PBI1. PBI1-treated macrophages (center) resembled those
polarized to an M1 phenotype (right), with a “flatter” appearance and more pseudopodia,
in comparison with non-treated cells (left). b) RT-PCR analysis of TNF-α (left) and iNOS
(right) expression in PBI1 treated cells revealed significantly greater expression of both
relative to non-treated controls. M2+PBI1 refers to cells polarized to the M2 phenotype
and subsequently treated with PBI1. c) ELISA analysis of IL-6 secretion following
treatment. Unpaired, two-tailed student T-tests with equal variance were used to determine
significance; *P≤0.05, **P≤0.005, ***P≤0.0005, ****P≤0.00005. n.s. = non-significant.
7.3. Results
7.3.1. Confocal microscopy
Following synthesis of PBI1 (Fig. 7.3), RAW 264.7 murine macrophages were
dosed with the compound, and changes in morphology and gene expression were assessed
using confocal microscopy and RT-PCR, respectively (Figure 7). Confocal microscopy
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revealed significant changes in macrophage morphology after 24 h. Treated macrophages
acquired a phenotype associated with M1-polarized macrophages (Fig. 7.2a): the cells
became flatter and produced longer pseudopodia16 compared to non-treated cells.

Figure 7.3. PBI1 Synthesis Scheme
7.3.2. RT-PCR analysis
RT-PCR analysis of the mRNA expression of two M1-related markers, tumor
necrosis factor-α (TNF-α) and inducible nitric oxide synthase (iNOS), 11 revealed that
PBI1-treated macrophages express significantly higher levels of both genes compared to
non-treated cells, in a similar trend as IFN-γ/LPS treatment (Figure 7.2b). This effect was
also observed in an immortalized primary macrophage cell line (Figure 7.4). Furthermore,
PBI1 treatment was also able to ‘re-educate’ macrophages that had been polarized toward
the anti-inflammatory M2 phenotype, resulting in enhanced levels of iNOS and TNF-α.
Alamar blue assays indicated that no significant toxicity occurred as a result of compound
treatment (Figure 7.5).
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Figure 7.4. RT-PCR analysis of M1 related genes in primary, immortalized macrophages
(PIMs) following PBI1 treatment. PIMs treated with PBI1 display increased levels of
TNFα and iNOS expression as analyzed by RT-PCR. Three biological replicates with three
technical replicates each were used in analyzing each treatment condition. Error bars
represent standard deviation.

Figure 7.5. Toxicity of PBI1 as evaluated by Alamar Blue Assay RAW 264.7 macrophages
were treated with increasing concentrations of PBI1; subsequent cellular viability was
assessed using Alamar blue reagent. Minimal differences in viability were observed at the
utilized concentrations. Three biological replicates were included per treatment condition;
error bars represent standard deviation. n.s. = non-significant. *P ≤ 0.05.
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7.3.3. ELISA analysis
ELISA analysis of the protein expression of the M1-related cytokines, interleukin
6 (IL-6) and TNF-α, revealed that cells secreted both cytokines to greater extents when
treated with PBI1 or the combination of IFN-γ/LPS compared to untreated cells (Figure
7.2c, 7.6). PBI1 treatment following M2 polarization also resulted in secretion of both
cytokines.

Figure 7.6. ELISA analysis of IL-6 secretion following treatment RAW 264.7
macrophages were treated with increasing amounts of PBI; subsequent cytokine secretion
was assessed via ELISA. Four biological replicates were included per treatment condition;
error bars represent standard deviation. Unpaired, two-tailed student T-tests were used to
determine significance; *P ≤ 0.05, **P ≤ 0.005, ***P ≤ 0.0005, ****P ≤ 0.00005.
7.3.4. Griess assay
Generation and release of reactive oxygen and nitrogen species (ROS and RNS,
respectively) are important processes of M1 macrophage anti-tumor and pathogen
responses.25 RNS are generally derived from nitric oxide (NO). To evaluate relative NO
production by PBI1-treated cells, a Griess assay was performed. 26 This method indirectly
measures NO via evaluation of nitrite (NO2-), one of its two primary stable and non-volatile
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breakdown products. The determined NO2- concentrations show that PBI1 effectively
induced production of NO2-, achieving significantly higher levels than non-treated samples,
and within 2-fold of LPS-treated cells (Figure 7.7). Additionally, pretreatment with the
TLR4 specific inhibitor TAK242 completely eliminated the induction of NO by PBI1
(Figure 7.3).27
7.3.5. Phagocytosis
A key aspect of the macrophage antitumor response is the identification and
phagocytosis, or engulfment, of cancerous cells.6 To assess the phagocytic efficacy of PBI1
treated macrophage cells, a fluorescent flow cytometry assay was conducted using Daudi
(B cell lymphoma) as the target cancer cell line (Figure 7.8, 7.9). RAW 264.7 cells treated
with PBI1 had a nearly 5-fold greater average phagocytic efficiency versus non-treated
macrophages. This was increased further when macrophage PBI1 treatment was combined
with antibody-mediated blocking of Daudi cell CD47, the “don’t eat me” signal involved
in phagocytosis inhibition signaling. Cytochalasin D, a potent phagocytosis inhibitor, was
used as a negative control.28
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Figure 7.7. Supernatant NO2- levels are increased following LPS or PBI1 treatment as
measured by Griess assay. Pretreatment with TAK242 inhibited TLR4 activity prior to
PBI1 addition (PBI1+TAK242). Unpaired, two-tailed student T-tests with equal variance
were used to determine significance; **P≤0.005, ***P≤0.0005, ****P≤0.00005. n.s. = nonsignificant.

Figure 7.8. Effects of PBI1 on phagocytosis of Daudi (B-cell lymphoma) cells. a)
Representative confocal microscopy images illustrating RAW 264.7 macrophage
(CellTracker Blue) phagocytosis of Daudi cells (phRodo Green). b) Phagocytosis indices
generated from flow cytometry data of RAW 264.7 macrophages phagocytosing Daudi
cells following various treatments.
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Figure 7.9. Representative flow cytometry scatter plots for analysis of macrophage
phagocytosis. For analysis of these data, the polygonal gate was placed relative to
populations in the “Cyto. D” group. The “macrophage” gate was positioned around the the
PE stained macrophage population (PE+ events), and the “phago event” was positioned to
the right extreme of the macrophage population. The “phago event” gate was identified as
PE+FITC+ events (macrophage phagocytosing cancer cells). Each scatter plot includes
30,000 events.

7.4. Discussion
In summary, PBI1 was demonstrated to polarize macrophages toward an anticancer phenotype. RAW 264.7 macrophages treated with PBI1 adopted an “M1-like” proinflammatory morphology, as cells became flattened and produced extended pseudopodia.
RT-PCR and ELISA results also corroborated this phenotype via an increase in the
expression of M1 inflammatory genes. PBI1 treatment increased the expression of TNF-α,
IL-6 and iNOS approximately 2.5, 200, and 500-fold, respectively. Dosing of PBI1 also
resulted in the re-education of M2-polarized macrophages, whereupon following
treatment, cells expressed higher levels of inflammatory cytokines. Notably, PBI1
treatment after M2 polarization increased TNF-α, IL-6, and iNOS to levels nearly identical
to those of M1 polarized macrophages. This is particularly relevant for the conversion of
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microenvironments.
We also evaluated the mechanism by which PBI1 promoted macrophage activation.
The most common pathways for macrophage stimulation include the TLR family of
receptors that recognize a wide variety of substrates.8 To confirm that TLR4 is the target
of PBI1 for macrophage activation, a competition experiment was performed. Cells were
treated with a highly specific TLR4 inhibitor, TAK242, and activation by PBI1 was
determined by Griess assay. This experiment revealed that macrophages treated with either
PBI1 or LPS released significant levels of nitric oxide, another confirmation of the
activation potential of PBI1. However, with pre-treatment of cells with TAK242, PBI1 did
not induce any detectable level of nitric oxide, confirming that TLR4 is the target of PBI1
and is crucial to resulting macrophage activation.
Having evaluated the pro-inflammatory responses of macrophages to PBI1
treatment, the ability of these cells to subsequently phagocytose cancers cells was
investigated. It has been previously shown that activation of local macrophages into an M1
inflammatory phenotype can result in significant anti-tumor macrophage activity, which is
of great interest for the generation of cancer immunotherapies.25 One of the major anticancer macrophage mechanisms involves phagocytosis of cancer cells. Inflammatory
macrophages can invade tumor tissue, engulf resident tumor cells, and release immune
signaling factors that drive further immune responses against the tumor site. 25 A
phagocytosis assay revealed that PBI1-treated macrophages engulfed targeted cancer cells
with a 5-fold higher efficacy than untreated macrophages, revealing that inflammatory
activation by PBI1 does in fact increase anti-tumor activity. It was also demonstrated that
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pre-treatment of the targeted cancer cells with a CD47 blocking antibody, which blocks the
SIRPα-CD47 phagocytosis inhibitory pathway, further increases the efficacy of PBI1induced phagocytosis. This effect occurred independently of PBI1-activation as well and
could be used to increase the anti-cancer efficacy of PBI1 treatment.
7.5. Conclusion
The immune system and cancer progression have a complex relationship. While
effective immune-based strategies are of interest in enervating and eliminating cancer
progression, their development can be challenging due to varying macrophage-activating
signals.29,30 PBI1 has significant macrophage activation capability. As a potential immune
adjuvant for cancer therapy, PBI1 is relatively non-toxic and effectively increases both
phagocytic and oxidative burst mechanisms of the macrophage anti-tumor response. While
PBI1 has shown promise as a therapeutic on its own, it will likely show the greatest efficacy
if used in conjugation with drug delivery vehicles or targeting elements. This is especially
relevant in trying to avoid broad immune-activation and runaway immune responses. As a
small molecule, it should be fairly straight-forward to attach to a variety of carriers,
including nanoparticles, proteins, and cells; further studies will explore these options.
Incorporation of PBI1 with more complex therapeutics, as opposed to its use
independently, could result in robust combinatorial anti-cancer strategies. Additional
studies will evaluate the anti-cancer efficacy of PBI1 in vivo, including in concert with
delivery vehicles, and as an adjuvant with other chemotherapeutics. In the future, we will
also seek to identify other potential therapeutic targets of PBI1-activated macrophages.
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CHAPTER 8
HIGH-CONTENT AND HIGH-THROUGHPUT IDENTIFICATION OF
MACROPHAGE POLARIZATION PHENOTYPES
8.1 Introduction
Macrophages are plastic leukocytes that perform a vast range of immune- and
homeostasis-related functions, with their function and behavior dictated by environmental
stimuli. Macrophages can be characterized as being activated into two major phenotypes,
M1 and M2.1 M1 macrophages are associated with inflammation, including secretion of
pro-inflammatory cytokines, engulfment of foreign entities, generation of reactive oxygen
and nitrogen species, and assistance in T-helper type1 (Th1) cell responses to fight
infection. Conversely, M2 macrophages perform anti-inflammatory and wound repair
functions.2,3 Disturbance of the mechanisms that govern the balance of M1 and M2 states
can result in a number of health problems, including infections, cancer, pregnancy
complications, and inflammatory and autoimmune diseases. 4,5 Given the significance and
complexity of the roles macrophages play in biology and disease, knowledge of their
activation and polarization state can provide critical information regarding the disease
microenvironment, and be useful in selecting therapeutic approaches. For example,
manipulation of tumor-associated macrophages provides a potential means to combat
cancer. The tumor microenvironment releases factors that drive macrophages toward an
M2-like phenotype,6 resulting in secretion of anti-inflammatory cytokines, promotion of
tumor growth and invasion, and facilitation of metastases. Therapies are being developed
to “re-educate” these tumor-associated macrophages (TAMs) from this immunesuppressing state to an antitumor M1 phenotype as a more effective, less toxic cancer
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treatment.7,8 The development of such entities would be facilitated by a means to evaluate
macrophage characteristics in a straightforward and high-throughput manner.
Efforts to generate therapies based on macrophage phenotypic conversion (to
stimulate immune activation or suppression) and evaluate macrophage immunes responses
to other agents in drug discovery and toxicology are challenging due to the complexity of
the polarization process. An increasing body of research reveals that macrophage
polarization is more intricate than a two-state, M1/M2 conversion; rather, a spectrum of
states exists.9-11 M2 macrophages can be further subclassified into M2a, M2b, M2c, among
others, depending on the activating stimulus and resulting surface markers displayed. 12 In
addition, the macrophage polarization/sub-polarization process is dynamic and can evolve
based on changes in the microenvironment.13-15 Complicating the matter further,
macrophages can have mixed or overlapping M1- and M2-associated indicators. For
instance, macrophages isolated from patients with advanced gastric and pancreatic cancers
show high levels of both pro-inflammatory and anti-inflammatory cytokines. Both sets
expressed IL-10 (M2-associated), while the former also had high levels of IL-12, and the
latter IL-1β and TNF-α (M1 associated).16,17 These factors make it challenging to identify
macrophage polarization states for diagnostic applications and fundamentally, to
understand or identify phenotypes that are relevant to disease states.
Currently, the presence or levels of cellular and/or secreted biomarkers is most
commonly used to detect and characterize macrophage polarization. 12,18,19 While providing
useful information, this approach is reliant on the specificity of the markers and requires
multiple assays to obtain sufficient information for cellular evaluation. Additional
limitations include: expression overlap between different polarization states (as mentioned
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above), poor phenotypic resolution of similar stimuli, non-translatable markers between
mice and humans,12 and the fact that mRNA levels do not necessarily signal a robust
difference in protein expression/at the functional level. 19 In addition, the techniques used
to identify the presence of biomarkers, such as RT-PCR, Western blot, and flow cytometry,
are expensive and not amenable to multiplexing or high-throughput applications. Thus,
there is a strong need for a general high-throughput method that can be used to evaluate
these cells and their characteristics to facilitate therapeutic design and understand
phenotypic responses of macrophages to stimuli.
As an alternative to marker-specific approaches, chemical nose or array-based
sensing employs and discerns selective interactions between analytes and sensor elements
to generate unique patterns for each analyte. The resulting pattern can be further analyzed
for quantitative classification. This approach has been successfully employed in a wide
range of systems including mammalian cells,20-22 bacteria,23-25 and proteins in biofluids.2628

The strategy is ideal for cell phenotyping because changes in cellular responses yield

variations in surface composition (e.g., protein, lipids, glycans, etc.) that result in different
fingerprints, providing high-content information for each cellular state. 29-31 Because
macrophage polarization is accompanied by changes in cellular metabolism and surface
protein expression,1,12,32 we hypothesized that an array-based sensing strategy would
provide a general platform for discriminating macrophage phenotypic and sub-phenotypic
states. Incorporation of this strategy into a multi-channel format would enable
multidimensional, high-content output from a single microwell, rendering this method
readily applicable to high-throughput screening.33
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In this chapter, we describe the development and application of a polymer-protein
supramolecular assembly as a sensor array to gather high-throughput, high-content
information on macrophage polarization state. The sensor is composed of only two
elements: a guanidine-functionalized cationic poly(oxanorborneneimide) (PONI) polymer,
and an anionic green fluorescent protein (GFP). The two entities form a complex through
electrostatic interactions, resulting in a Förster resonance energy transfer (FRET) pair.
When this sensor is applied to macrophages in different polarization/sub-polarization
states, it yields fluorescent signals in five channels. The multidimensional output is then
quantitatively analyzed using linear discriminant analysis (LDA) to reproducibly classify
different macrophage activation states (Figure 8.1). To the best of our knowledge, the 5channel output sensor has not been reported previously and the high level of information
density enables us to accurately profile a spectrum of activation state of macrophages. We
validated the sensor with model macrophage RAW 264.7 cells and primary bone marrowderived macrophages (BMDMs) stimulated with known M1 and M2 polarizing cytokines.
The successful discrimination of M1 and M2 macrophages among the five subtypes
demonstrates the ability of the sensor to accurately differentiate subtle phenotypic changes.
We further evaluated the efficacy of the sensor system in a model disease environment,
where macrophages were cultured in cancer cell-conditioned media, generating distinct
patterns for macrophages exposed to different cancer types. Taken together, the sensor
platform can classify macrophage phenotypes in a matter of minutes. Furthermore, this
platform can read out the effects of subtle environmental changes on macrophages,
providing a new tool for diagnostics and for fundamental studies of macrophage behavior.
The information generated can provide valuable insights on macrophages in diseases,
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potentially improving efficiency of existing therapies and facilitating the development of
new treatments.

Figure 8.1. Schematic illustration of phenotyping macrophage activation states using
array-based sensor. (A) FRET-based sensor assembly was formed between PONI-C3Guanidine-Pyrene and GFP. Selective interactions of sensor elements at cell surface
membrane resulted in fluorescence changes in all five channels, generating a distinct
fingerprint for each cell activation state. (B) Chemical structure of PONI-C3-GuanidinePyrene and the resulting five fluorescence channels in the FRET complex.
8.2 Results
8.2.1. Supramolecular assembly of sensor
The sensor is designed to provide an information-rich, five-channel output with
only two sensor elements. The first element of the sensor is a cationic poly(oxanorbornene)
(PONI) random copolymer scaffold that incorporates a guanidine group and a pyrene dye
molecule (C3-Gu-Py). The positively charged guanidine group ensures that selective
interactions occur only when the complex is close to negatively charged cell surface
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functionalities. The solvatochromic pyrene molecule will alter its spectral properties when
local environmental factors, such as polarity and hydrophobicity, change. 34 In this way,
both selectivity and sensitivity of the sensor are ensured. Through electrostatic interactions,
cationic C3-Gu-Py forms a polymeric complex with an anionic green fluorescent protein
(EGFP). In practice, the pyrene unit provides three signals, two corresponding to the free
pyrene and one to the excimer form. The EGFP then adds two channels: free GFP
fluorescence and FRET with the two pyrene channels (Figure 8.1B).
Initial studies focused on the optical characterization of the C 3-Gu-Py/EGFP
supramolecular assembly. Polymer C 3-Gu-Py was titrated with increasing concentrations
of EGFP. After 30 min of incubation, a simultaneous decrease in pyrene emission at 470
nm and increase of GFP emission at 510 nm was observed upon irradiation with 344 nm
light (Figure 8.2 and 8.3A). Efficient fluorescence quenching of C3-Gu-Py was observed
(Figure 8.3B) at higher concentrations of assembly. The association constant Ka of 7.17 ×
105 M-1 was derived by fitting the fluorescent titration curve.

Figure 8.2. Optical properties of PONI-C3-Gu-Py. Absorbance and emission spectra of
PONI-C3-Gu-Py polymer was measured using Molecular Devices Spectramax M2 plate
reader.
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Figure 8.3. Fluorescence titrations (a) and quenching (b). 0.5 µM C 3-Gu-Py was titrated
with varying concentrations of EGFP in 10 mM HEPES buffer. Fluorescence spectrum was
recorded at pyrene excitation of 344 nm. A decrease in pyrene emission at 470 nm and
increase of EGFP emission at 510 nm was observed. Each value is the average of three
independent measurements.
The overall spectrum featured five output peaks that can be recorded from the
sensor: pyrene monomers at 344/390 and 344/420, pyrene excimer at 344/470, EGFP at
475/510, and FRET signal at 344/510. Based on the spectral flexibility, a concentration of
0.5 µM C3-Gu-Py and 50 nM EGFP was selected for experiments. Dynamic light scattering
(DLS) data revealed the polymer assembly was ~ 230 nm in diameter and the size slightly
increased to ~237 nm when EGFP was added (Figure 8.4). Transmission electron
microscopy (TEM) images confirmed these results (Figure 8.5), indicating that a
supramolecular assembly was formed between C 3-Gu-Py and EGFP.
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Figure 8.4. Hydrodynamic size of PONI-C3-Gu-Py polymer (a) and polymer-GFP
assembly (b) in 10mM HEPEs buffer. C3-Gu-Py polymer formed a complex with an
average diameter of 230 ± 84.4 nm. With the addition of EGFP, the size of polymer-EGFP
assembly is approximately 237 ± 97.7 nm in diameter.

Figure 8.5. TEM images of PONI-C3-Gu-Py polymer (a) and polymer-EGFP assembly (b)
in 10 mM HEPEs buffer. C3-Gu-Py polymer formed a complex of size ~25 nm. The
difference in sizes measured by DLS and TEM can be attributed to the drying process
during TEM sample preparation as well as the high vacuum conditions in the TEM
chamber. Upon the addition of EGFP, larger complexes were observed.
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8.2.2. Discrimination of M1 and M2 subtypes using RAW 264.7 cells
We first tested the ability of the sensor system to distinguish among macrophage
phenotypes using the RAW 264.7 macrophage cell line. Established cytokines were used,
each activating macrophages through a different mechanism (Table 8.1), generating a
distinct phenotypic state. In general, RT-PCR results assessing standard M1 and M2
markers confirmed that after 48 h activation, cells were polarized into corresponding states
(Figure 8.6). LPS and IFN-γ treated cells (M1 stimulation) showed significant increases in
TNF-α and iNOS mRNA expression whereas the IL-4 (M2a stimulation) group had an
increase in EGR2 and mannose receptor (MR) expression. Although the IL-10 group (M2c
stimulation) was tested against multiple M2 markers, including EGR2, MR, and TGF-β, as
well as the reduction of M1 marker iNOS, no significant changes in the levels of expression
of any associated genes were observed (Figure 8.7).
Polarization

Mechanism

Surface marker change

Phenotype

Lipopolysaccharide
(LPS)

Binds TLR4, induces
pro-inflammatory
cytokines35

M1

Interferon-γ
(IFN-γ)

Binds IFN-γ receptor37

Increased expression levels of
MHC-II, CD80, CD86;
decreased levels of MRC1 or
Fc-γ RII36

Combo (LPS
+ IFN-γ)

Synergizes LPS and
IFN-γ

Interleukin 4
(IL-4)

Binds IL-4Rα and IL2R, down-regulates
proinflammatory
mediators1,32

Decreased expression of
CD14 and CCR5;38 regulation
of MHC-II, β2 integrins,
chemokine CCL22/MDC39

M2a

Interleukin
10 (IL-10)

Inhibitsproduction of
pro-inflammatory
cytokines

Down-regulation of MHC II
and co-stimulatory molecules

M2c

Table 8.1. Mechanisms and effects of in vitro macrophage polarization via different
cytokines
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Figure 8.6. Macrophage activation confirmed by RT-PCR. (A) mRNA quantification
of M1-associated genes, TNF-α and iNOS. (B) mRNA quantification of M2-associated
genes, EGR2 and MR, according to treatment group. Control = non-treated cells, combo =
LPS + IFN-γ treated. Fold changes in mRNA level were normalized to β-actin. Statistical
significance was determined by two-tailed student t-test. *= p < 0.1, **= p < 0.05, ***= p
< 0.005, n = 3 biological replicates (3 technical replicates were used each). n.s. = not
significant.

Figure 8.7. RT-PCR quantification of M2 state in IL-10 activated RAW 264.7
macrophages. TGF-β is M2-associated gene. Reduction of M1-associated gene iNOS is
used to evaluate M2 state. Control = non-treated cells. Fold changes in mRNA level were
normalized to β- actin. Statistical significance was determined by two-tailed student t-test.
*= p < 0.1, **= p < 0.05, ***= p < 0.005, n = 3 biological replicates (3 technical replicates
were used each). n.s. = not significant.

Having confirmed that polarization had occurred, cells from each treatment group
were plated on a 96-well microplate for overnight attachment. Equivalent cell numbers
(10,000 per sample) were used to ensure that changes in sensor response were due to
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alterations in cell surface functionalities, not density. For the sensing process, C 3-Gu-Py
and EGFP were premixed for 30 min to allow formation of stable FRET complexes.
Subsequently, cells were washed once with phosphate buffered saline (PBS) and incubated
with the sensor complex in the dark. Fluorescence signals were recorded every 15 min until
equilibrium was reached. The 5-channel readout generated a distinct fluorescence pattern
for each treatment group (Figure 8.8A). We further utilized linear discriminate analysis
(LDA) to test whether the six cell phenotypes could be robustly discriminated based upon
their fluorescent signatures. As shown in Figure 8.3B, the LDA plot revealed six distinct
clusters for M1 and M2 subtypes with a correct classification of 100%, demonstrating that
each activation pathway resulted in a distinct cellular response. We further validated the
reliability of the sensor by performing unknown sample identification. Among the 45 tested
unknowns, 41 samples were binned correctly into their corresponding group, giving a high
percentage of correct unknown identification at 91%. Next, we investigated the necessity
of having 5 channels of information from the sensor by comparing the performance of
classification and unknown identification using either an individual sensor element or
different combinations. The highest percentage of accuracy was achieved when all 5
channels were used, demonstrating the importance of multidimensional data in
discriminating complex cell phenotypes. (Figure 8.8C-D).
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Figure 8.8. Discrimination of RAW 264.7 macrophages activated by M1 or M2 subtype
stimuli using sensor complexes. (A) Fluorescence intensities of each treatment group were
obtained at 30 min and normalized against sensor only. n = 8 biological replicates. (B) The
fluorescence patterns were analyzed through linear discriminant analysis (LDA) and the
first two canonical scores were plotted with 95% confidence ellipse (n=8). Correct
classification percentage (C) and unknown identification (D) of M1 and M2 subtypes using
different combinations of sensor channels.
Accurate phenotyping was obtained in less than an hour, which is highly desirable
for high-throughput applications. By generating a distinct fluorescence pattern
corresponding to each activation stimulus, this method can discriminate among major cell
polarization states (M1 and M2) in a simple, robust, and rapid manner. In addition, this
method can further distinguish different subtypes of major macrophage phenotypes. Since
this system does not rely on specific markers, the global information gathered from the 5-
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channel sensor can discern less-characterized sub-phenotypes, such as IL-10 stimulated
macrophages, which are challenging to identify using traditional methods like RT-PCR.
8.2.3. Discrimination of M1 and M2 subtypes with primary macrophages
Immortalized macrophage cell lines provide a useful tool for assessing sensor
response, however these models differ in multiple aspects from their primary cell analogs.
We next tested the sensor using physiologically relevant primary bone marrow-derived
macrophages (BMDM). Progenitor cells were isolated from C57/B6 mice and induced to
differentiate into macrophages using previously reported procedures. 40 Once macrophage
cells were obtained, we exposed them to M1 and M2 subtype polarization stimuli for 48
hours as used above for RAW 264.7 cells. RT-PCR results confirmed appropriate
activations in each case, with increases in TNF-α and iNOS mRNA expression for M1
related stimuli (LPS and/or IFN-γ) and EGR2 and MR mRNA levels for IL-4 stimulated
M2 cells. Although IL-10 activation did not show substantial enhancement in EGR2 levels,
a nearly 6-fold increase in MR expression was observed (Figure 8.9 and 8.10). Following
macrophage polarization, the sensor complex was added to equal numbers of cells under
each treatment group and fluorescence results were obtained after 15 min. Complete
discrimination among the five assessed groups of M1 and M2 phenotypes was achieved
with 96% correct classification (Figure 8.11). 92% of correct unknown identification
confirmed the high reliability of our sensor.
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Figure 8.9. RT-PCR quantification of M1-associated genes in primary bone marrowderived macrophages, according to treatment group. Control = non-treated cells; combo =
cells treated with both IFN-γ and LPS. Fold changes in mRNA level were normalized to
β-actin. *= p < 0.1, **= p < 0.05, ***= p < 0.005, n = 3 biological replicates (3 technical
replicates were used each). n.s. = not significant.

Figure 8.10. RT-PCR quantification of key M2 genes in primary bone marrow-derived
macrophages, according to treatment group. Control = non-treated cells. Fold changes in
mRNA level were normalized to β- actin. *= p < 0.1, **= p < 0.05, ***= p < 0.005, n = 3
biological replicates (3 technical replicates were used each). n.s. = not significant.
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Figure 8.11. Discrimination of M1 and M2 subtypes of bone marrow-derived
macrophages. (A) Fluorescence signals of the five sensor channels were obtained and
normalized to sensor only. n = 8 biological replicates. (B) LDA plot of the first two
canonical scores was plotted with 95% confidence ellipse (n=8).
When the sensor complex interacts with cells, in most cases, all monitored
fluorescence channels show an increase in signal intensity. This suggests that upon
interacting with macrophages, the sensor complex disaggregates, exposing its individual
components to interact with the cell surface. Depending upon the local environment, the
fluorescence intensities for individual molecules (pyrene, EGFP, and FRET) also change.
Since distinct fluorescence patterns were consistently observed for each stimulus, we
believe this disruption process is modulated by cell surface functionalities and
composition. Our previous studies have indicated that the sensor complex is highly
sensitive to glycosylation patterns on cell surfaces.30 However, more mechanistic studies
are needed in order to elucidate what other cell components are also interacting with sensor
elements.
8.2.4. Discrimination of macrophages exposed to conditioned media from different
cancer cells
The above studies demonstrate that our sensor array was able to discriminate
macrophages polarized with specific cytokines. However, biological microenvironments
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are often far more complex and have multiple stimuli. Hence, we assessed whether the
sensor could discern macrophage phenotype in a model disease environment to address
this issue. First, conditioned media was generated by culturing different types of cancer
cells (HeLa, cervical carcinoma, and MCF7, mammary carcinoma) until ~80% confluence
was reached. Then, the culture media was extracted and used to stimulate macrophages for
48 h. RT-PCR results revealed different activation patterns for macrophages activated with
media conditioned from different cell (Figure 8.12). C 3-Gu-Py and EGFP complexes were
added to cells and the 5-channel fluorescence readouts were collected.
Distinct fluorescence signals were obtained for macrophages subjected to each of
the conditioned media types. An LDA plot showed three well-separated clusters with 100%
classification accuracy (Figure 8.13). When macrophages were exposed to cultured media
conditioned by cervical cancer versus breast cancer cells, the sensing readout was
dramatically different, indicating that a unique state of activation was present following
each type of stimulation. A high percentage (96%) of correct unknown identification was
also achieved. These results are exciting because they demonstrate that this method not
only functions following single cytokine stimulation, but also in more complex
environments. This is promising evidence that with careful evaluation, this sensing method
could be applied to profile macrophages from individual patients, offering insights for
precision medicine.
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Figure 8.12. RT-PCR quantification macrophages exposed to conditioned media from
different cancer cells. (a) mRNA quantification of M1-associated genes, TNF-α and iNOS.
(b) mRNA quantification of M2-associated genes, EGR2 and MR. Control = non-treated
cells. MCF7-M and HeLa-M = conditioned media from MCF7 and HeLa cells,
respectively. Fold changes in mRNA level were normalized to β-actin. *= p < 0.1, **= p <
0.05, ***= p < 0.005, n = 3 biological replicates (3 technical replicates were used each).
n.s. = not significant.

Figure 8.13. Discrimination of macrophage cells cultured under exposure to conditioned
media from different cancer cell types for 48 h. The LDA plot of the first two canonical
scores was obtained and plotted with 95% confidence ellipses (n=8). CM is cancer cell
conditioned medium, with the cell line type preceding it, control represent macrophages
cultured using standard growth media.
8.3 Discussion
Macrophage polarization is a complex and dynamic process. With its roles in
homeostasis and disease, it is important to be able to discern macrophages characteristics
in a rapid and straight-forward manner. In this chapter, we report a simple and robust
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sensing method that can quickly capture the overall responses of activated macrophages
under different environmental stimuli.
Compared with current methods of characterizing macrophage polarization, the
sensor reported in this study has advantages of generating a multidimensional, high-content
chemical readout regarding the cell surface, in a high-throughput matter. Standard methods
such as RT-PCR and ELISA, can only capture a limited number of well-established
markers for each cell activation state, and are independent (not multiplexed) assays,
requiring a separate analysis for each. Considering the heterogeneity of macrophage
polarization and the overlapping nature of M1 and M2 markers, 11,12 it is also difficult to
elucidate and differentiate activation states with standard methods. For instance, the
multiple IL-10 markers used in our RT-PCR studies did not reveal significant changes. The
ambiguity of a less-well characterized sub-phenotype could be because the end-point
evaluation missed the dynamic changes in macrophage marker expression during the 48 h
activation.
In contrast, the array-based sensor utilizes selective interactions between sensor
elements and the entire analyte surface to generate high-content fingerprints for each
activation state. Once trained, the sensor can rapidly identify target analytes through pattern
recognition. Although the C3-Gu-Py moiety has been utilized for bacterial sensing, 41 its
capability in mammalian cell sensing has not been investigated. By coupling the polymer
with GFP through supramolecular interactions, we observed that the IL-10 treated group
has a distinct set of characteristics in comparison with the other M2 subgroups in both
tested cell models (Figures 8.8 and 8.11). The 5-channel, high-content information
gathered from the sensor is crucial in achieving a high level of classification accuracy and
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allows us to address challenging biological questions from a chemical perspective. In
addition, running assays like RT-PCR and ELISA can be time-consuming and error prone,
with relatively high costs for thorough characterizations consisting of multiple markers. In
contrast, the sensor material used here is synthetically easy to generate, and all components
can be mixed in one microplate well, which not only reduces sensor material but is also
compatible for high-throughput screening applications.
Due to the robust and facile nature of the system, there are many potential
applications for the array-based sensing strategy. Altered immune states are a major factor
in diseases including cancer, atherosclerosis, and auto-immune disorders. 42-44 Macrophage
polarization states are key in driving forward disease progression. Rapid assessment of
their activation states can provide valuable information in selecting appropriate therapeutic
strategies.45,46 Notably, the high-throughput nature of the method would facilitate the rapid
screening of immune states for individual patients, enabling personalized medicine
approaches in tackling these immune-driven diseases. Furthermore, this strategy could be
applied to other plastic immune cells, such as dendritic cells and T cells. 47,48 By extending
this sensor to other cell types, the status of major components of the immune system could
be rapidly determined. This strategy can also greatly improve the drug discovery process,
by allowing for rapid identification of altered cell states, and/or evaluation of
immunogenicity following agent treatment.49 Potential immune adjuvants or antiinflammatory entities could be screened together by using the sensor on immune cells in a
multi-well plate format. With these capabilities, the sensor system not only has utility as a
fundamental research tool, but as a high-throughput, high-content means for therapeutic
screening against other plastic cell types.
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8.4. Experimental methods
8.4.1. Materials
All reagents were purchased from Thermo-Fisher Scientific except where otherwise noted.
All DMSO utilized was cell culture grade (Sigma). RT-PCR data was generated using a
CFX Connect Real-Time PCR Detection System (Biorad, Hercules, CA). For assays
requiring absorbance and fluorescence measurements, a SpectraMax M2 plate reader was
used (Molecular Devices, San Jose, CA).
8.4.2. PONI-C3-Guanidine polymer synthesis
Monomers and polymers were synthesized according to previous reports. 50
8.4.3. Green fluorescent protein expression
EGFP was constructed and characterized according to reported protocols. 51 In
short, Escherichia coli strain BL21 was transformed with plasmids containing EGFP
recombinant protein. After transformation and induction with IPTG, cells were lysed and
purified by Co2+ nitrilotriacetate columns. Fluorescent proteins were further characterized
by SDS-PAGE gel, scanning absorbance and emission spectrum. The results are consistent
with previously reported work.30
8.4.4. Transmission electron microscopy
TEM samples were prepared by either 0.5 µM of C3-Gu-Py only or mixing 0.5 µM
of C3-Gu-Py with 50 nM of EGFP in 10 mM HEPES buffer for 30 min in dark at room
temperature. 5 μL of the solutions were then placed on 300 mesh Copper grids (with
formvar films) obtained from Electron Microscopy Sciences (EMS FF300-Cu) and allowed
to dry overnight. The samples were analyzed using a TEM JOEL 2000FX at an acceleration
voltage of 200kV.
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8.4.5. Fluorescent titration
0.5 µM C3-Gu-Py polymer was titrated with EGFP at a concentration range from 0
to 200 µM in a black 96 well-microplate. The solution was mixed in 10 mM HEPES buffer.
After 30 min incubation at room temperature in dark, the fluorescence spectrum was
measured at an excitation wavelength of 344 nm.
8.4.6. Binding affinity calculation
Fluorescence titration was utilized to calculate the binding affinity of the C 3-Gu-Py
polymer with EGFP. The fluorescence decay of the C 3-Gu-Py excimer as a function of
EGFP concentration was fitted to a one-site binding equation, 52 which is:

where I is the
fluorescence intensity of C3-Gu-Py excimer at a given concentration of EGFP, I0 is the
fluorescence intensity of C3-Gu-Py in the absence of EGFP, Ilim is the fluorescence
intensity when the quenching reaches a plateau, C 0 refers to the concentration of C3-GuPy, and C is the concentration of EGFP. Based on the equation, microscopic binding
constant K was determined by using the non-linear least-squares curve fitting analysis in
OriginPro (OriginLab Co., Northampton, USA).
8.4.7. Linear discriminant analysis
Linear discriminant analysis (LDA) was applied on normalized fluorescence data
to statistically classify each group, using SYSTAT software (version 11.0, SystatSoftware,
Richmond, CA, U.S.A.). All variables were used in the complete mode and the tolerance
was set as 0.001. Input data was transformed to canonical scores to best separate each group
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where the between-class variance was maximized while the within-class variance was
minimized.
8.4.8. Unknown identification
The identity of unknown samples was predicted by computing the Mahalanobis
distance of the unknown data to the training groups using LDA. 53 First, the normalized
fluorescence responses of the unknown samples were converted to canonical scores in
LDA, using the discriminant functions established from the reference set. Next,
Mahalanobis distance of that case to the centroid of each training cluster in the LDA space
was computed.53,54 The unknown sample was predicted to belong to the closest group,
defined by the shortest Mahalanobis distance.
8.4.9. Cell culture
RAW 264.7 cells, HeLa, and MCF7 cell lines were purchased from American Type
Culture Collection (ATCC, Manassas, VA). Primary bone marrow derived macrophages
(BMDMs) were isolated from freshly euthanized C57/B6 mice, donated generously by Dr.
Jessie Mager, Department of Veterinary and Animal Science, University of Massachusetts
Amherst. The BMDMs were isolated, differentiated and cultured according to previously
reported methods.40 All cells were cultured at 37 °C under a humidified atmosphere
containing 5% CO2. Standard growth media consisted of high glucose Dulbecco's Modified
Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1%
antibiotics (100 µg/ml penicillin and 100 µg/ml streptomycin). Under the above culture
conditions, the cells were sub-cultured approximately once every two to five days.
8.4.10. Macrophage polarization via activation agents
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Both RAW 264.7 cells and BMDMs were treated with the following polarization
stimuli for 48 hours to induce the desired polarization state: LPS group, 50 ng/mL; IFN-γ
group, 50 ng/mL; combo group, 50 ng/mL LPS and IFN-γ; IL-4 group, 30 ng/mL; and IL10 group, 30 ng/mL. After 2-day polarization, cells were washed with PBS, trypsinized,
and plated as 10,000 cells per well on a 96-well plate overnight before proceeding to
sensing studies.
8.4.11. Macrophage polarization via cancer cell conditioned media
HeLa and MCF7 cell lines were cultured using DMEM medium supplemented with
10% FBS and 1% antibiotics for 2 days to reach above 90% confluence. At this time, the
media was replaced with fresh standard, growth media and cells were incubated for an
additional 5-7 days. The supernatant from each cell line was then collected, centrifuged for
5 min, and filtered using a 0.45 µm syringe filter. Subsequently, growth and conditioned
media at a 1:1 ratio were transferred into a T25 culture flask containing RAW cells. After
48 h of culture, RAW 264.7 cells were washed with PBS, trypsinized and plated as 10,000
cells/well on a 96-well plate for overnight attachment.
8.4.12. Sensing studies
The sensor was prepared by mixing 0.5 µM of C 3-Gu-Py with 50 nM of EGFP in
10 mM HEPES buffer for 30 minutes in dark at room temperature. Subsequently, 150 µL
of sensor solution was incubated with and without the cell populations (washed once with
PBS) in 96-well microplates. The change in fluorescence intensity for each channel was
recorded every 15 minutes at its respective wavelength (pyrene monomer: 344/390 nm and
344/420 nm, pyrene excimer: 344/470 nm, EGFP: 475/510 nm, FRET: 344/510 nm) on a
Molecular Devices SpectraMax M2 microplate reader using appropriate filters.
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8.4.13. RT-PCR preparation
Cells were plated in 24 well plates at a density of 50,000 cells/well. Cells were
treated with the appropriate polarization stimulus for 48 h. Following treatments, RNA was
extracted following the procedure below.
8.4.14. RNA extraction and cDNA conversion
Approximately 1.5 µg RNA was harvested using the PureLink RNA Mini Kit
(Ambion) following the manufacturer's instructions. SuperScript IV Reverse Transcriptase
was used for the conversion of approximately 150 ng of RNA to cDNA, along with
RNaseOut, 10 mM dNTPs, and 50 µM Random Hexamers (ThermoFisher), also following
the manufacturer's instructions.
8.4.15. Quantitative RT-PCR
RT-PCR was performed on cDNA as prepared above using a CFX Connect realtime system with iTaq Universal SYBR Green Supermix (Biorad). All DNA primers were
purchased from Integrated DNA Technologies. The following primer sequences were used:
β-actin (forward) 5’-GATCAGCAAGCAGGAGTACGA-3’, (reverse) 5’-AAAACGCAGCGCAGTAACAGT-3’; iNOS (forward) 5’-GTTCTCAGCCCAACAATACAAGA3’, (reverse) 5’-GTGGACGGGTCGATGTCAC-3’; TNF-α (forward) 5’-CCTGTAGCCCACGTCGTAG-3’,

(reverse)

5’-GGGAGTCAAGGTACAACCC-3’;

EGR2

(forward) 5’-TGAGAGAGCAGCGATTGATT-3’, (reverse) 5’-ATAACAGTCAGTGTGTCCCC-3’; Mannose Receptor (MR) (forward) 5’-GGATGTTGATGGCTACTGGA-3’,
(reverse) 5’-AGTAGCAGGGATTTCGTCTG-3’; TGF-β (forward) 5’-GCGGACTACTATGCTAAAGA-3’, (reverse) 5’-TTCTCATAGATGGCGTTGTT-3’. Analyses were
performed as follows: the samples were first activated at 50 °C for 2 min, then 95 °C for 2
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min. Then denaturing occurred at 95 °C for 30 s followed by annealing at 57 °C; the
denature/anneal process was repeated over 40 cycles. Relative gene expression was
determined by comparing the Ct value of the gene of interest to that of the β-actin
housekeeping gene, by the 2ΔΔCt method.55 Three biological replicates were performed for
each control group and three technical replicates were used for each biological replicate.
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CHAPTER 9
CONCLUSION AND OUTLOOK
Macrophages are a key component of the innate immune system, and as such, will
continue to draw interest as therapeutic targets for a range of unsolved diseases. Due to
their complex and fluid nature, a diverse toolset will need to be developed to effectively
alter macrophage function to affect the entire array of macrophage-related health issues. In
this thesis, I have developed a number of nanomaterial- and chemical- based strategies for
manipulating macrophage behavior for therapeutic applications. On the nanomaterial side,
I have applied a nanocapsule vehicle, capable of delivering biologics and normally
insoluble drugs, to targeting the cytosol of macrophages.

Additionally, I utilized a

nanozyme platform for the site-selective activation of pro-drug molecules separately using
macrophages as both vehicle and target. Finally, I developed a polymer-protein complex
as an array-based sensor for the rapid phenotyping of activated macrophages. From a more
traditional chemical perspective, I developed tools for directly modifying macrophage
surfaces with small molecules entities, as well as generated and investigated a novel
macrophage-activating small molecule drug. Taken altogether, this array of strategies
represents not only a set of new macrophage manipulating tools, but also examples of the
variety of approaches that can be utilized to achieve therapeutics benefits from targeting
macrophages.
Despite the amount of work presentin this thesis, there are still many unsolved
questions and much progress needs to be made prior to the application of any of the
demonstrated technologies in a real world setting. First, the methods described in this thesis
all require further experiments in vivo to evaluate efficacy and elucidate any currently
unknown liabilities for clinical treatment. It is likely that many nanomaterial therapeutics
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will initially possess poor pharmacokinetic profiles,and thus will require optimization of
chemistries and formulations for effective use in patients. Furthermore, the synthesis of the
gold nanoparticle platform is currently difficult to scale for mass production. For
widespread application of these technologies in a clinical setting, either new scalable
synthetic methods need to be developed or materials made of alternative scalable materials,
such as polymers, need to be created. Future work in pursuit of the strategies demonstrated
in this thesis should focus on generating materials that are easily scaled, reproducable and
have adjustable chemistries that allow for specific control of biodistribution in vivo.
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